THE JOURNAL OF Allergy AND Clinical Immunology

AMERICAN ACADEMY OF ALLERGY ASTHMA & IMMUNOLOGY

Editor in Chief **DONALD Y. M. LEUNG, MD, PhD** *Denver, Colo*

Deputy Editor **STANLEY J. SZEFLER, MD** *Denver, Colo*

Associate Editors **CEZMI A. AKDIS, MD** *Davos, Switzerland* **ANDREA J. APTER, MD, MSC** *Philadelphia, Pa*
PEDRO AVILA, MD *Chicago, Ill* **BRUCE BOCHNER, MD** *Baltimore, Md*
JOSHUA A. BOYCE, MD *Boston, Mass* **ROBERT K. BUSH, MD** *Madison, Wis*
FRED FINKELMAN, MD *Cincinnati, Ohio* **DENNIS K. LEDFORD, MD** *Tampa, Fla*
DEBORAH MEYERS, PHD *Winston-Salem, NC* **LUIGI D. NOTARANGELO, MD** *Boston, Mass*
DAVID B. PEDEN, MD, MS *Chapel Hill, NC* **MARC E. ROTHENBERG, MD** *Cincinnati, Ohio*
WILLIAM T. SHEARER, MD, PHD *Houston, Tex* **SCOTT SICHERER, MD** *New York, NY*
DONATA VERCELLI, MD *Tucson, Ariz* AND **ERIKA VON MUTIUS, MD, MSC** *Munich, Germany*
Statistics Editor **VERNON M. CHINCHILLI, PHD** *Hershey, Pa*

Editorial Board

JOHN P. ATKINSON, MD *St Louis, Mo* 2012
A. WESLEY BURKS, MD *Durham, NC* 2012
MITCHELL GRAYSON, MD *Milwaukee, Wis* 2012
SIMON P. HOGAN, PHD *Cincinnati, Ohio* 2012
NATALIJA NOVAK, MD *Bonn, Germany* 2012
HIROHISA SAITO, MD, PHD *Tokyo, Japan* 2012
TALAL A. CHATILA, MD *Los Angeles, Calif* 2013
ELIZABETH C. MATSUI, MD *Baltimore, Md* 2013
THOMAS A. E. PLATTS-MILLS, MD, PHD *Charlottesville, Va* 2013
GORDON R. BLOOMBERG, MD *St Louis, Mo* 2014
LARRY BORISH, MD *Charlottesville, Va* 2014
ANGELA HACZKU, MD, PHD *Philadelphia, Pa* 2014
JORDAN S. ORANGE, MD, PHD *Philadelphia, Pa* 2014
DARRYL C. ZELDIN, MD *Research Triangle Park, NC* 2014

LEONARD B. BACHARIER, MD *St Louis, Mo* 2015
STEN DREBORG, MD, PHD *Uppsala, Sweden* 2015
JAMES T. LI, MD, PHD *Rochester, Minn* 2015
HUGH A. SAMPSON, MD *New York, NY* 2015
WAYNE G. SHREFFLER, MD, PHD *Charlestown, Mass* 2015
JUDITH A. WOODFOLK, MB CHB, PHD *Charlottesville, Va* 2015
SEEMA S. ACEVES, MD, PHD *San Diego, Calif* 2016
MÜBECCEL AKDIS, MD, PHD *Davos, Switzerland* 2016
CEM AKIN, MD, PHD *Boston, Mass* 2016
ALAIN FISCHER, MD *Paris, France* 2016
ANNE M. FITZPATRICK, PHD *Atlanta, Ga* 2016
PETER J. GERGEN, MD, MPH *Bethesda, Md* 2016
GIDEON LACK, MD, FRCPCH *London, United Kingdom* 2016

Published monthly

OFFICIAL PUBLICATION OF THE AMERICAN ACADEMY OF ALLERGY, ASTHMA & IMMUNOLOGY

Volume 127, January-June 2011

Elsevier Inc, Philadelphia 2011

THE JOURNAL OF Allergy AND Clinical Immunology

AMERICAN ACADEMY OF ALLERGY ASTHMA & IMMUNOLOGY

Editor in Chief **DONALD Y. M. LEUNG, MD, PhD** *Denver, Colo*

Deputy Editor **STANLEY J. SZEFLER, MD** *Denver, Colo*

Associate Editors **CEZMI A. AKDIS, MD** *Davos, Switzerland* **ANDREA J. APTER, MD, MSC** *Philadelphia, Pa*
PEDRO AVILA, MD *Chicago, Ill* **BRUCE BOCHNER, MD** *Baltimore, Md*
JOSHUA A. BOYCE, MD *Boston, Mass* **ROBERT K. BUSH, MD** *Madison, Wis*
FRED FINKELMAN, MD *Cincinnati, Ohio* **DENNIS K. LEDFORD, MD** *Tampa, Fla*
DEBORAH MEYERS, PHD *Winston-Salem, NC* **LUIGI D. NOTARANGELO, MD** *Boston, Mass*
DAVID B. PEDEN, MD, MS *Chapel Hill, NC* **MARC E. ROTHENBERG, MD** *Cincinnati, Ohio*
WILLIAM T. SHEARER, MD, PHD *Houston, Tex* **SCOTT SICHERER, MD** *New York, NY*
DONATA VERCELLI, MD *Tucson, Ariz* AND **ERIKA VON MUTIUS, MD, MSC** *Munich, Germany*
Statistics Editor **VERNON M. CHINCHILLI, PHD** *Hershey, Pa*

Editorial Board

JOHN P. ATKINSON, MD *St Louis, Mo* 2012
A. WESLEY BURKS, MD *Durham, NC* 2012
MITCHELL GRAYSON, MD *Milwaukee, Wis* 2012
SIMON P. HOGAN, PHD *Cincinnati, Ohio* 2012
NATALIJA NOVAK, MD *Bonn, Germany* 2012
HIROHISA SAITO, MD, PHD *Tokyo, Japan* 2012
TALAL A. CHATILA, MD *Los Angeles, Calif* 2013
ELIZABETH C. MATSUI, MD *Baltimore, Md* 2013
THOMAS A. E. PLATTS-MILLS, MD, PHD *Charlottesville, Va* 2013
GORDON R. BLOOMBERG, MD *St Louis, Mo* 2014
LARRY BORISH, MD *Charlottesville, Va* 2014
ANGELA HACZKU, MD, PHD *Philadelphia, Pa* 2014
JORDAN S. ORANGE, MD, PHD *Philadelphia, Pa* 2014
DARRYL C. ZELDIN, MD *Research Triangle Park, NC* 2014

LEONARD B. BACHARIER, MD *St Louis, Mo* 2015
STEN DREBORG, MD, PHD *Uppsala, Sweden* 2015
JAMES T. LI, MD, PHD *Rochester, Minn* 2015
HUGH A. SAMPSON, MD *New York, NY* 2015
WAYNE G. SHREFFLER, MD, PHD *Charlestown, Mass* 2015
JUDITH A. WOODFOLK, MB CHB, PHD *Charlottesville, Va* 2015
SEEMA S. ACEVES, MD, PHD *San Diego, Calif* 2016
MÜBECCEL AKDIS, MD, PHD *Davos, Switzerland* 2016
CEM AKIN, MD, PHD *Boston, Mass* 2016
ALAIN FISCHER, MD *Paris, France* 2016
ANNE M. FITZPATRICK, PHD *Atlanta, Ga* 2016
PETER J. GERGEN, MD, MPH *Bethesda, Md* 2016
GIDEON LACK, MD, FRCPCH *London, United Kingdom* 2016

Published monthly

OFFICIAL PUBLICATION OF THE AMERICAN ACADEMY OF ALLERGY, ASTHMA & IMMUNOLOGY

Volume 127, January-June 2011

Elsevier Inc, Philadelphia 2011

VOLUME 127
COPYRIGHT © 2011 by
American Academy of Allergy, Asthma & Immunology

Printed in the United States of America

Index to Volume 127

Author index*

A

aan de Kerk DJ (*see* Kuijpers et al). 2011;127:1411-4 (Letter to the editor)
Aberer W (*see* Geroldinger-Simic et al). 2011;127:616-22
Abinun M (*see* Slatter et al). 2011;127:533-5 (Letter to the Editor)
Abonia JP (*see* Blanchard et al). 2011;127:208-17
Abramson MJ (*see* Martin et al). 2011;127:1473-9
Accetta D, Syverson G, Bonacci B, Reddy S, Bengtson C, Surfus J, Harbeck R, Huttenlocher A, Grossman W, Routes J, Verbsky J. Human phagocyte defect caused by a *Rac2* mutation detected by means of neonatal screening for T-cell lymphopenia. 2011;127:535-8 (Letter to the Editor)
Achatz G (*see* Wallner et al). 2011;127:1571-8
Adamko DJ (*see* Saude et al). 2011;127:757-64
Agarwal S (*see* Pessach et al). 2011;127:1400-7
Aghamohammadi A (*see* Rezaei et al). 2011;127:1329-41
Ahlstedt S (*see* Custovic et al). 2011;127:1480-5
Ahlstedt S (*see* Vereda et al). 2011;127:603-7
Ahrens A (*see* Blanchard et al). 2011;127:208-17
Aiuti A (*see* Bosticardo et al). 2011;127:1376-84
Aiuti A (*see* Grunebaum et al). 2011;127:1417-9 (Letter to the Editor)
Aiuti A (*see* Selleri et al). 2011;127:1368-75
Akdis CA (*see* Akdis et al). 2011;127:701-21
Akdis CA (*see* Fujita et al). 2011;127:1612-21
Akdis CA (*see* Lötvall et al). 2011;127:355-60
Akdis CA (*see* Palomares et al). 2011;127:1541-2 (Editorial)
Akdis CA (*see* Vanbervliet et al). 2011;127:943-53
Akdis CA (*see* Zimmermann et al). 2011;127:200-7
Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. 2011;127:18-27
Akdis M (*see* Akdis et al). 2011;127:18-27
Akdis M (*see* Fujita et al). 2011;127:1612-21
Akdis M (*see* Vanbervliet et al). 2011;127:943-53
Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H, Gomez E, Klunker S, Meyer N, O'Mahony L, Palomares O, Rhyner C, Quaked N, Schaffartzik A, Van De Veen W, Zeller S, Zimmermann M, Akdis CA. Interleukins, from 1 to 37, and interferon-γ: Receptors, functions, and roles in diseases. 2011;127:701-21
Aker M (*see* Selleri et al). 2011;127:1368-75
Akin C, Valent P, Metcalfe DD. Reply. 2011;127:1311-2 (Correspondence)
Akiyama K (*see* Fukutomi et al). 2011;127:531-3 (Letter to the Editor)
Akkaya A (*see* Fujita et al). 2011;127:1612-21
Al-Alwan L (*see* Chang et al). 2011;127:1046-53
Al-Herz W (*see* Massaad et al). 2011;127:998-1005
Al-Herz W (*see* Pessach et al). 2011;127:1400-7
Albert C (*see* Kerstan et al). 2011;127:495-501
Alexander ES (*see* Blanchard et al). 2011;127:208-17
Alizadehfar R (*see* Brown et al). 2011;127:661-7
Allakhverdi Z, Comeau MR, Delespesse G. Dexamethasone regulation of thymic stromal lymphopoietin receptor expression on mast cells and their precursors. 2011;127:523-4 (Letter to the Editor)
Allen KJ (*see* Martin et al). 2011;127:1473-9
Allen KJ (*see* Osborne et al). 2011;127:668-76
Allgaeuer M (*see* Naumann et al). 2011;127:1187-94
Allgaier M (*see* Huang et al). 2011;127:372-81
Almqvist C (*see* Ludvigsson et al). 2011;127:1071-3 (Letter to the Editor)
Alonzi C, Campi P, Gaeta F, Pineda F, Romano A. Diagnosing IgE-mediated hypersensitivity to sesame by an immediate-reading "contact test" with sesame oil. 2011;127:1627-9 (Letter to the Editor)
Altin JA, Tian L, Liston A, Bertram EM, Goodnow CC, Cook MC. Decreased T-cell receptor signaling through CARD11 differentially compromises forkhead box protein 3–positive regulatory versus T_H2 effector cells to cause allergy. 2011;127:1277-85
Alvarado Arnez LE, Venegas EN, Ober C, Thompson EE. Sequence variation in the *IL4* gene and resistance to *Trypanosoma cruzi* infection in Bolivians. 2011;127:279-82 (Letter to the Editor)
Alvarez-Puebla MJ (*see* Tabar et al). 2011;127:57-63
Alysandratos K-D (*see* Zhang et al). 2011;127:1522-31
Amouyal M (*see* Costa et al). 2011;127:920-6
Ampleford EJ (*see* Li et al). 2011;127:1457-65
An P, Barron-Casella EA, Strunk RC, Hamilton RG, Casella JF, DeBaun MR. Elevation of IgE in children with sickle cell disease is associated with doctor diagnosis of asthma and increased morbidity. 2011;127:1440-6
Anderson J (*see* Pityn et al). 2011;127:1063-4 (Letter to the Editor)
Andersson CK, Bergqvist A, Mori M, Mauad T, Bjermer L, Erjefält JS. Mast cell–associated alveolar inflammation in patients with atopic uncontrolled asthma. 2011;127:905-12
Andersson S (*see* Siltanen et al). 2011;127:935-42
Angelidou A (*see* Zhang et al). 2011;127:1522-31
Angus B (*see* Slatter et al). 2011;127:533-5 (Letter to the Editor)
Apter AJ (*see* Krishnan et al). 2011;127:123-7
Apter AJ. Advances in adult asthma diagnosis and treatment and HEDQ in 2010. 2011;127:116-22
Arai K (*see* Nomura et al). 2011;127:685-8 (Letter to the Editor)
Aranda A (*see* Rondón et al). 2011;127:1069-71 (Letter to the Editor)

*January, part 1, pp. 1-296; part 2, pp. S1-S58; February, part 1, pp. 297-552; part 2, pp. AB1-AB412; March, part 1, pp. 553-840; part 2, pp. S59-S84; April, pp. 841-1084; May, pp. 1085-1316; June, pp. 1317-1714.

Arbab E (*see* Kränke et al). 2011;127:1645 (Correspondence)
Arbes SJ Jr (*see* Salo et al). 2011;127:1226-35
Arbes SJ, Matsui EC. Can oral pathogens influence allergic disease? 2011;127:1119-27
Ardusso LRF (*see* Simons et al). 2011;127:587-93
Arias K, Chu DK, Flader K, Botelho F, Walker T, Arias N, Humbles AA, Coyle AJ, Oettgen HC, Chang H-D, Van Rooijen N, Waserman S, Jordana M. Distinct immune effector pathways contribute to the full expression of peanut-induced anaphylactic reactions in mice. 2011;127: 1552-61
Arias N (*see* Arias et al). 2011;127:1552-61
Arkestål K, Sibanda E, Thors C, Troye-Blomberg M, Mduluza T, Valenta R, Grönlund H, van Hage M. Impaired allergy diagnostics among parasite-infected patients caused by IgE antibodies to the carbohydrate epitope galactose-α1,3-galactose. 2011;127:1024-8
Armstrong B (*see* Leung et al). 2011;127:965-73
Arnoldussen DL, Linehan M, Sheikh A. BCG vaccination and allergy: A systematic review and meta-analysis. 2011;127:246-53
Arnoldussen DL, Linehan M, Sheikh A. Reply. 2011;127: 1081-2 (Correspondence)
Arroabarren E (*see* Tabar et al). 2011;127:57-63
Asadi S (*see* Zhang et al). 2011;127:1522-31
Asai K (*see* Kanazawa et al). 2011;127:899-904
Asai Y (*see* Brown et al). 2011;127:661-8
Asam C (*see* Wallner et al). 2011;127:1571-8
Askew DJ (*see* Sivaprasad et al). 2011;127:254-61
Aujla S (*see* Fitzpatrick et al). 2011;127:382-9
Avila PC (*see* Sabin et al). 2011;127:342-50
Ayars AG (*see* Borish et al). 2011;127:541-3 (Letter to the Editor)
Ayuso R (*see* Chawla et al). 2011;127:680-2 (Letter to the Editor)
Azzari C, la Marca G, Resti M. Neonatal screening for severe combined immunodeficiency caused by an adenosine deaminase defect: A reliable and inexpensive method using tandem mass spectrometry. 2011;127:1394-9

B

Baars PA (*see* Kuijpers et al). 2011;127:1411-4 (Letter to the editor)
Bacchelli C, Buckland KF, Buckridge S, Salzer U, Schneider P, Thrasher AJ, Gaspar HB. The C76R transmembrane activator and calcium modulator cyclophilin ligand interactor mutation disrupts antibody production and B-cell homeostasis in heterozygous and homozygous mice. 2011;127:1253-9
Bacharier LB (*see* Fitzpatrick et al). 2011;127:382-9
Bacharier LB (*see* Lötvall et al). 2011;127:355-60
Bacharier LB (*see* Simon et al). 2011;127:550 (Correspondence)
Bachert C (*see* Bousquet et al). 2011;127:49-56
Bachert C, Zhang N, Holtappels G, Tomassen P, Liu S, Lin P, Bousquet J. Reply. 2011;127:1313-4 (Correspondence)
Bachmann M (*see* Hänsel et al). 2011;127:787-94
Bader R (*see* Kohan et al). 2011;127:439-46
Baek MS (*see* Huang et al). 2011;127:372-81
Baena-Cagnani CE (*see* Brożek et al). 2011;127:1643-5 (Correspondence)
Bahna SL (*see* Sampson et al). 2011;127:1309-10 (Letter to the Editor)
Baines KJ, Simpson JL, Wood LG, Scott RJ, Gibson PG. Transcriptional phenotypes of asthma defined by gene expression profiling of induced sputum samples. 2011;127:153-60
Bakdash G (*see* van der Aar et al). 2011;127:1532-40
Baker JW (*see* Wasserman et al). 2011;127:290-1 (Correspondence)
Bakirtas A (*see* Türktaş et al). 2011;127:1078 (Correspondence)
Baldari CT (*see* Paccani et al). 2011;127:1635-7 (Letter to the Editor)
Baldassano R (*see* Orange et al). 2011;127:1360-7
Ballmer-Weber BK (*see* Geroldinger-Simic et al). 2011;127: 616-22
Ballmer-Weber BK (*see* Le et al). 2011;127:677-9 (Letter to the Editor)
Balloch A, Licciardi PV, Russell FM, Mulholland EK, Tang MLK. Reply. 2011;127:1080-1 (Correspondence)
Ballow M. The IgG molecule as a biological immune response modifier: Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. 2011;127:315-23
Banerji A (*see* Clark et al). 2011;127:682-3 (Letter to the Editor)
Barnes K (*see* Baumann et al). 2011;127:875-82
Barnes KC (*see* De Benedetto et al). 2011;127:773-86
Barnes KC (*see* Leung et al). 2011;127:965-73
Barnes N (*see* Price et al). 2011;127:835-6 (Correspondence)
Barnett SBL, Nurmagambetov TA. Costs of asthma in the United States: 2002-2007. 2011;127:145-52
Baroody FM, Brown D, Gavanescu L, DeTineo M, Naclerio RM. Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis. 2011;127:927-34
Barron-Casella EA (*see* An et al). 2011;127:1440-6
Bartlett SJ (*see* Clerisme-Beaty et al). 2011;127:406-11
Basinski T (*see* Zimmermann et al). 2011;127:200-7
Basma H (*see* Sato et al). 2011;127:1595-603
Bass SA (*see* Sivaprasad et al). 2011;127:254-61
Bates A (*see* Nahum et al). 2011;127:528-31 (Letter to the Editor)
Bauer C-P (*see* Koletzko et al). 2011;127:836-8 (Correspondence)
Baumann LM, Robinson CL, Combe JM, Gomez A, Romero K, Gilman RH, Cabrera L, Hansel NN, Wise RA, Breysse PN, Barnes K, Hernandez JE, Checkley W. Effects of distance from a heavily transited avenue on asthma and atopy in a periurban shantytown in Lima, Peru. 2011;127: 875-82
Baurecht H (*see* Naumann et al). 2011;127:1187-94
Bayry J (*see* Maddur et al). 2011;127:823-30
Beaty TH (*see* De Benedetto et al). 2011;127:773-86
Beck I (*see* Gilles et al). 2011;127:454-61
Beck LA (*see* De Benedetto et al). 2011;127:773-86
Beck LA (*see* Leung et al). 2011;127:965-73

Becker A (*see* Saude et al). 2011;127:757-64
Bégin P, Des Roches A, Nguyen M, Masse M-S, Paradis J, Paradis L. Freezing does not alter antigenic properties of fresh fruits for skin testing in patients with birch tree pollen–induced oral allergy syndrome. 2011;127:1624-6 (Letter to the Editor)
Behrendt H (*see* Gilles et al). 2011;127:454-61
Belgrave D (*see* Nicolaou et al). 2011;127:684-5 (Letter to the Editor)
Belohradsky BH (*see* Horn et al). 2011;127:544-6 (Letter to the Editor)
Belozeroff V (*see* Meltzer et al). 2011;127:167-72
Belozeroff V (*see* Sullivan et al). 2011;127:363-9
Ben-Shoshan M (*see* Brown et al). 2011;127:661-8
Ben-Zvi A (*see* Saude et al). 2011;127:757-64
Benagiano M (*see* Paccani et al). 2011;127:1635-7 (Letter to the Editor)
Bencharitiwong R (*see* Chawla et al). 2011;127:680-2 (Letter to the Editor)
Bencharitiwong R (*see* Martos et al). 2011;127:990-7
Benetière J (*see* Vanbervliet et al). 2011;127:943-53
Bengtson C (*see* Accetta et al). 2011;127:535-8 (Letter to the Editor)
Benninger M (*see* Chipps et al). 2011;127:1640-1 (Correspondence)
Bennuru S (*see* Santiago et al). 2011;127:479-86
Berdel D (*see* Koletzko et al). 2011;127:836-8 (Correspondence)
Berger AE (*see* De Benedetto et al). 2011;127:773-86
Bergqvist A (*see* Andersson et al). 2011;127:905-12
Bergström A (*see* Rosenlund et al). 2011;127:1219-25
Berkman N (*see* Kohan et al). 2011;127:439-46
Bernstein D (*see* Golden et al). 2011;127:852-4
Bernstein D (*see* Spector et al). 2011;127:1641-2 (Correspondence)
Bernstein DI (*see* Liss et al). 2011;127:1298-300 (Letter to the Editor)
Bernstein DI (*see* Nelson et al). 2011;127:72-80
Bernstein DI (*see* Prenner et al). 2011;127:289 (Correspondence)
Berroa F (*see* Ferrer et al). 2011;127:1300-2 (Letter to the Editor)
Bertram EM (*see* Altin et al). 2011;127:1277-85
Bérubé J (*see* Roussel et al). 2011;127:1632-4 (Letter to the Editor)
Bhan I, Camargo CA Jr, Wenger J, Ricciardi C, Ye J, Borregaard N, Thadhani R. Circulating levels of 25-hydroxyvitamin D and human cathelicidin in healthy adults. 2011;127:1302-4 (Letter to the Editor)
Biagtan MJ, Viswanathan RK, Evans MD, Mathur SK. Clinical utility of the Chronic Urticaria Index. 2011;127:1626-7 (Letter to the editor)
Bianchi M, Niemiec MJ, Siler U, Urban CF, Reichenbach J. Restoration of anti-*Aspergillus* defense by neutrophil extracellular traps in human chronic granulomatous disease after gene therapy is calprotectin-dependent. 2011;127:1243-52
Bieli C (*see* Ege et al). 2011;127:138-44
Bieli C (*see* Roduit et al). 2011;127:179-85
Bier A (*see* Dreschler et al). 2011;127:487-94
Bilò MB (*see* Simons et al). 2011;127:587-93
Bin L, Howell MD, Kim BE, Streib JE, Hall CF, Leung DYM. Specificity protein 1 is pivotal in the skin's antiviral response. 2011;127:430-8
Binia A (*see* Holt et al). 2011;127:1054-62
Bird JA (*see* Kim et al). 2011;127:640-6
Bisgaard H, Pipper CB, Bønnelykke K. Endotyping early childhood asthma by quantitative symptom assessment. 2011;127:1155-64
Bitter S (*see* Roduit et al). 2011;127:179-85
Bjermer L (*see* Andersson et al). 2011;127:905-12
Bjermer L (*see* Lötvall et al). 2011;127:355-60
Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. 2011;127:64-71
Blanc-Caille M (*see* Bonniaud et al). 2011;127:295 (Correspondence)
Blanca M (*see* Rondón et al). 2011;127:1069-71 (Letter to the Editor)
Blanca M (*see* Romano et al). 2011;127:S59
Blanca M (*see* Romano et al). 2011;127:S67-3
Blanca-López N (*see* Rondón et al). 2011;127:1069-71 (Letter to the Editor)
Blanchard C, Stucke EM, Rodriguez-Jimenez B, Burwinkel K, Collins MH, Ahrens A, Alexander ES, Buckmeier Butz BK, Jameson SC, Kaul A, Franciosi JP, Kushner JP, Putnam PE, Abonia JP, Rothenberg ME. A striking local esophageal cytokine expression profile in eosinophilic esophagitis. 2011;127:208-17
Blanche S (*see* Lugo Reyes et al). 2011;127:543-4 (Letter to the Editor)
Blatt K (*see* Niespodziana et al). 2011;127:1562-70
Bleecker ER (*see* Busse et al). 2011;127:130-7
Bleecker ER (*see* Fitzpatrick et al). 2011;127:382-9
Bleecker ER (*see* Holguin et al). 2011;127:1486-93
Bleecker ER (*see* Li et al). 2011;127:1457-65
Blessing-Moore J (*see* Golden et al). 2011;127:852-4
Blessing-Moore J (*see* Spector et al). 2011;127:1641-2 (Correspondence)
Bloomberg GR (*see* Wood et al). 2011;127:913-9
Blume C (*see* Gilles et al). 2011;127:454-61
Bochenek G (*see* Sanak et al). 2011;127:1141-7
Bochner BS (*see* Broide et al). 2011;127:689-95
Boguniewicz M (*see* De Benedetto et al). 2011;127:773-86
Boguniewicz M (*see* Leung et al). 2011;127:965-73
Bohle B (*see* Geroldinger-Simic et al). 2011;127:616-22
Bohle B (*see* Schmetterer et al). 2011;127:238-45
Bohle B (*see* Wallner et al). 2011;127:1571-8
Bonacci B (*see* Accetta et al). 2011;127:535-8 (Letter to the Editor)
Bonini S (*see* Brożek et al). 2011;127:1643-5 (Correspondence)
Bønnelykke K (*see* Bisgaard et al). 2011;127:1155-64
Bonniaud P, Georges M, Blanc-Caille M, Collet E, Camus P. Salbutamol inhaler misuse resulting in skin burn. 2011;127:295 (Correspondence)

Borgers H (*see* Bossuyt et al). 2011;127:1079-80 (Correspondence)
Bories J-C (*see* Vince et al). 2011;127:538-41 (Letter to the Editor)
Borish L (*see* Laidlaw et al). 2011;127:815-22
Borish L, Ayars AG, Kirkpatrick CH. Common variable immunodeficiency presenting as herpes simplex virus encephalitis. 2011;127:541-3 (Letter to the Editor)
Borras I (*see* Nadeau et al). 2011;127:1622-4 (Letter to the Editor)
Borregaard N (*see* Bhan et al). 2011;127:1302-4 (Letter to the Editor)
Bossuyt X, Borgers H, Moens L, Verbinnen B, Meyts I. Age- and serotype-dependent antibody response to pneumococcal polysaccharides. 2011;127:1079-80 (Correspondence)
Bosticardo M, Draghici E, Schena F, Sauer AV, Fontana E, Castiello MC, Catucci M, Locci M, Naldini L, Aiuti A, Roncarolo MG, Poliani PL, Traggiai E, Villa A. Lentiviral-mediated gene therapy leads to improvement of B-cell functionality in a murine model of Wiskott-Aldrich syndrome. 2011;127:1376-84
Boswell MG (*see* Newcomb et al). 2011;127:1006-13
Botelho F (*see* Arias et al). 2011;127:1552-61
Bougault V, Turmel J, Boulet L-P. Airway hyperresponsiveness in elite swimmers: Is it a transient phenomenon? 2011;127:892-8
Boulet L-P (*see* Bougault et al). 2011;127:892-8
Boushey HA (*see* Huang et al). 2011;127:372-81
Bousquet J (*see* Bachert et al). 2011;127:1313-4 (Correspondence)
Bousquet J (*see* Bousquet et al). 2011;127:49-56
Bousquet J (*see* Brożek et al). 2011;127:1643-5 (Correspondence)
Bousquet J (*see* Calderón et al). 2011;127:30-8
Bousquet J (*see* Costa et al). 2011;127:920-6
Bousquet J (*see* Rothenberg et al). 2011;127:1-2, 297-8, 423-4, 553-4, 841-2, 1085-6, 1317-8
Bousquet PJ (*see* Costa et al). 2011;127:920-6
Bousquet PJ (*see* Romano et al). 2011;127:1638 (Correspondence)
Bousquet PJ, Calderon MA, Demoly P, Larenas D, Passalacqua G, Bachert C, Brozek J, Walter Canonica G, Casale T, Fonseca J, Dahl R, Durham SR, Merk H, Worm M, Wahn U, Zuberbier T, Schünemann HJ, Bousquet J. The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: A Global Allergy and Asthma European Network (GA^2LEN) article. 2011;127:49-56
Boutboul D (*see* Vince et al). 2011;127:538-41 (Letter to the Editor)
Bowcock AM (*see* Suárez-Fariñas et al). 2011;127:954-64
Boyce JA (*see* Laidlaw et al). 2011;127:815-22
Boyd A (*see* Santiago et al). 2011;127:479-86
Boznanski A (*see* Ege et al). 2011;127:138-44
Brand PLP. The Asthma Predictive Index: Not a useful tool in clinical practice. 2011;127:293-4 (Correspondence)
Brandt EB (*see* Sivaprasad et al). 2011;127:254-61
Bratke K (*see* Dreschler et al). 2011;127:487-94
Braun-Fahrländer C (*see* Ege et al). 2011;127:138-44
Braun-Fahrländer C (*see* Roduit et al). 2011;127:179-85
Brenna OV. Quality of life and pets. 2011;127:287 (Correspondence)
Breysse PN (*see* Baumann et al). 2011;127:875-82
Brigida I (*see* Grunebaum et al). 2011;127:1417-9 (Letter to the Editor)
Brigida I (*see* Selleri et al). 2011;127:1368-75
Bristow J (*see* Huang et al). 2011;127:372-81
Briza P (*see* Wallner et al). 2011;127:1571-8
Broccardo CJ, Mahaffey S, Schwarz J, Wruck L, David G, Schlievert PM, Reisdorph NA, Leung DYM. Comparative proteomic profiling of patients with atopic dermatitis based on history of eczema herpeticum infection and *Staphylococcus aureus* colonization. 2011;127:186-93
Bröcker E-B (*see* Kerstan et al). 2011;127:495-501
Brodie EL (*see* Huang et al). 2011;127:372-81
Broide DH, Finkelman F, Bochner BS, Rothenberg ME. Advances in mechanisms of asthma, allergy, and immunology in 2010. 2011;127:689-95
Brown D (*see* Baroody et al). 2011;127:927-34
Brown LAS (*see* Fitzpatrick et al). 2011;127:1604-11
Brown SJ, Asai Y, Cordell HJ, Campbell LE, Zhao Y, Liao H, Northstone K, Henderson J, Alizadehfar R, Ben-Shoshan M, Morgan K, Roberts G, Masthoff LJN, Pasmans SGMA, van den Akker PC, Wijmenga C, Hourihane JO'B, Palmer CNA, Lack G, Clarke A, Hull PR, Irvine AD, McLean WHI. Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy. 2011;127:661-8
Brozek J (*see* Bousquet et al). 2011;127:49-56
Brożek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, van Wijk RG, Ohta K, Zuberbier T, Schünemann HJ. Reply. 2011;127:1643-5 (Correspondence)
Bruijnzeel-Koomen CAFM (*see* van Hoffen et al). 2011;127:100-1 (Letter to the Editor)
Brunekreef B (*see* Savenije et al). 2011;127:1505-12
Brunekreef B (*see* Savenije et al). 2011;127:750-6
Brunekreef B (*see* Wijga et al). 2011;127:275-7 (Letter to the Editor)
Brussino L (*see* Bucca et al). 2011;127:412-9
Bryce PJ (*see* Hsu Blatman et al). 2011;127:1307-8 (Letter to the Editor)
Bublin M (*see* Le et al). 2011;127:677-9 (Letter to the Editor)
Bucca CB, Bugiani M, Culla B, Guida G, Heffler E, Mietta S, Moretto A, Rolla G, Brussino L. Chronic cough and irritable larynx. 2011;127:412-9
Büchele G (*see* Ege et al). 2011;127:138-44
Büchele G (*see* Roduit et al). 2011;127:179-85
Buckland KF (*see* Bacchelli et al). 2011;127:1253-9
Buckmeier Butz BK (*see* Blanchard et al). 2011;127:208-17
Buckridge S (*see* Bacchelli et al). 2011;127:1253-9
Bugiani M (*see* Bucca et al). 2011;127:412-9
Buhl T, Meynberg HC, Kaune KM, Hünecke P, Schön MP, Fuchs T. Long-term follow-up of patients with hypersensitivity to nonsteroidal anti-inflammatory drugs reveals shortcomings in compliance and care. 2011;127:284-5 (Letter to the Editor)
Buhot C (*see* Worm et al). 2011;127:89-97

Bukstein D (*see* Chipps et al). 2011;127:1640-1 (Correspondence)
Bulley S (*see* Le et al). 2011;127:677-9 (Letter to the Editor)
Bunyavanich S (*see* Lange et al). 2011;127:734-40
Burgess JA (*see* Martin et al). 2011;127:1473-9
Burgler S (*see* Akdis et al). 2011;127:701-21
Burks AW (*see* Kim et al). 2011;127:640-6
Burks AW (*see* Sampson et al). 2011;127:1309-10 (Letter to the Editor)
Burks AW (*see* Thyagarajan et al). 2011;127:291-2 (Correspondence)
Burks AW (*see* Varshney et al). 2011;127:654-60
Burks AW (*see* Vickery et al). 2011;127:576-84
Burks W (*see* Kulis et al). 2011;127:81-8
Burwell L (*see* Fitzpatrick et al). 2011;127:1604-11
Burwinkel K (*see* Blanchard et al). 2011;127:208-17
Bush RK (*see* Peden et al). 2011;127:696-700
Bush RK, Swenson C, Fahlberg B, Evans MD, Esch R, Busse WW. House dust mite sublingual immunotherapy: Results of a US trial. 2011;127:974-81
Busse W (*see* Massanari et al). 2011;127:548 (Correspondence)
Busse WW (*see* Bush et al). 2011;127:974-81
Busse WW (*see* Holguin et al). 2011;127:1486-93
Busse WW (*see* Li et al). 2011;127:1457-65
Busse WW (*see* Meltzer et al). 2011;127:167-72
Busse WW, Peters SP, Fenton MJ, Mitchell H, Bleecker ER, Castro M, Wenzel S, Erzurum SC, Fitzpatrick AM, Teague WG, Jarjour N, Moore WC, Sumino K, Simeone S, Ratanamaneechat S, Penugonda M, Gaston B, Ross TM, Sigelman S, Schiepan JR, Zaccaro DJ, Crevar CJ, Carter DM, Togias A. Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccine. 2011;127:130-7
Bustamante J (*see* Lugo Reyes et al). 2011;127:543-4 (Letter to the Editor)

C

Cabrera L (*see* Baumann et al). 2011;127:875-82
Cabrera-Freitag P (*see* Ferrer et al). 2011;127:1300-2 (Letter to the Editor)
Cakebread JA, Xu Y, Grainge C, Kehagia V, Howarth PH, Holgate ST, Davies DE. Exogenous IFN-β has antiviral and anti-inflammatory properties in primary bronchial epithelial cells from asthmatic subjects exposed to rhinovirus. 2011;127:1148-54
Calatroni A (*see* Salo et al). 2011;127:1226-35
Calderon MA (*see* Bousquet et al). 2011;127:49-56
Calderón MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P. Allergen-specific immunotherapy for respiratory allergies: From meta-analysis to registration and beyond. 2011;127:30-8
Calhoun WJ (*see* Holguin et al). 2011;127:1486-93
Calhoun WJ (*see* Huang et al). 2011;127:372-81
Calhoun WJ (*see* Li et al). 2011;127:1457-65
Callan H (*see* Elsheikh et al). 2011;127:1543-51
Camargo CA Jr (*see* Bhan et al). 2011;127:1302-4 (Letter to the Editor)
Camargo CA (*see* Clark et al). 2011;127:682-3 (Letter to the Editor)
Campbell LE (*see* Brown et al). 2011;127:661-8
Campi P (*see* Alonzi et al). 2011;127:1627-9 (Letter to the Editor)
Campo P (*see* Rondón et al). 2011;127:1069-71 (Letter to the Editor)
Camus P (*see* Bonniaud et al). 2011;127:295 (Correspondence)
Cancrini C (*see* Selleri et al). 2011;127:1368-75
Canino G (*see* Lange et al). 2011;127:734-40
Canniff J (*see* Leung et al). 2011;127:965-73
Canonica GW (*see* Brożek et al). 2011;127:1643-5 (Correspondence)
Canonica GW, Passalacqua G. Disease-modifying effect and economic implications of sublingual immunotherapy. 2011;127:44-5
Cant AJ (*see* Slatter et al). 2011;127:533-5 (Letter to the Editor)
Canto G (*see* Rondón et al). 2011;127:1069-71 (Letter to the Editor)
Cappelli B (*see* Selleri et al). 2011;127:1368-75
Carbonell-Estrany X (*see* Simões et al). 2011;127:293 (Correspondence)
Cardinale I (*see* Suárez-Fariñas et al). 2011;127:954-64
Carlisle S (*see* Varshney et al). 2011;127:654-60
Carr W (*see* Chipps et al). 2011;127:1640-1 (Correspondence)
Carroll KN (*see* Miller et al). 2011;127:883-91
Carter DM (*see* Busse et al). 2011;127:130-7
Caruso C (*see* Romano et al). 2011;127:1638 (Correspondence)
Casale T (*see* Bousquet et al). 2011;127:49-56
Casale T (*see* Massanari et al). 2011;127:548 (Correspondence)
Casale TB (*see* Brożek et al). 2011;127:1643-5 (Correspondence)
Casale TB (*see* Calderón et al). 2011;127:30-8
Casale TB (*see* Lötvall et al). 2011;127:355-60
Casale TB, Stokes JR. Future forms of immunotherapy. 2011;127:8-15
Casanova J-L (*see* Lugo Reyes et al). 2011;127:543-4 (Letter to the Editor)
Casanova J-L (*see* Pessach et al). 2011;127:1400-7
Casanova J-L (*see* Vince et al). 2011;127:538-41 (Letter to the Editor)
Casella JF (*see* An et al). 2011;127:1440-6
Casiraghi M (*see* Selleri et al). 2011;127:1368-75
Cassani B (*see* Selleri et al). 2011;127:1368-75
Castagno E (*see* Monti et al). 2011;127:679-80 (Letter to the Editor)
Castells M (*see* Romano et al). 2011;127:S67-3
Castiello MC (*see* Bosticardo et al). 2011;127:1376-84
Castrejon L (*see* Elsheikh et al). 2011;127:1543-51
Castro M (*see* Busse et al). 2011;127:130-7
Castro M (*see* Clerisme-Beaty et al). 2011;127:406-11
Castro M (*see* Fitzpatrick et al). 2011;127:382-9
Castro M (*see* Holguin et al). 2011;127:1486-93
Castro M (*see* Huang et al). 2011;127:372-81
Castro M (*see* Li et al). 2011;127:1457-65

Castro-Rodriguez JA, Cifuentes L, Rodríguez-Martínez CE. The asthma predictive index remains a useful tool to predict asthma in young children with recurrent wheeze in clinical practice. 2011;127:1082-3 (Correspondence)
Catucci M (*see* Bosticardo et al). 2011;127:1376-84
Caubet J-C, Kaiser L, Lemaître B, Fellay B, Gervaix A, Eigenmann PA. The role of penicillin in benign skin rashes in childhood: A prospective study based on drug rechallenge. 2011;127:218-22
Caudri D (*see* Savenije et al). 2011;127:1505-12
Cavazzana-Calvo M (*see* Fischer et al). 2011;127:1356-9
Caviglia AG. Asthma in the elderly: β-Adrenergic receptor blockers may worsen, β-receptor agonists relieve (with caveats). 2011;127:1639 (Correspondence)
Cecilia Berin M (*see* Martos et al). 2011;127:990-7
Celedón JC (*see* Forno et al). 2011;127:741-9
Celedón JC (*see* Ly et al). 2011;127:1087-94
Celedón JC (*see* Lange et al). 2011;127:734-40
Cerutti A (*see* Chinen et al). 2011;127:1579-86
Chaker AM (*see* Dumitru et al). 2011;127:1515-21
Chakir J (*see* Sivaprasad et al). 2011;127:254-61
Chalubinski M (*see* Fujita et al). 2011;127:1612-21
Chanez P (*see* Thamrin et al). 2011;127:1494-502
Chang H-D (*see* Arias et al). 2011;127:1552-61
Chang Y, Al-Alwan L, Risse P-A, Roussel L, Rousseau S, Halayko AJ, Martin JG, Hamid Q, Eidelman DH. T_H17 cytokines induce human airway smooth muscle cell migration. 2011;127:1046-53
Chapel H (*see* Orange et al). 2011;127:1360-7
Charalambous BM (*see* Chua et al). 2011;127:1410-1 (Letter to the Editor)
Chatila TA (*see* Mathias et al). 2011;127:795-805
Chawla KK, Bencharitiwong R, Ayuso R, Grishina G, Nowak-Węgrzyn A. Shea butter contains no IgE-binding soluble proteins. 2011;127:680-2 (Letter to the Editor)
Cheadle C (*see* De Benedetto et al). 2011;127:773-86
Checkley W (*see* Baumann et al). 2011;127:875-82
Chee R (*see* Chua et al). 2011;127:1410-1 (Letter to the Editor)
Chee R (*see* Marashi et al). 2011;127:1385-93
Chen R (*see* Fan et al). 2011;127:1312 (Correspondence)
Chen S (*see* Fan et al). 2011;127:521-3 (Letter to the Editor)
Chen Y, Stirling RG, Paul E, Hore-Lacy F, Thompson BR, Douglass JA. Longitudinal decline in lung function in patients with primary immunoglobulin deficiencies. 2011;127:1414-7 (Letter to the Editor)
Chiavacci R (*see* Orange et al). 2011;127:1360-7
Chinchilli VM (*see* Simon et al). 2011;127:550 (Correspondence)
Chinen J, Martinez-Gallo M, Gu W, Cols M, Cerutti A, Radigan L, Zhang L, Potocki L, Withers M, Lupski JR, Cunningham-Rundles C. Transmembrane activator and CAML interactor *(TACI)* haploinsufficiency results in B-cell dysfunction in patients with Smith-Magenis syndrome. 2011;127:1579-86
Chinen J, Shearer WT. Advances in basic and clinical immunology in 2010. 2011;127:336-41
Chinn IK, Markert ML. Induction of tolerance to parental parathyroid grafts using allogeneic thymus tissue in patients with DiGeorge anomaly. 2011;127:1351-5
Chiou C-F (*see* Meltzer et al). 2011;127:167-72
Chipps B, Spector S, Farrar J, Carr W, Meltzer E, Storms W, Kaliner M, Luskin A, Bukstein D, Oppenheimer J, Smart B, Derebery J, Harder J, Dykewicz M, Benninger M. Differences in recommendations between the Allergic Rhinitis and its Impact on Asthma Update 2010 and US Rhinitis Practice Parameters. 2011;127:1640-1 (Correspondence)
Chiricozzi A (*see* Suárez-Fariñas et al). 2011;127:954-64
Chisholm A (*see* Price et al). 2011;127:835-6 (Correspondence)
Chon Y (*see* Meltzer et al). 2011;127:167-72
Christensen LH (*see* Holm et al). 2011;127:1029-37
Chu DK (*see* Arias et al). 2011;127:1552-61
Chua I, Lagos M, Charalambous BM, Workman S, Chee R, Grimbacher B. Pathogen-specific IgG antibody levels in immunodeficient patients receiving immunoglobulin replacement do not provide additional benefit to therapeutic management over total serum IgG. 2011;127:1410-1 (Letter to the Editor)
Chung CT-S (*see* Grunebaum et al). 2011;127:1417-9 (Letter to the Editor)
Chung KF (*see* Li et al). 2011;127:1457-65
Chung W-H (*see* Phillips et al). 2011;127:S60-6
Cicalese MP (*see* Grunebaum et al). 2011;127:1417-9 (Letter to the Editor)
Cifuentes L (*see* Castro-Rodriguez et al). 2011;127:1082-3 (Correspondence)
Ciprandi G, Cirillo I. Forced expiratory flow between 25% and 75% of vital capacity may be a marker of bronchial impairment in allergic rhinitis. 2011;127:549-50 (Correspondence)
Ciprandi G, Cirillo I. Reply. 2011;127:550 (Correspondence)
Cirillo I (*see* Ciprandi et al). 2011;127:549-50 (Correspondence)
Cirillo I (*see* Ciprandi et al). 2011;127:550 (Correspondence)
Civaj V (*see* Niespodziana et al). 2011;127:1562-70
Clark S, Espinola J, Rudders SA, Banerji A, Camargo CA Jr. Frequency of US emergency department visits for food-related acute allergic reactions. 2011;127:682-3 (Letter to the Editor)
Clarke A (*see* Brown et al). 2011;127:661-8
Clearie K (*see* Vaidyanathan et al). 2011;127:173-8
Clerisme-Beaty EM, Bartlett SJ, Teague WG, Lima J, Irvin CG, Cohen R, Castro M, Wise RA, Rand CS. The Madison Avenue effect: How drug presentation style influences adherence and outcome in patients with asthma. 2011;127:406-11
Cohen A (*see* Katz et al). 2011;127:647-53
Cohen A (*see* Katz et al). 2011;127:839-40 (Correspondence)
Cohen J (*see* Maarof et al). 2011;127:1296-8 (Letter to the Editor)
Cohen R (*see* Clerisme-Beaty et al). 2011;127:406-11
Colice G (*see* Price et al). 2011;127:835-6 (Correspondence)
Collet E (*see* Bonniaud et al). 2011;127:295 (Correspondence)
Collins MH (*see* Blanchard et al). 2011;127:208-17
Cols M (*see* Chinen et al). 2011;127:1579-86

Combe JM (*see* Baumann et al). 2011;127:875-82
Comeau MR (*see* Allakhverdi et al). 2011;127:523-4 (Letter to the Editor)
Commins SP, James HR, Kelly LA, Pochan SL, Workman LJ, Perzanowski MS, Kocan KM, Fahy JV, Nganga LW, Ronmark E, Cooper PJ, Platts-Mills TAE. The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1,3-galactose. 2011;127:1286-93
Conley ME (*see* Vince et al). 2011;127:538-41 (Letter to the Editor)
Conroy K (*see* Wood et al). 2011;127:913-9
Cook K (*see* Saude et al). 2011;127:657-64
Cook MC (*see* Altin et al). 2011;127:1277-85
Cookson WO (*see* Holt et al). 2011;127:1054-62
Cookson WOCM (*see* Ege et al). 2011;127:138-44
Cooper PJ (*see* Commins et al). 2011;127:1286-93
Cordell HJ (*see* Brown et al). 2011;127:661-8
Corren J, Wood RA, Patel D, Zhu J, Yegin A, Dhillon G, Fish JE. Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge. 2011;127:398-405
Costa DJ, Amouyal M, Lambert P, Ryan D, Schünemann HJ, Daures JP, Bousquet J, Bousquet PJ. How representative are clinical study patients with allergic rhinitis in primary care? 2011;127:920-6
Cox L (*see* Golden et al). 2011;127:852-4
Cox L (*see* Spector et al). 2011;127:1641-2 (Correspondence)
Coyle AJ (*see* Arias et al). 2011;127:1552-61
Crameri R (*see* Akdis et al). 2011;127:701-21
Crawford L (*see* Reece et al). 2011;127:447-53
Creticos P (*see* Nelson et al). 2011;127:72-80
Crevar CJ (*see* Busse et al). 2011;127:130-7
Cromwell O, Häfner D, Nandy A. Recombinant allergens for specific immunotherapy. 2011;127:865-72
Crump C, Sundquist K, Sundquist J, Winkleby MA. Gestational age at birth and risk of allergic rhinitis in young adulthood. 2011;127:1173-9
Cuesta-Herranz J (*see* Vereda et al). 2011;127:1304-7 (Letter to the Editor)
Cuesta-Herranz J (*see* Vereda et al). 2011;127:603-7
Culla B (*see* Bucca et al). 2011;127:412-9
Cullinan P (*see* Ege et al). 2011;127:138-44
Cullinane C (*see* DunnGalvin et al). 2011;127:633-9
Cunningham-Rundles C (*see* Chinen et al). 2011;127:1579-86
Cunningham-Rundles C (*see* Orange et al). 2011;127:1360-7
Custovic A (*see* Lötvall et al). 2011;127:355-60
Custovic A (*see* Nicolaou et al). 2011;127:684-5 (Letter to the Editor)
Custovic A, Nicolaou N. Peanut allergy: Overestimated in epidemiology or underdiagnosed in primary care? 2011;127:631-2
Custovic A, Rothers J, Stern D, Simpson A, Woodcock A, Wright AL, Nicolaou NC, Hankinson J, Halonen M, Martinez FD. Effect of day care attendance on sensitization and atopic wheezing differs by Toll-like receptor 2 genotype in 2 population-based birth cohort studies. 2011;127:390-7
Custovic A, Soderstrom L, Ahlstedt S, Sly PD, Simpson A, Holt PG. Allergen-specific IgG antibody levels modify the relationship between allergen-specific IgE and wheezing in childhood. 2011;127:1480-5

D

Dacumos-Hill A (*see* Prickett et al). 2011;127:608-15
Dadi H (*see* Grunebaum et al). 2011;127:1417-9 (Letter to the Editor)
Dadi H (*see* Nahum et al). 2011;127:528-31 (Letter to the Editor)
Dadi H (*see* Newell et al). 2011;127:517-9 (Letter to the Editor)
Dahl R (*see* Bousquet et al). 2011;127:49-56
Dai X, Sayama K, Tohyama M, Shirakata Y, Hanakawa Y, Tokumaru S, Yang L, Hirakawa S, Hashimoto K. Mite allergen is a danger signal for the skin via activation of inflammasome in keratinocytes. 2011;127:803-11
Daines MO (*see* Sivaprasad et al). 2011;127:254-61
Daley GQ (*see* Pessach et al). 2011;127:1400-7
Dalphin J-C (*see* Roduit et al). 2011;127:179-85
Daly D (*see* DunnGalvin et al). 2011;127:633-9
Datta S, Milner JD. Altered T-cell receptor signaling in the pathogenesis of allergic disease. 2011;127:351-4
Daures JP (*see* Costa et al). 2011;127:920-6
David G (*see* Broccardo et al). 2011;127:186-93
Davies DE (*see* Cakebread et al). 2011;127:1148-54
De Benedetto A, Rafaels NM, McGirt LY, Ivanov AI, Georas SN, Cheadle C, Berger AE, Zhang K, Vidyasagar S, Yoshida T, Boguniewicz M, Hata T, Schneider LC, Hanifin JM, Gallo RL, Novak N, Weidinger S, Beaty TH, Leung DYM, Barnes KC, Beck LA. Tight junction defects in patients with atopic dermatitis. 2011;127:773-86
de Jong EC (*see* van der Aar et al). 2011;127:1532-40
de Jongste JC (*see* Savenije et al). 2011;127:1505-12
de Jongste JC (*see* Savenije et al). 2011;127:750-6
de Jongste JC (*see* Wijga et al). 2011;127:275-7 (Letter to the Editor)
de Suremain M (*see* Lugo Reyes et al). 2011;127:543-4 (Letter to the Editor)
DeBaun MR (*see* An et al). 2011;127:1440-6
Debeer S (*see* Hennino et al). 2011;127:1064-7 (Letter to the Editor)
Décline J-L (*see* Maarof et al). 2011;127:1296-8 (Letter to the Editor)
Delespesse G (*see* Allakhverdi et al). 2011;127:523-4 (Letter to the Editor)
Delivanis D-A (*see* Zhang et al). 2011;127:1522-31
DeLong JH, Hetherington Simpson K, Wambre E, James EA, Robinson D, Kwok WW. Ara h 1–reactive T cells in individuals with peanut allergy. 2011;127:1211-18
Demoly P (*see* Bousquet et al). 2011;127:49-56
Demoly P (*see* Calderón et al). 2011;127:30-8
Denburg JA (*see* Reece et al). 2011;127:447-53
Denlinger LC (*see* Huang et al). 2011;127:372-81
Depner M (*see* Lluis et al). 2011;127:1587-94
DeRavin SS (*see* Kang et al). 2011;127:1319-26

Derebery J (*see* Chipps et al). 2011;127:1640-1 (Correspondence)
Des Roches A (*see* Bégin et al). 2011;127:1624-6 (Letter to the Editor)
DeSantis TZ (*see* Huang et al). 2011;127:372-81
DeTineo M (*see* Baroody et al). 2011;127:927-34
Devereux G (*see* Nurmatov et al). 2011;127:724-33
Dharmage SC (*see* Martin et al). 2011;127:1473-9
Dharmage SC (*see* Osborne et al). 2011;127:668-76
Dhillon G (*see* Corren et al). 2011;127:398-405
Di Bona D (*see* Di Lorenzo et al). 2011;127:1077-8 (Correspondence)
Di Lorenzo G, Di Bona D. Reply. 2011;127:1077-8 (Correspondence)
Diamond B (*see* Yildirim-Toruner et al). 2011;127:303-12
Dickson I (*see* Mushtaq et al). 2011;127:1236-42
DiMango E (*see* Huang et al). 2011;127:372-81
Dixon AL (*see* Holt et al). 2011;127:1054-62
Doekes G (*see* Naumann et al). 2011;127:1187-94
Dorinsky P (*see* Price et al). 2011;127:835-6 (Correspondence)
Dors N (*see* Kuijpers et al). 2011;127:1411-4 (Letter to the editor)
Douglass JA (*see* Chen et al). 2011;127:1414-7 (Letter to the Editor)
Draghici E (*see* Bosticardo et al). 2011;127:1376-84
Dreschler K, Bratke K, Petermann S, Bier A, Thamm P, Kuepper M, Virchow JC, Lommatzsch M. Impact of immunotherapy on blood dendritic cells in patients with *Hymenoptera* venom allergy. 2011;127:487-94
Dresen A (*see* Wood et al). 2011;127:913-9
D'Elios MM (*see* Paccani et al). 2011;127:1635-7 (Letter to the Editor)
D'Vaz N (*see* Tulic et al). 2011;127:470-8
Duan S (*see* Suárez-Fariñas et al). 2011;127:954-64
Dumitru AF, Shamji M, Wagenmann M, Hindersin S, Scheckenbach K, Greve J, Klenzner T, Hess L, Nebel S, Zimmermann C, Zahner C, Schmidt-Weber CB, Chaker AM. Petasol butenoate complex (Ze 339) relieves allergic rhinitis–induced nasal obstruction more effectively than desloratadine. 2011;127:1515-21
DunnGalvin A, Daly D, Cullinane C, Stenke E, Keeton D, Erlewyn-Lajeunesse M, Roberts GC, Lucas J, Hourihane JO'B. Highly accurate prediction of food challenge outcome using routinely available clinical data. 2011;127:633-9
Dupont WD (*see* Miller et al). 2011;127:883-91
Durham SR (*see* Bousquet et al). 2011;127:49-56
Durham SR (*see* Calderón et al). 2011;127:30-8
Durham SR (*see* James et al). 2011;127:509-16
Durham SR, Leung DYM. One hundred years of allergen immunotherapy: Time to ring the changes. 2011;127:3-7
Durkin HG (*see* Silverberg et al). 2011;127:1180-6
Dworski R, Simon H-U, Hoskins A, Yousefi S. Eosinophil and neutrophil extracellular DNA traps in human allergic asthmatic airways. 2011;127:1260-6
Dykewicz M (*see* Chipps et al). 2011;127:1640-1 (Correspondence)

E

Eberhard M (*see* Santiago et al). 2011;127:479-86
Ebner C (*see* Geroldinger-Simic et al). 2011;127:616-22
Echechipía S (*see* Tabar et al). 2011;127:57-63
Ege MJ, Strachan DP, Cookson WOCM, Moffatt MF, Gut I, Lathrop M, Kabesch M, Genuneit J, Büchele G, Sozanska B, Boznanski A, Cullinan P, Horak E, Bieli C, Braun-Fahrländer C, Heederik D, von Mutius E. Gene-environment interaction for childhood asthma and exposure to farming in Central Europe. 2011;127:138-44
Egger C (*see* Geroldinger-Simic et al). 2011;127:616-22
Eidelman DH (*see* Chang et al). 2011;127:1046-53
Eigenmann PA (*see* Caubet et al). 2011;127:218-22
Eisenberg E (*see* Katz et al). 2011;127:839-40 (Correspondence)
Eiwegger T (*see* Akdis et al). 2011;127:701-21
Eiwegger T (*see* Zimmermann et al). 2011;127:200-7
El-Gamal YM (*see* Simons et al). 2011;127:587-93
El-Ghaiesh S (*see* Elsheikh et al). 2011;127:1543-51
El-Zein M, Parent M-É, Rousseau M-C. Comments on a recent meta-analysis: BCG vaccination and allergic conditions. 2011;127:1081 (Correspondence)
Elsheikh A, Castrejon L, Lavergne SN, Whitaker P, Monshi M, Callan H, El-Ghaiesh S, Farrell J, Pichler WJ, Peckham D, Park BK, Naisbitt DJ. Enhanced antigenicity leads to altered immunogenicity in sulfamethoxazole-hypersensitive patients with cystic fibrosis. 2011;127:1543-51
Emery VC (*see* Marashi et al). 2011;127:1385-93
Epstein T (*see* Liss et al). 2011;127:1298-300 (Letter to the Editor)
Ericksen MB (*see* Sivaprasad et al). 2011;127:254-61
Eriksson JG (*see* Siltanen et al). 2011;127:935-42
Erjefält JS (*see* Andersson et al). 2011;127:905-12
Erlewyn-Lajeunesse M (*see* DunnGalvin et al). 2011;127:633-9
Erzurum SC (*see* Busse et al). 2011;127:130-7
Erzurum SC (*see* Holguin et al). 2011;127:1486-93
Erzurum SC (*see* Li et al). 2011;127:1457-65
Esch R (*see* Bush et al). 2011;127:974-81
Espinola J (*see* Clark et al). 2011;127:682-3 (Letter to the Editor)
Etzoni A (*see* Hanna et al). 2011;127:1433-7
Evans DM (*see* Wan et al). 2011;127:223-31
Evans MD (*see* Biagtan et al). 2011;127:1626-7 (Letter to the editor)
Evans MD (*see* Bush et al). 2011;127:974-81
Ezaki J (*see* Ushio et al). 2011;127:1267-76
Ezzati M (*see* Mushtaq et al). 2011;127:1236-42

F

Fahlberg B (*see* Bush et al). 2011;127:974-81
Fahy JV (*see* Commins et al). 2011;127:1286-93
Falk TM (*see* Kasperkiewicz et al). 2011;127:267-70 (Letter to the Editor)

Fan Y, Chen S, Qu X, Zuo K, Li X, Huang J, Xu G, Mi J, Li H. A lower prevalence of asthma among patients with chronic rhinosinusitis in southern China. 2011;127:521-2 (Letter to the Editor)
Fan Y, Xia W, Liu W, Chen R, Li X, Xu R, Xu G, Shi J, Li H. Increased nasal IL-5 levels act as a predisposing factor of asthma in southern China. 2011;127:1312 (Correspondence)
Farid M (*see* Sato et al). 2011;127:1595-603
Farrar J (*see* Chipps et al). 2011;127:1640-1 (Correspondence)
Farrell J (*see* Elsheikh et al). 2011;127:1543-51
Feinberg J (*see* Lugo Reyes et al). 2011;127:543-4 (Letter to the Editor)
Fekete A (*see* Gilles et al). 2011;127:454-61
Fellay B (*see* Caubet et al). 2011;127:218-22
Feng C (*see* Laidlaw et al). 2011;127:815-22
Feng JY (*see* Meltzer et al). 2011;127:167-72
Fenton MJ (*see* Busse et al). 2011;127:130-7
Ferreira F (*see* Wallner et al). 2011;127:1571-8
Ferrer M, Gamboa P, Sanz ML, Goikoetxea MJ, Cabrera-Freitag P, Javaloyes G, Berroa F, Kaplan AP. Omalizumab is effective in nonautoimmune urticaria. 2011;127:1300-2 (Letter to the Editor)
Ferrua F (*see* Grunebaum et al). 2011;127:1417-9 (Letter to the Editor)
Ferrua F (*see* Selleri et al). 2011;127:1368-75
Ferry B (*see* Orange et al). 2011;127:1360-7
Ferstl R (*see* Fujita et al). 2011;127:1612-21
Fieschi C (*see* Vince et al). 2011;127:538-41 (Letter to the Editor)
Filipiak-Pittroff B (*see* Koletzko et al). 2011;127:836-8 (Correspondence)
Finetti F (*see* Paccani et al). 2011;127:1635-7 (Letter to the Editor)
Finkelman F (*see* Broide et al). 2011;127:689-95
Finkelman FD (*see* Strait et al). 2011;127:982-89
Fischer A (*see* Lugo Reyes et al). 2011;127:543-4 (Letter to the Editor)
Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. Gene therapy for primary adaptive immune deficiencies. 2011;127:1356-9
Fish JE (*see* Corren et al). 2011;127:398-405
Fitzpatrick AM (*see* Busse et al). 2011;127:130-7
Fitzpatrick AM (*see* Holguin et al). 2011;127:1486-93
Fitzpatrick AM (*see* Li et al). 2011;127:1457-65
Fitzpatrick AM (*see* Sorkness et al). 2011;127:1073-4 (Letter to the Editor)
Fitzpatrick AM, Stephenson ST, Hadley GR, Burwell L, Penugonda M, Simon DM, Hansen J, Jones DP, Brown LAS. Thiol redox disturbances in children with severe asthma are associated with posttranslational modification of the transcription factor nuclear factor (erythroid-derived 2)–like 2. 2011;127:1604-11
Fitzpatrick AM, Teague WG, Meyers DA, Peters SP, Li X, Li H, Wenzel SE, Aujla S, Castro M, Bacharier LB, Gaston BM, Bleecker ER, Moore WC. Heterogeneity of severe asthma in childhood: Confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. 2011;127:382-9
Fitzpatrick AM, Teague WG. Progressive airflow limitation is a feature of children with severe asthma. 2011;127:282-4 (Letter to the Editor)
FitzPatrick S (*see* Thamrin et al). 2011;127:1494-502
Flader K (*see* Arias et al). 2011;127:1552-61
Flood TJ (*see* Slatter et al). 2011;127:533-5 (Letter to the Editor)
Flynn TH. Identifying seasonal variation in allergic rhinoconjunctivitis. 2011;127:1314-5 (Correspondence)
Focke-Tejkl M (*see* Niespodziana et al). 2011;127:1562-70
Focke-Tejkl M (*see* Valenta et al). 2011;127:860-4
Fölster-Holst R (*see* Naumann et al). 2011;127:1187-94
Fonseca J (*see* Bousquet et al). 2011;127:49-56
Fontana E (*see* Bosticardo et al). 2011;127:1376-84
Forno E, Lescher R, Strunk R, Weiss S, Fuhlbrigge A, Celedón JC. Decreased response to inhaled steroids in overweight and obese asthmatic children. 2011;127:741-9
Forsberg A (*see* Tulic et al). 2011;127:470-8
Frambach Y (*see* Kasperkiewicz et al). 2011;127:267-70 (Letter to the Editor)
Franciosi JP (*see* Blanchard et al). 2011;127:208-17
Francis JN (*see* James et al). 2011;127:509-16
Franke A (*see* Naumann et al). 2011;127:1187-94
Frati F, Incorvaia C, Scurati S, Sensi L, Marcucci F. Dose-dependence of sublingual immunotherapy shown by meta-analysis. 2011;127:1076-7 (Correspondence)
Fredrick L (*see* Simões et al). 2011;127:293 (Correspondence)
Freeman T (*see* Golden et al). 2011;127:852-74
Frei R (*see* Roduit et al). 2011;127:179-85
Frey U (*see* Leonardi et al). 2011;127:1466-72
Frey U (*see* Thamrin et al). 2011;127:1494-502
Freyschmidt E-J (*see* Mathias et al). 2011;127:795-805
Frieling T (*see* Molderings et al). 2011;127:1311 (Correspondence)
Fritsche P (*see* Le et al). 2011;127:677-9 (Letter to the Editor)
Fryer AD (*see* Kaufman et al). 2011;127:462-9
Fuchs T (*see* Buhl et al). 2011;127:284-5 (Letter to the Editor)
Fuhlbrigge A (*see* Forno et al). 2011;127:741-9
Fuhlbrigge AL. Predicting asthma exacerbations: Peak expiratory flow revisited. 2011;127:1503-4 (Editorial)
Fujita H (*see* Akdis et al). 2011;127:701-21
Fujita H (*see* Jung et al). 2011;127:420-9
Fujita H, Chalubinski M, Rhyner C, Indermitte P, Meyer N, Ferstl R, Treis A, Gomez E, Akkaya A, O'Mahony L, Akdis M, Akdis CA. Claudin-1 expression in airway smooth muscle exacerbates airway remodeling in asthmatic subjects. 2011;127:1612-21
Fujiwara T (*see* Okano et al). 2011;127:277-9 (Letter to the Editor)
Fukuie T (*see* Nomura et al). 2011;127:685-8 (Letter to the Editor)
Fukutomi Y, Itagaki Y, Taniguchi M, Saito A, Yasueda H, Nakazawa T, Hasegawa M, Nakamura H, Akiyama K.

Rhinoconjunctival sensitization to hydrolyzed wheat protein in facial soap can induce wheat-dependent exercise-induced anaphylaxis. 2011;127:531-3 (Letter to the Editor)

G

Gaeta F (*see* Alonzi et al). 2011;127:1627-9 (Letter to the Editor)
Gaeta F (*see* Romano et al). 2011;127:1638 (Correspondence)
Gaffin JM, Israel E, Phipatanakul W. The effect of prophylactic palivizumab on recurrent wheezing in children with an atopic family history. 2011;127:292-3 (Correspondence)
Gallo RL (*see* De Benedetto et al). 2011;127:773-86
Gamboa P (*see* Ferrer et al). 2011;127:1300-2 (Letter to the Editor)
Gao P-S (*see* Leung et al). 2011;127:965-73
García BE (*see* Tabar et al). 2011;127:57-63
Garcia-Lloret M (*see* Mathias et al). 2011;127:795-805
Garg ML (*see* Wood et al). 2011;127:1133-40
Gaspar HB (*see* Bacchelli et al). 2011;127:1253-9
Gaspar HB. Induced pluripotent stem cells and primary immunodeficiencies: A new frontier reached, a new world beyond? 2011;127:1408-9 (Editorial)
Gaston B (*see* Busse et al). 2011;127:130-7
Gaston B (*see* Holguin et al). 2011;127:1486-93
Gaston B (*see* Li et al). 2011;127:1457-65
Gaston BM (*see* Fitzpatrick et al). 2011;127:382-9
Gavanescu L (*see* Baroody et al). 2011;127:927-34
Gawchik S (*see* Blaiss et al). 2011;127:64-71
Gebretsadik T (*see* Miller et al). 2011;127:883-91
Geha RS (*see* Massaad et al). 2011;127:998-1005
Gennery AR (*see* Pessach et al). 2011;127:1400-7
Gennery AR (*see* Slatter et al). 2011;127:533-5 (Letter to the Editor)
Genuneit J (*see* Ege et al). 2011;127:138-44
Georas SN (*see* De Benedetto et al). 2011;127:773-86
Georges M (*see* Bonniaud et al). 2011;127:295 (Correspondence)
Gergen PJ (*see* Salo et al). 2011;127:1226-35
Gergen PJ (*see* Wood et al). 2011;127:913-9
Gergen PJ. Surveillance of the cost of asthma in the 21st century. 2011;127:370-1 (Editorial)
Gerhard M (*see* Naumann et al). 2011;127:1187-94
Gern JE (*see* Wood et al). 2011;127:913-9
Geroldinger-Simic M, Zelniker T, Aberer W, Ebner C, Egger C, Greiderer A, Prem, MD N, Lidholm J, Ballmer-Weber BK, Vieths S, Bohle B. Birch pollen–related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG_4 antibodies. 2011;127:616-22
Gervaix A (*see* Caubet et al). 2011;127:218-22
Ghushchyan VH (*see* Sullivan et al). 2011;127:363-9
Gibson AM (*see* Sivaprasad et al). 2011;127:254-61
Gibson PG (*see* Baines et al). 2011;127:153-60
Gibson PG (*see* Wood et al). 2011;127:1133-40
Gielicz A (*see* Sanak et al). 2011;127:1141-7
Giles GG (*see* Martin et al). 2011;127:1473-9
Giliani S (*see* Massaad et al). 2011;127:998-1005
Giliani S (*see* Pessach et al). 2011;127:1400-7
Gilles S, Fekete A, Zhang X, Beck I, Blume C, Ring J, Schmidt-Weber C, Behrendt H, Schmitt-Kopplin P, Traidl-Hoffmann C. Pollen metabolome analysis reveals adenosine as a major regulator of dendritic cell–primed T_H cell responses. 2011;127:454-61
Gilman RH (*see* Baumann et al). 2011;127:875-82
Giordano-Labadie F (*see* Hennino et al). 2011;127:1064-7 (Letter to the Editor)
Glessner JT (*see* Orange et al). 2011;127:1360-7
Globe D (*see* Meltzer et al). 2011;127:167-72
Globe DR (*see* Sullivan et al). 2011;127:363-9
Goikoetxea MJ (*see* Ferrer et al). 2011;127:1300-2 (Letter to the Editor)
Gold DR (*see* Ly et al). 2011;127:1087-94
Gold DR (*see* Sordillo et al). 2011;127:1165-72
Gold DR (*see* Wood et al). 2011;127:913-9
Goldberg MR (*see* Katz et al). 2011;127:289-90 (Correspondence)
Goldberg MR (*see* Katz et al). 2011;127:647-53
Goldberg MR (*see* Katz et al). 2011;127:839-40 (Correspondence)
Goldberg R (*see* Newell et al). 2011;127:517-19 (Letter to the Editor)
Golden DBK, Moffitt J, Nicklas RA, Freeman T, Graft DF, Reisman RE, Tracy JM, Bernstein D, Blessing-Moore J, Cox L, Khan DA, Lang DM, Oppenheimer J, Portnoy JM, Randolph C, Schuller DE, Spector SL, Tilles SA, Wallace D. Stinging insect hypersensitivity: A practice parameter update 2011. 2011;127:852-4
Goleniewska K (*see* Newcomb et al). 2011;127:1006-13
Gomez A (*see* Baumann et al). 2011;127:875-82
Gomez E (*see* Akdis et al). 2011;127:701-21
Gomez E (*see* Fujita et al). 2011;127:1612-21
Gonsalves N (*see* Hsu Blatman et al). 2011;127:1307-8 (Letter to the Editor)
Goodnow CC (*see* Altin et al). 2011;127:1277-85
Graft DF (*see* Golden et al). 2011;127:852-4
Grainge C (*see* Cakebread et al). 2011;127:1148-54
Granell R (*see* Savenije et al). 2011;127:1505-12
Grazia Roncarolo M (*see* Selleri et al). 2011;127:1368-75
Greenberger PA (*see* Lötvall et al). 2011;127:355-60
Greiderer A (*see* Geroldinger-Simic et al). 2011;127:616-22
Greve J (*see* Dumitru et al). 2011;127:1515-21
Grigg J (*see* Mushtaq et al). 2011;127:1236-44
Grigoryev DN (*see* Leung et al). 2011;127:965-73
Grimbacher B (*see* Chua et al). 2011;127:1410-1 (Letter to the Editor)
Grishina G (*see* Chawla et al). 2011;127:680-2 (Letter to the Editor)
Grönlund H (*see* Arkestål et al). 2011;127:1024-8
Grönlund H (*see* Niespodziana et al). 2011;127:1562-70
Groothuis JR (*see* Simões et al). 2011;127:293 (Correspondence)
Grossman W (*see* Accetta et al). 2011;127:535-8 (Letter to the Editor)
Grübl A (*see* Koletzko et al). 2011;127:836-8 (Correspondence)

Grunebaum E (*see* Newell et al). 2011;127:517-9 (Letter to the Editor)
Grunebaum E, Chung CT-S, Dadi H, Kim P, Brigida I, Ferrua F, Cicalese MP, Aiuti A, Roifman CM. Purine metabolism, immune reconstitution, and abdominal adipose tumor after gene therapy for adenosine deaminase deficiency. 2011;127:1417-9 (Letter to the Editor)
Gu W (*see* Chinen et al). 2011;127:1579-86
Guida G (*see* Bucca et al). 2011;127:412-9
Günther C (*see* Hänsel et al). 2011;127:787-94
Gurish MF (*see* Mathias et al). 2011;127:795-805
Gurrin L (*see* Martin et al). 2011;127:1473-9
Gurrin LC (*see* Osborne et al). 2011;127:668-76
Gut I (*see* Ege et al). 2011;127:138-44
Guttman-Yassky E (*see* Suárez-Fariñas et al). 2011;127:954-64
Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis—Part I: Clinical and pathologic concepts. 2011;127:1110-8
Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis—Part II: Immune cell subsets and therapeutic concepts. 2011;127:1420-32

H

Håberg SE, London SJ, Nafstad P, Nilsen RM, Ueland PM, Vollset SE, Nystad W. Maternal folate levels in pregnancy and asthma in children at age 3 years. 2011;127:262-4 (Letter to the Editor)
Habes D (*see* Maarof et al). 2011;127:1296-8 (Letter to the Editor)
Hacein-Bey-Abina S (*see* Fischer et al). 2011;127:1356-9
Hadley GR (*see* Fitzpatrick et al). 2011;127:1604-11
Häfner D (*see* Cromwell et al). 2011;127:865-72
Hafner RP (*see* Worm et al). 2011;127:89-97
Haiderer D (*see* Schmetterer et al). 2011;127:238-45
Hakonarson H (*see* Orange et al). 2011;127:1360-7
Halayko AJ (*see* Chang et al). 2011;127:1046-53
Hall CF (*see* Bin et al). 2011;127:430-8
Hall IP (*see* Wan et al). 2011;127:223-31
Hall L (*see* Mushtaq et al). 2011;127:1236-42
Halonen M (*see* Custovic et al). 2011;127:390-7
Hambleton S (*see* Slatter et al). 2011;127:533-5 (Letter to the Editor)
Hamid Q (*see* Chang et al). 2011;127:1046-53
Hamid Q (*see* Roussel et al). 2011;127:1632-4 (Letter to the Editor)
Hamilton RG (*see* An et al). 2011;127:1440-6
Hamilton RG. Reply. 2011;127:547-8 (Correspondence)
Hanakawa Y (*see* Dai et al). 2011;127:806-814
Hanifin JM (*see* De Benedetto et al). 2011;127:773-86
Hanifin JM (*see* Leung et al). 2011;127:965-73
Hankin CS (*see* Lockey et al). 2011;127:39-43
Hankin CS, Lockey RF. Patient characteristics associated with allergen immunotherapy initiation and adherence. 2011;127:46-8
Hankinson J (*see* Custovic et al). 2011;127:390-7
Hanna S, Etzoni A. New host defense mechanisms against *Candida* species clarify the basis of clinical phenotypes. 2011;127:1433-7
Hänsel A, Günther C, Ingwersen J, Starke J, Schmitz M, Bachmann M, Meurer M, Rieber EP, Schäkel K. Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong T_H17/T_H1 T-cell responses. 2011;127:787-94
Hansel NN (*see* Baumann et al). 2011;127:875-82
Hansen J (*see* Fitzpatrick et al). 2011;127:1604-11
Hara M (*see* Nakamura et al). 2011;127:1038-45
Harama D (*see* Nakamura et al). 2011;127:1038-45
Harbeck R (*see* Accetta et al). 2011;127:535-8 (Letter to the Editor)
Harde V (*see* Naumann et al). 2011;127:1187-94
Harder J (*see* Chipps et al). 2011;127:1640-1 (Correspondence)
Hargreave FE (*see* Nair et al). 2011;127:834 (Correspondence)
Harmancı K (*see* Razi et al). 2011;127:1078-9 (Correspondence)
Harrer A (*see* Wallner et al). 2011;127:1571-8
Hartert TV (*see* Miller et al). 2011;127:883-91
Haruna T (*see* Okano et al). 2011;127:277-9 (Letter to the Editor)
Hasegawa M (*see* Fukutomi et al). 2011;127:531-3 (Letter to the Editor)
Hashimoto K (*see* Dai et al). 2011;127:806-814
Hata T (*see* De Benedetto et al). 2011;127:773-86
Hata TR (*see* Leung et al). 2011;127:965-73
Hauser M (*see* Wallner et al). 2011;127:1571-8
Havstad S (*see* Wegienka et al). 2011;127:287-8 (Correspondence)
Havstad SL (*see* Joseph et al). 2011;127:1203-10
Hawkins GA (*see* Li et al). 2011;127:1457-65
Healey D (*see* Worm et al). 2011;127:89-97
Hedayat M (*see* Rezaei et al). 2011;127:1329-41
Heederik D (*see* Ege et al). 2011;127:138-44
Heffler E (*see* Bucca et al). 2011;127:412-9
Hegde P (*see* Maddur et al). 2011;127:823-30
Heil L (*see* Miller et al). 2011;127:883-91
Heinrich J (*see* Koletzko et al). 2011;127:836-8 (Correspondence)
Hemminki K (*see* Ludvigsson et al). 2011;127:1071-3 (Letter to the Editor)
Henderson J (*see* Brown et al). 2011;127:661-8
Henderson J (*see* Savenije et al). 2011;127:1505-12
Henderson J (*see* Wan et al). 2011;127:223-31
Hennino A (*see* Vanbervliet et al). 2011;127:943-53
Hennino A, Jean-Decoster C, Giordano-Labadie F, Debeer S, Vanbervliet B, Rozières A, Schmitt A-M, Nicolas J-F. $CD8^+$ T cells are recruited early to allergen exposure sites in atopy patch test reactions in human atopic dermatitis. 2011;127:1064-7 (Letter to the Editor)
Herbigneaux R-M (*see* Lugo Reyes et al). 2011;127:543-4 (Letter to the Editor)
Hernandez JE (*see* Baumann et al). 2011;127:875-82
Herrera R (*see* Rondón et al). 2011;127:1069-71 (Letter to the Editor)

Hess L (*see* Dumitru et al). 2011;127:1515-21
Hetherington Simpson K (*see* DeLong et al). 2011;127:1211-18
Heyman E (*see* Katz et al). 2011;127:839-40 (Correspondence)
Hiegel A (*see* Varshney et al). 2011;127:654-60
Higaki T (*see* Okano et al). 2011;127:277-9 (Letter to the Editor)
Hillyer EV (*see* Price et al). 2011;127:835-6 (Correspondence)
Himes BE, Klanderman B, Kohane IS, Weiss ST. Assessing the reproducibility of asthma genome-wide association studies in a general clinical population. 2011;127:1067-9 (Letter to the Editor)
Himly M (*see* Wallner et al). 2011;127:1571-8
Hindersin S (*see* Dumitru et al). 2011;127:1515-27
Hirakawa S (*see* Dai et al). 2011;127:806-814
Hirano I (*see* Hsu Blatman et al). 2011;127:1307-8 (Letter to the Editor)
Hirata K (*see* Kanazawa et al). 2011;127:899-904
Ho C-Y (*see* Liu et al). 2011;127:1014-23
Hobday J (*see* Houliston et al). 2011;127:98-9
Hobson SA (*see* Mathias et al). 2011;127:792-802
Hodder M (*see* Tulic et al). 2011;127:470-8
Hoekstra MO (*see* Wijga et al). 2011;127:275-7 (Letter to the Editor)
Hoesli S (*see* Simon et al). 2011;127:194-9
Hoffman E (*see* Sordillo et al). 2011;127:1165-72
Hoffmann-Sommergruber K (*see* Le et al). 2011;127:677-9 (Letter to the Editor)
Hofmann SC, Pfender N, Weckesser S, Huss-Marp J, Jakob T. Added value of IgE detection to rApi m 1 and rVes v 5 in patients with Hymenoptera venom allergy. 2011;127:265-7 (Letter to the Editor)
Hogan S (*see* Strait et al). 2011;127:982-9
Holgate ST (*see* Cakebread et al). 2011;127:1148-54
Holguin F, Bleecker ER, Busse WW, Calhoun WJ, Castro M, Erzurum SC, Fitzpatrick AM, Gaston B, Israel E, Jarjour NN, Moore WC, Peters SP, Yonas M, Teague WG, Wenzel SE. Obesity and asthma: An association modified by age of asthma onset. 2011;127:1486-93
Holland SM (*see* Kang et al). 2011;127:1319-26
Hollenbeak CS (*see* Wang et al). 2011;127:161-6
Holloway JW (*see* Wan et al). 2011;127:223-31
Holm J, Willumsen N, Würtzen PA, Christensen LH, Lund K. Facilitated antigen presentation and its inhibition by blocking IgG antibodies depends on IgE repertoire complexity. 2011;127:1029-37
Holt PG (*see* Custovic et al). 2011;127:1480-5
Holt RJ, Zhang Y, Binia A, Dixon AL, Vandiedonck C, Cookson WO, Knight JC, Moffatt MF. Allele-specific transcription of the asthma-associated PHD finger protein 11 gene *(PHF11)* modulated by octamer-binding transcription factor 1 (Oct-1). 2011;127:1054-62
Holtappels G (*see* Bachert et al). 2011;127:1313-4 (Correspondence)
Homann J (*see* Molderings et al). 2011;127:1311 (Correspondence)
Hoppin JA (*see* Salo et al). 2011;127:1226-35
Horak E (*see* Ege et al). 2011;127:138-44
Hore-Lacy F (*see* Chen et al). 2011;127:1414-7 (Letter to the Editor)
Horn PC, Belohradsky BH, Urban C, Weber-Mzell D, Meindl A, Schuster V. Two new families with X-linked inhibitor of apoptosis deficiency and a clinical review of all 26 published. 2011;127:544-6 (Letter to the Editor)
Hoshina H (*see* Nomura et al). 2011;127:685-8 (Letter to the Editor)
Hoskins A (*see* Dworski et al). 2011;127:1260-6
Hosokawa S (*see* Nomura et al). 2011;127:685-8 (Letter to the Editor)
Hou C (*see* Orange et al). 2011;127:1360-7
Houliston L, Nolan R, Noble V, Pascoe E, Hobday J, Loh R, Mallon D. Honeybee venom immunotherapy in children using a 50-μg maintenance dose. 2011;127:98-9
Hourihane JO'B (*see* Brown et al). 2011;127:661-8
Hourihane JO'B (*see* DunnGalvin et al). 2011;127:633-9
Hovi P (*see* Siltanen et al). 2011;127:935-42
Howard TD (*see* Li et al). 2011;127:1457-65
Howarth PH (*see* Cakebread et al). 2011;127:1148-54
Howell MD (*see* Bin et al). 2011;127:430-8
Howell MD (*see* Leung et al). 2011;127:965-73
Hoyte L (*see* Nadeau et al). 2011;127:1622-4 (Letter to the Editor)
Hsu Blatman KS, Gonsalves N, Hirano I, Bryce PJ. Expression of mast cell–associated genes is upregulated in adult eosinophilic esophagitis and responds to steroid or dietary therapy. 2011;127:1307-8 (Letter to the Editor)
Huang J (*see* Fan et al). 2011;127:521-2 (Letter to the Editor)
Huang YJ, Nelson CE, Brodie EL, DeSantis TZ, Baek MS, Liu J, Woyke T, Allgaier M, Bristow J, Wiener-Kronish JP, Sutherland ER, King TS, Icitovic N, Martin RJ, Calhoun WJ, Castro M, Denlinger LC, DiMango E, Kraft M, Peters SP, Wasserman SI, Wechsler ME, Boushey HA, Lynch SV. Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. 2011;127:372-81
Huber H (*see* Valenta et al). 2011;127:860-4
Huckabee MM (*see* Newcomb et al). 2011;127:1006-13
Hull PR (*see* Brown et al). 2011;127:661-8
Humbles AA (*see* Arias et al). 2011;127:1552-61
Hünecke P (*see* Buhl et al). 2011;127:284-5 (Letter to the Editor)
Huss-Marp J (*see* Hofmann et al). 2011;127:265-7 (Letter to the Editor)
Huttenlocher A (*see* Accetta et al). 2011;127:535-8 (Letter to the Editor)
Hylkema MN (*see* Melgert et al). 2011;127:831-3 (Letter to the Editor)

I

Ibañez MD (*see* Vereda et al). 2011;127:603-7
Ichimaru Y (*see* Kanazawa et al). 2011;127:899-904
Ichimura Y (*see* Ushio et al). 2011;127:1267-76
Icitovic N (*see* Huang et al). 2011;127:372-81
Illi S (*see* Lluis et al). 2011;127:1587-94
Illig T (*see* Naumann et al). 2011;127:1187-94
Incorvaia C (*see* Frati et al). 2011;127:1076-7 (Correspondence)

Indermitte P (*see* Fujita et al). 2011;127:1612-21
Ingwersen J (*see* Hänsel et al). 2011;127:787-94
Irvin CG (*see* Clerisme-Beaty et al). 2011;127:406-11
Irvine AD (*see* Brown et al). 2011;127:661-8
Ishii T (*see* Ushio et al). 2011;127:1267-76
Ishimaru K (*see* Nakamura et al). 2011;127:1038-45
Israel E (*see* Gaffin et al). 2011;127:292-3 (Correspondence)
Israel E (*see* Holguin et al). 2011;127:1486-93
Israel E (*see* Li et al). 2011;127:1457-65
Israel E (*see* Price et al). 2011;127:835-6 (Correspondence)
Itagaki Y (*see* Fukutomi et al). 2011;127:531-3 (Letter to the Editor)
Ito Y (*see* Nomura et al). 2011;127:685-8 (Letter to the Editor)
Ivanov AI (*see* De Benedetto et al). 2011;127:773-86

J

Jacobson MR (*see* James et al). 2011;127:509-16
Jacoby DB (*see* Kaufman et al). 2011;127:462-9
Jacquemin E (*see* Maarof et al). 2011;127:1296-8 (Letter to the Editor)
Jahn-Schmid B (*see* Schmetterer et al). 2011;127:238-45
Jakob T (*see* Hofmann et al). 2011;127:265-7 (Letter to the Editor)
James EA (*see* DeLong et al). 2011;127:1211-18
James HR (*see* Commins et al). 2011;127:1286-93
James LK, Shamji MH, Walker SM, Wilson DR, Wachholz PA, Francis JN, Jacobson MR, Kimber I, Till SJ, Durham SR. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. 2011;127:509-16
Jameson SC (*see* Blanchard et al). 2011;127:208-17
Jansen MH (*see* Kuijpers et al). 2011;127:1411-4 (Letter to the editor)
Jaramillo R (*see* Salo et al). 2011;127:1226-35
Jariwala S (*see* Sharief et al). 2011;127:1195-202
Jarjour N (*see* Busse et al). 2011;127:130-7
Jarjour NN (*see* Holguin et al). 2011;127:1486-93
Jarjour NN (*see* Li et al). 2011;127:1457-65
Järvenpää A-L (*see* Siltanen et al). 2011;127:935-42
Javaloyes G (*see* Ferrer et al). 2011;127:1300-2 (Letter to the Editor)
Jean-Decoster C (*see* Hennino et al). 2011;127:1064-7 (Letter to the Editor)
Jee Y (*see* Jung et al). 2011;127:420-9
Jin Y (*see* Ma et al). 2011;127:1447-56
Johnson CC (*see* Joseph et al). 2011;127:1203-10
Johnson CC (*see* Wegienka et al). 2011;127:287-8 (Correspondence)
Joks R (*see* Silverberg et al). 2011;127:1180-6
Jones DP (*see* Fitzpatrick et al). 2011;127:1604-11
Jones SM (*see* Sampson et al). 2011;127:1309-10 (Letter to the Editor)
Jones SM (*see* Thyagarajan et al). 2011;127:291-2 (Correspondence)
Jones SM (*see* Varshney et al). 2011;127:654-60
Jones SM (*see* Vickery et al). 2011;127:576-84
Jordana M (*see* Arias et al). 2011;127:1552-61
Joseph CLM, Ownby DR, Havstad SL, Woodcroft KJ, Wegienka G, MacKechnie H, Zoratti E, Peterson EL, Johnson CC. Early complementary feeding and risk of food sensitization in a birth cohort. 2011;127:1203-10
Jung K, Tanaka A, Fujita H, Matsuda A, Oida K, Karasawa K, Okamoto N, Ohmori K, Jee Y, Shin T, Matsuda H. Peroxisome proliferator–activated receptor γ–mediated suppression of dendritic cell function prevents the onset of atopic dermatitis in NC/Tnd mice. 2011;127:420-9
Just N (*see* Vince et al). 2011;127:538-41 (Letter to the Editor)

K

Kabesch M (*see* Ege et al). 2011;127:138-44
Kabesch M (*see* Lluis et al). 2011;127:1587-94
Kabesch M (*see* Naumann et al). 2011;127:1187-94
Kabesch M (*see* Roduit et al). 2011;127:179-85
Kaczmarek J (*see* Kuna et al). 2011;127:502-8
Kainz JT (*see* Kränke et al). 2011;127:1645 (Correspondence)
Kaiser L (*see* Caubet et al). 2011;127:218-22
Kajantie E (*see* Siltanen et al). 2011;127:935-42
Kalali BN (*see* Naumann et al). 2011;127:1187-94
Kaliner M (*see* Chipps et al). 2011;127:1640-1 (Correspondence)
Kalogeromitros D (*see* Zhang et al). 2011;127:1522-31
Kamel J (*see* Sordillo et al). 2011;127:1165-72
Kamilaris J (*see* Kim et al). 2011;127:640-6
Kamilaris J (*see* Varshney et al). 2011;127:654-60
Kanai K (*see* Okano et al). 2011;127:277-9 (Letter to the Editor)
Kanaji N (*see* Sato et al). 2011;127:1595-603
Kanazawa H, Tochino Y, Kyoh S, Ichimaru Y, Asai K, Hirata K. Potential roles of pentosidine in age-related and disease-related impairment of pulmonary functions in patients with asthma. 2011;127:899-904
Kang EM, Marciano BE, DeRavin SS, Zarember KA, Holland SM, Malech HL. Chronic granulomatous disease: Overview and hematopoietic stem cell transplantation. 2011;127:1319-26
Kaplan AP (*see* Ferrer et al). 2011;127:1300-2 (Letter to the Editor)
Kapsenberg ML (*see* van der Aar et al). 2011;127:1532-40
Karasawa K (*see* Jung et al). 2011;127:420-9
Kariya S (*see* Okano et al). 2011;127:277-9 (Letter to the Editor)
Kasperkiewicz M, Schmidt E, Frambach Y, Rose C, Meier M, Nitschke M, Falk TM, Reich K, Ludwig RJ, Zillikens D. Improvement of treatment-refractory atopic dermatitis by immunoadsorption: A pilot study. 2011;127:267-70 (Letter to the Editor)
Kaszuba M (*see* Sanak et al). 2011;127:1141-7
Katoh R (*see* Nakamura et al). 2011;127:1038-45
Katsarou-Katsari A (*see* Zhang et al). 2011;127:1522-31
Kattan M (*see* Wood et al). 2011;127:913-9
Katz Y, Goldberg MR, Rajuan N, Cohen A, Leshno M. The prevalence and natural course of food protein–induced enterocolitis syndrome to cow's milk: A large-scale, prospective population-based study. 2011;127:647-53

Katz Y, Goldberg MR, Stein M, Levy M. Oral immunotherapy: Ready for prime time? 2011;127:289-90 (Correspondence)
Katz Y, Rajuan N, Goldberg MR, Eisenberg E, Heyman E, Cohen A, Leshno M. Reply. 2011;127:839-40 (Correspondence)
Kaufman EH, Fryer AD, Jacoby DB. Toll-like receptor 7 agonists are potent and rapid bronchodilators in guinea pigs. 2011;127:462-9
Kaul A (*see* Blanchard et al). 2011;127:208-17
Kaune KM (*see* Buhl et al). 2011;127:284-5 (Letter to the Editor)
Kaveri SV (*see* Maddur et al). 2011;127:823-30
Kay AB (*see* Worm et al). 2011;127:89-97
Kay AB. Calcitonin gene-related peptide– and vascular endothelial growth factor–positive inflammatory cells in late-phase allergic skin reactions in atopic subjects. 2011;127:232-7
Keeton D (*see* DunnGalvin et al). 2011;127:633-9
Kehagia V (*see* Cakebread et al). 2011;127:1148-54
Keith P, Lee LA. Fluticasone furoate nasal spray is the only intranasal corticosteroid to reduce the ocular symptoms of seasonal allergic rhinitis consistently. 2011;127:294 (Correspondence)
Kelly LA (*see* Commins et al). 2011;127:1286-93
Kemeny L (*see* Zimmermann et al). 2011;127:200-7
Kemp L (*see* Price et al). 2011;127:835-6 (Correspondence)
Kemper A (*see* Varshney et al). 2011;127:654-60
Kere J (*see* Naumann et al). 2011;127:1187-94
Kerkhof M (*see* Savenije et al). 2011;127:1505-12
Kerkhof M (*see* Savenije et al). 2011;127:750-6
Kerkhof M (*see* Wijga et al). 2011;127:275-7 (Letter to the Editor)
Kerstan A, Albert C, Klein D, Bröcker E-B, Trautmann A. Wasp venom immunotherapy induces activation and homing of $CD4^+CD25^+$ forkhead box protein 3–positive regulatory T cells controlling T_H1 responses. 2011;127:495-501
Khan D (*see* Spector et al). 2011;127:1641-2 (Correspondence)
Khan DA (*see* Golden et al). 2011;127:852-4
Khodoun M (*see* Strait et al). 2011;127:982-9
Khurana Hershey GK (*see* Newcomb et al). 2011;127:1006-13
Khurana Hershey GK (*see* Sivaprasad et al). 2011;127:254-61
Kim BE (*see* Bin et al). 2011;127:430-8
Kim CE (*see* Orange et al). 2011;127:1360-7
Kim EH, Bird JA, Kulis M, Laubach S, Pons L, Shreffler W, Steele P, Kamilaris J, Vickery B, Burks AW. Sublingual immunotherapy for peanut allergy: Clinical and immunologic evidence of desensitization. 2011;127:640-7
Kim M (*see* Sato et al). 2011;127:1595-603
Kim P (*see* Grunebaum et al). 2011;127:1417-9 (Letter to the Editor)
Kimber I (*see* James et al). 2011;127:509-16
King TS (*see* Huang et al). 2011;127:372-81
Kirkpatrick CH (*see* Borish et al). 2011;127:541-3 (Letter to the Editor)
Kirwan M (*see* Mushtaq et al). 2011;127:1236-42
Klanderman B (*see* Himes et al). 2011;127:1067-9 (Letter to the Editor)
Kleiman E (*see* Silverberg et al). 2011;127:1180-6
Klein D (*see* Kerstan et al). 2011;127:495-501
Kleine-Tebbe J (*see* Worm et al). 2011;127:89-97
Klenerman P (*see* Marashi et al). 2011;127:1385-93
Klenzner T (*see* Dumitru et al). 2011;127:1515-21
Klunker S (*see* Akdis et al). 2011;127:701-21
Knight JC (*see* Holt et al). 2011;127:1054-62
Knol EF (*see* van Hoffen et al). 2011;127:100-1 (Letter to the Editor)
Knulst AC (*see* Le et al). 2011;127:677-9 (Letter to the Editor)
Knulst AC (*see* van Hoffen et al). 2011;127:100-1 (Letter to the Editor)
Kocan KM (*see* Commins et al). 2011;127:1286-93
Koch J (*see* Naumann et al). 2011;127:1187-94
Kohan M, Muro AF, Bader R, Berkman N. The extra domain A of fibronectin is essential for allergen-induced airway fibrosis and hyperresponsiveness in mice. 2011;127:439-46
Kohane IS (*see* Himes et al). 2011;127:1067-9 (Letter to the Editor)
Kojima Y (*see* Ushio et al). 2011;127:1267-76
Koletzko S, Filipiak-Pittroff B, von Berg A, Grübl A, Heinrich J, Krämer U, Wichmann H-E, Bauer C-P, Reinhardt D, Berdel D. Supplementation with cow's milk at birth is not recommended. 2011;127:836-8 (Correspondence)
Kolls JK (*see* Newcomb et al). 2011;127:1006-13
Komatsu M (*see* Ushio et al). 2011;127:1267-76
Komazawa-Sakon S (*see* Ushio et al). 2011;127:1267-76
Kominami E (*see* Ushio et al). 2011;127:1267-76
Koplin JJ (*see* Osborne et al). 2011;127:668-76
Koppelman GH (*see* Savenije et al). 2011;127:1505-12
Koppelman GH (*see* Savenije et al). 2011;127:750-6
Koreck A (*see* Zimmermann et al). 2011;127:200-7
Kotz D, Simpson CR, Sheikh A. Incidence, prevalence, and trends of general practitioner–recorded diagnosis of peanut allergy in England, 2001 to 2005. 2011;127:623-30
Kraft M (*see* Huang et al). 2011;127:372-81
Krämer U (*see* Koletzko et al). 2011;127:836-8 (Correspondence)
Kränke B, Reiter H, Kainz JT, Arbab E. How to improve the safety of adrenaline (epinephrine) autoinjectors. 2011;127:1645 (Correspondence)
Krishnan JA, Schatz M, Apter AJ. A call for action: Comparative effectiveness research in asthma. 2011;127:123-7
Krueger JG (*see* Guttman-Yassky et al). 2011;127:1110-8
Krueger JG (*see* Guttman-Yassky et al). 2011;127:1420-32
Krueger JG (*see* Suárez-Fariñas et al). 2011;127:954-64
Krzysiek R (*see* Maarof et al). 2011;127:1296-8 (Letter to the Editor)
Kuehni CE (*see* Leonardi et al). 2011;127:1466-72
Kuehni CE (*see* Marquis et al). 2011;127:270-2 (Letter to the Editor)

Kuepper M (*see* Dreschler et al). 2011;127:487-94
Kugathasan S (*see* Orange et al). 2011;127:1360-7
Kuijpers TW, Baars PA, aan de Kerk DJ, Jansen MH, Dors N, van Lier RAW, Pals ST. Common variable immunodeficiency and hemophagocytic features associated with a *FAS* gene mutation. 2011;127:1411-4 (Letter to the editor)
Kulis M (*see* Kim et al). 2011;127:640-6
Kulis M (*see* Varshney et al). 2011;127:654-60
Kulis M, Li Y, Lane H, Pons L, Burks W. Single–tree nut immunotherapy attenuates allergic reactions in mice with hypersensitivity to multiple tree nuts. 2011;127:81-8
Kull I (*see* Naumann et al). 2011;127:1187-94
Kull I (*see* Rosenlund et al). 2011;127:1219-25
Kumar J (*see* Sharief et al). 2011;127:1195-202
Kuna P, Kaczmarek J, Kupczyk M. Efficacy and safety of immunotherapy for allergies to *Alternaria alternata* in children. 2011;127:502-8
Küng HJ (*see* Schmetterer et al). 2011;127:238-45
Kupczyk M (*see* Kuna et al). 2011;127:502-8
Kushner JP (*see* Blanchard et al). 2011;127:208-17
Kwan D (*see* Sordillo et al). 2011;127:1165-72
Kwok WW (*see* DeLong et al). 2011;127:1211-18
Kyoh S (*see* Kanazawa et al). 2011;127:899-904

L

la Marca G (*see* Azzari et al). 2011;127:1394-9
Lack G (*see* Brown et al). 2011;127:661-8
Lack G (*see* Sampson et al). 2011;127:1309-10 (Letter to the Editor)
Lacroix-Desmazes S (*see* Maddur et al). 2011;127:823-30
Lagos M (*see* Chua et al). 2011;127:1410-1 (Letter to the Editor)
Laidlaw TM, Steinke JW, Tiñana AM, Feng C, Xing W, Lam BK, Paruchuri S, Boyce JA, Borish L. Characterization of a novel human mast cell line that responds to stem cell factor and expresses functional FcεRI. 2011;127:815-22
Laidler P (*see* Worm et al). 2011;127:89-97
Lam BK (*see* Laidlaw et al). 2011;127:815-22
Lambert P (*see* Costa et al). 2011;127:920-6
Lane H (*see* Kulis et al). 2011;127:81-8
Lang D (*see* Spector et al). 2011;127:1641-2 (Correspondence)
Lang DM (*see* Golden et al). 2011;127:852-4
Lange NE, Bunyavanich S, Silberg JL, Canino G, Rosner BA, Celedón JC. Parental psychosocial stress and asthma morbidity in Puerto Rican twins. 2011;127:734-40
Lanier BQ (*see* Prenner et al). 2011;127:289 (Correspondence)
Larché M (*see* Worm et al). 2011;127:89-97
Larenas D (*see* Bousquet et al). 2011;127:49-56
Lathrop M (*see* Ege et al). 2011;127:138-44
Laubach S (*see* Kim et al). 2011;127:640-6
Laubach S (*see* McKinney et al). 2011;127:1629-32 (Letter to the Editor)
Lauener R (*see* Naumann et al). 2011;127:1187-94
Lauener R (*see* Roduit et al). 2011;127:179-85
Lavergne SN (*see* Elsheikh et al). 2011;127:1543-51
Lawson G (*see* Mathias et al). 2011;127:795-805
Le Bras S (*see* Massaad et al). 2011;127:998-1005
Le Cras TD (*see* Sivaprasad et al). 2011;127:254-61
Le T-M, Fritsche P, Bublin M, Oberhuber C, Bulley S, van Hoffen E, Ballmer-Weber BK, Knulst AC, Hoffmann-Sommergruber K. Differences in the allergenicity of 6 different kiwifruit cultivars analyzed by prick-to-prick testing, open food challenges, and ELISA. 2011;127:677-9 (Letter to the Editor)
Leb-Reichl VM (*see* Schmetterer et al). 2011;127:238-45
Ledford DK (*see* Simons et al). 2011;127:587-93
Lee AJ (*see* Price et al). 2011;127:835-6 (Correspondence)
Lee H-H (*see* Worm et al). 2011;127:89-97
Lee LA (*see* Keith et al). 2011;127:288-9 (Correspondence)
Leeman SE (*see* Zhang et al). 2011;127:1522-31
Lemaitre B (*see* Caubet et al). 2011;127:218-22
Lemanske RF Jr (*see* Lötvall et al). 2011;127:355-60
Lemanske RF Jr (*see* Simon et al). 2011;127:550 (Correspondence)
Lemanske RF Jr (*see* Wang et al). 2011;127:161-6
Leonardi NA, Spycher BD, Strippoli M-PF, Frey U, Silverman M, Kuehni CE. Validation of the Asthma Predictive Index and comparison with simpler clinical prediction rules. 2011;127:1466-72
Lescher R (*see* Forno et al). 2011;127:741-9
Leshno M (*see* Katz et al). 2011;127:647-53
Leshno M (*see* Katz et al). 2011;127:839-40 (Correspondence)
Leslie D (*see* Rachid et al). 2011;127:524-8 (Letter to the Editor)
Lester T (*see* Slatter et al). 2011;127:533-5 (Letter to the Editor)
Leung DYM (*see* Bin et al). 2011;127:430-8
Leung DYM (*see* Broccardo et al). 2011;127:186-93
Leung DYM (*see* De Benedetto et al). 2011;127:773-86
Leung DYM (*see* Durham et al). 2011;127:3-7
Leung DYM (*see* Sampson et al). 2011;127:1309-10 (Letter to the Editor)
Leung DYM (*see* Sicherer et al). 2011;127:326-35
Leung DYM, Gao P-S, Grigoryev DN, Rafaels NM, Streib JE, Howell MD, Taylor PA, Boguniewicz M, Canniff J, Armstrong B, Zaccaro DJ, Schneider LC, Hata TR, Hanifin JM, Beck LA, Weinberg A, Barnes KC. Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-γ response. 2011;127:965-73
Leung DYM, Szefler SJ. The Editors' choice. 2011;127: 128-9, 361-2, 722-3, 873-4, 1131-2, 1438-9
Leung DYM. Food allergy: Are we getting closer to a cure? 2011;127:555-7
Lev-Tov H (*see* Silverberg et al). 2011;127:1180-6
Levy M (*see* Katz et al). 2011;127:289-90 (Correspondence)
Li CW, Shi L, Zhang KK, Li TY, Lin ZB, Lim MK, McKeon F, Xian W, Wang DY. Role of p63/p73 in epithelial remodeling and their response to steroid treatment in nasal polyposis. 2011;127:765-72
Li H (*see* Fan et al). 2011;127:1312-3 (Correspondence)
Li H (*see* Fan et al). 2011;127:521-2 (Letter to the Editor)
Li H (*see* Fitzpatrick et al). 2011;127:382-9
Li H (*see* Li et al). 2011;127:1457-65

Li TY (*see* Li et al). 2011;127:765-72
Li X (*see* Fan et al). 2011;127:1312 (Correspondence)
Li X (*see* Fan et al). 2011;127:521-2 (Letter to the Editor)
Li X (*see* Fitzpatrick et al). 2011;127:382-9
Li X, Howard TD, Moore WC, Ampleford EJ, Li H, Busse WW, Calhoun WJ, Castro M, Chung KF, Erzurum SC, Fitzpatrick AM, Gaston B, Israel E, Jarjour NN, Teague WG, Wenzel SE, Peters SP, Hawkins GA, Bleecker ER, Meyers DA. Importance of hedgehog interacting protein and other lung function genes in asthma. 2011;127:1457-65
Li Y (*see* Kulis et al). 2011;127:81-8
Li Y (*see* Sato et al). 2011;127:1595-603
Liao H (*see* Brown et al). 2011;127:661-8
Licciardi PV (*see* Balloch et al). 2011;127:1080-1 (Correspondence)
Lidholm J (*see* Geroldinger-Simic et al). 2011;127:616-22
Liguori SA (*see* Monti et al). 2011;127:679-80 (Letter to the Editor)
Lim MK (*see* Li et al). 2011;127:765-72
Lima J (*see* Clerisme-Beaty et al). 2011;127:406-11
Lin P (*see* Bachert et al). 2011;127:1313-4 (Correspondence)
Lin S-L (*see* Meltzer et al). 2011;127:167-72
Lin S-L (*see* Sullivan et al). 2011;127:363-9
Lin ZB (*see* Li et al). 2011;127:765-72
Linehan M (*see* Arnoldussen et al). 2011;127:1081-2 (Correspondence)
Linehan M (*see* Arnoldussen et al). 2011;127:246-53
Linhart B (*see* Niespodziana et al). 2011;127:1562-70
Lipworth B (*see* Vaidyanathan et al). 2011;127:173-8
Liss GM (*see* Seth et al). 2011;127:275-7 (Letter to the Editor)
Liss GM, Murphy-Berendts K, Epstein T, Bernstein DI. Factors associated with severe versus mild immunotherapy-related systemic reactions: A case-referent study. 2011;127:1298-300 (Letter to the Editor)
Liston A (*see* Altin et al). 2011;127:1277-85
Litonjua A (*see* Ly et al). 2011;127:1087-94
Liu J (*see* Huang et al). 2011;127:372-81
Liu J (*see* Lluis et al). 2011;127:1587-94
Liu S (*see* Bachert et al). 2011;127:1313-4 (Correspondence)
Liu S-Y, Wang W-Z, Yen C-L, Tsai M-Y, Yang P-W, Wang J-Y, Ho C-Y, Shieh C-C. Leukocyte nicotinamide adenine dinucleotide phosphate-reduced oxidase is required for isocyanate-induced lung inflammation. 2011;127:1014-23
Liu W (*see* Fan et al). 2011;127:1312 (Correspondence)
Liu X (*see* Sato et al). 2011;127:1595-603
Liu Z (*see* Miller et al). 2011;127:883-91
Lluis A, Schedel M, Liu J, Illi S, Depner M, von Mutius E, Kabesch M, Schaub B. Asthma-associated polymorphisms in 17q21 influence cord blood *ORMDL3* and *GSDMA* gene expression and IL-17 secretion. 2011;127:1587-94
Locci M (*see* Bosticardo et al). 2011;127:1376-84
Lockey RF (*see* Hankin et al). 2011;127:46-8
Lockey RF, Hankin CS. Health economics of allergen-specific immunotherapy in the United States. 2011;127:39-43
Loeliger S (*see* Roduit et al). 2011;127:179-85
Loh R (*see* Houliston et al). 2011;127:98-9
Lommatzsch M (*see* Dreschler et al). 2011;127:487-94
London SJ (*see* Håberg et al). 2011;127:262-4 (Letter to the Editor)
Lopez-Exposito I (*see* Martos et al). 2011;127:990-7
Lötvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, Lemanske Jr RF, Wardlaw AJ, Wenzel SE, Greenberger PA. Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome. 2011;127:355-60
Lowe AJ (*see* Martin et al). 2011;127:1473-9
Lowe AJ (*see* Osborne et al). 2011;127:668-76
Loza MJ (*see* Silkoff et al). 2011;127:834 (Correspondence)
Lucas J (*see* DunnGalvin et al). 2011;127:633-9
Lucas M (*see* Orange et al). 2011;127:1360-7
Ludvigsson JF, Hemminki K, Wahlström J, Almqvist C. Celiac disease confers a 1.6-fold increased risk of asthma: A nationwide population-based cohort study. 2011;127:1071-3 (Letter to the Editor)
Ludwig RJ (*see* Kasperkiewicz et al). 2011;127:267-70 (Letter to the Editor)
Lugo Reyes SO, Suarez F, Herbigneaux R-M, Pacquement H, Réguerre Y, Rivière J-P, de Suremain M, Rose Y, Feinberg J, Malahoui N, Fischer A, Blanche S, Casanova J-L, Picard C, Bustamante J. Hodgkin lymphoma in 2 children with chronic granulomatous disease. 2011;127:543-4 (Letter to the Editor)
Lund K (*see* Holm et al). 2011;127:1029-37
Lupica MM (*see* Monti et al). 2011;127:679-80 (Letter to the Editor)
Lupski JR (*see* Chinen et al). 2011;127:1579-86
Luskin A (*see* Chipps et al). 2011;127:1640-1 (Correspondence)
Ly NP, Litonjua A, Gold DR, Celedón JC. Gut microbiota, probiotics, and vitamin D: Interrelated exposures influencing allergy, asthma, and obesity? 2011;127:1087-94
Lynch SV (*see* Huang et al). 2011;127:372-81

M

Ma J, Yang A, Qin W, Shi Y, Zhao B, Jin Y, Xie Y. Alleviating allergic airway diseases by means of short-term administration of IL-2 and dexamethasone. 2011;127:1447-56
Maarof G, Krzysiek R, Décline J-L, Cohen J, Habes D, Jacquemin E. Management of post–liver transplant–associated IgE-mediated food allergy in children. 2011;127:1296-8 (Letter to the Editor)
MacGinnitie A (*see* Owens et al). 2011;127:264-5 (Letter to the Editor)
MacKechnie H (*see* Joseph et al). 2011;127:1203-10

Macy E. Penicillin allergy might not be very common in subjects with cephalosporin allergy. 2011;127:1638 (Correspondence)
Maddur MS, Vani J, Hegde P, Lacroix-Desmazes S, Kaveri SV, Bayry J. Inhibition of differentiation, amplification, and function of human T_H17 cells by intravenous immunoglobulin. 2011;127:823-30
Mahaffey S (*see* Broccardo et al). 2011;127:186-93
Mahler A (*see* Strait et al). 2011;127:982-9
Maillère B (*see* Worm et al). 2011;127:89-97
Majak P, Olszowiec-Chlebna M, Smejda K, Stelmach I. Vitamin D supplementation in children may prevent asthma exacerbation triggered by acute respiratory infection. 2011;127:1294-6 (Letter to the Editor)
Majak P, Stelmach I. Reply. 2011;127:286-7 (Correspondence)
Makihara S (*see* Okano et al). 2011;127:277-9 (Letter to the Editor)
Malahoui N (*see* Lugo Reyes et al). 2011;127:543-4 (Letter to the Editor)
Malech HL (*see* Kang et al). 2011;127:1319-26
Mallal SA (*see* Phillips et al). 2011;127:S60-6
Mallon D (*see* Houliston et al). 2011;127:98-9
Maloney J (*see* Blaiss et al). 2011;127:64-71
Maloney J (*see* Nelson et al). 2011;127:72-80
Malphettes M (*see* Vince et al). 2011;127:538-41 (Letter to the Editor)
Manno M (*see* Seth et al). 2011;127:272-5 (Letter to the Editor)
Manos PD (*see* Pessach et al). 2011;127:1400-7
Mansfield L (*see* Wasserman et al). 2011;127:290-1 (Correspondence)
Marashi SM, Raeiszadeh M, Workman S, Rahbar A, Soderberg-Naucler C, Klenerman P, Chee R, Webster AD, Milne RSB, Emery VC. Inflammation in common variable immunodeficiency is associated with a distinct $CD8^+$ response to cytomegalovirus. 2011;127:1385-93
Marciano BE (*see* Kang et al). 2011;127:1319-26
Marcucci F (*see* Frati et al). 2011;127:1076-7 (Correspondence)
Markert ML (*see* Chinn et al). 2011;127:1351-5
Marktel S (*see* Selleri et al). 2011;127:1368-75
Marquis A, Strippoli M-PF, Spycher BD, Rebholz CE, von der Weid NX, Kuehni CE. Paracetamol, nonsteroidal anti-inflammatory drugs, and risk of asthma in adult survivors of childhood cancer. 2011;127:270-2 (Letter to the Editor)
Marth K (*see* Valenta et al). 2011;127:860-4
Martin JG (*see* Chang et al). 2011;127:1046-53
Martin PE (*see* Osborne et al). 2011;127:668-76
Martin PE, Matheson MC, Gurrin L, Burgess JA, Osborne N, Lowe AJ, Morrison S, Mészáros D, Giles GG, Abramson MJ, Walters EH, Allen KJ, Dharmage SC. Childhood eczema and rhinitis predict atopic but not nonatopic adult asthma: A prospective cohort study over 4 decades. 2011;127:1473-9
Martin RJ (*see* Huang et al). 2011;127:372-81
Martin RJ (*see* Price et al). 2011;127:835-6 (Correspondence)
Martin S (*see* Tabar et al). 2011;127:57-63
Martinez FD (*see* Custovic et al). 2011;127:390-7
Martinez FD (*see* Wang et al). 2011;127:161-6
Martinez-Gallo M (*see* Chinen et al). 2011;127:1579-86
Martos G, Lopez-Exposito I, Bencharitiwong R, Cecilia Berin M, Nowak-Węgrzyn A. Mechanisms underlying differential food allergy response to heated egg. 2011;127:990-7
Massaad MJ, Ramesh N, Le Bras S, Giliani S, Notarangelo LD, Al-Herz W, Notarangelo LD, Geha RS. A peptide derived from the Wiskott-Aldrich syndrome (WAS) protein-interacting protein (WIP) restores WAS protein level and actin cytoskeleton reorganization in lymphocytes from patients with *WAS* mutations that disrupt WIP binding. 2011;127:998-1005
Massanari M, Nelson H, Casale T, Busse W. Reply. 2011;127:548 (Correspondence)
Masse M-S (*see* Bégin et al). 2011;127:1624-6 (Letter to the Editor)
Masthoff LJN (*see* Brown et al). 2011;127:661-7
Matheson MC (*see* Martin et al). 2011;127:1473-9
Matheson MC (*see* Osborne et al). 2011;127:668-76
Mathias CB, Hobson SA, Garcia-Lloret M, Lawson G, Poddighe D, Freyschmidt E-J, Xing W, Gurish MF, Chatila TA, Oettgen HC. IgE-mediated systemic anaphylaxis and impaired tolerance to food antigens in mice with enhanced IL-4 receptor signaling. 2011;127:795-805
Mathur SK (*see* Biagtan et al). 2011;127:1626-7 (Letter to the editor)
Matsuda A (*see* Jung et al). 2011;127:420-9
Matsuda H (*see* Jung et al). 2011;127:420-9
Matsui EC (*see* Arbes et al). 2011;127:1119-27
Matsumoto K (*see* Nomura et al). 2011;127:685-8 (Letter to the Editor)
Mauad T (*see* Andersson et al). 2011;127:905-12
Mauger DT (*see* Wang et al). 2011;127:161-6
Mayorga C (*see* Rondón et al). 2011;127:1069-71 (Letter to the Editor)
McCarthy S (*see* Tulic et al). 2011;127:470-8
McGirt LY (*see* De Benedetto et al). 2011;127:773-86
McKeever T (*see* Wan et al). 2011;127:223-31
McKeon F (*see* Li et al). 2011;127:765-72
McKinney KK, Webb L, Petersen M, Nelson M, Laubach S. Ovalbumin content of 2010-2011 influenza vaccines. 2011;127:1629-32 (Letter to the Editor)
McLean WHI (*see* Brown et al). 2011;127:661-7
McLoughlin RM, Mills KHG. Influence of gastrointestinal commensal bacteria on the immune responses that mediate allergy and asthma. 2011;127:1097-107
Mduluza T (*see* Arkestål et al). 2011;127:1024-8
Meaney C (*see* Slatter et al). 2011;127:533-5 (Letter to the Editor)
Meier M (*see* Kasperkiewicz et al). 2011;127:267-70 (Letter to the Editor)
Meiler F (*see* Zimmermann et al). 2011;127:200-7
Meindl A (*see* Horn et al). 2011;127:544-6 (Letter to the Editor)
Melamed ML (*see* Sharief et al). 2011;127:1195-202
Melén E (*see* Naumann et al). 2011;127:1187-94

Melgert BN, ten Hacken NH, Rutgers B, Timens W, Postma DS, Hylkema MN. More alternative activation of macrophages in lungs of asthmatic patients. 2011;127: 831-3 (Letter to the Editor)
Meltzer E (*see* Chipps et al). 2011;127:1640-1 (Correspondence)
Meltzer EO, Busse WW, Wenzel SE, Belozeroff V, Weng HH, Feng JY, Chon Y, Chiou C-F, Globe D, Lin S-L. Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbation. 2011;127:167-72
Mempel M (*see* Naumann et al). 2011;127:1187-94
Merk H (*see* Bousquet et al). 2011;127:49-56
Mészáros D (*see* Martin et al). 2011;127:1473-9
Metcalfe DD (*see* Akin et al). 2011;127:1311-2 (Correspondence)
Meurer M (*see* Hänsel et al). 2011;127:787-94
Meyer N (*see* Akdis et al). 2011;127:701-21
Meyer N (*see* Fujita et al). 2011;127:1612-21
Meyer N (*see* Zimmermann et al). 2011;127:200-7
Meyers DA (*see* Fitzpatrick et al). 2011;127:382-9
Meyers DA (*see* Li et al). 2011;127:1457-65
Meynberg HC (*see* Buhl et al). 2011;127:284-5 (Letter to the Editor)
Meyts I (*see* Bossuyt et al). 2011;127:1079-80 (Correspondence)
Mi J (*see* Fan et al). 2011;127:521-2 (Letter to the Editor)
Miao B (*see* Zhang et al). 2011;127:1522-31
Michalski J (*see* Sato et al). 2011;127:1595-603
Mietta S (*see* Bucca et al). 2011;127:412-9
Miller EK, Williams JV, Gebretsadik T, Carroll KN, Dupont WD, Mohamed YA, Morin L-L, Heil L, Minton PA, Woodward K, Liu Z, Hartert TV. Host and viral factors associated with severity of human rhinovirus–associated infant respiratory tract illness. 2011;127:883-91
Mills KHG (*see* McLoughlin et al). 2011;127:1097-107
Milne RSB (*see* Marashi et al). 2011;127:1385-93
Milner JD (*see* Datta et al). 2011;127:351-4
Milton DK (*see* Sordillo et al). 2011;127:1165-72
Miniati A (*see* Zhang et al). 2011;127:1522-31
Minton PA (*see* Miller et al). 2011;127:883-91
Mireku-Akomeah N (*see* Wasserman et al). 2011;127:290-1 (Correspondence)
Mitchell H (*see* Busse et al). 2011;127:130-7
Mitchell I (*see* Simões et al). 2011;127:293 (Correspondence)
Mockenhaupt M (*see* Phillips et al). 2011;127:S60-6
Moens L (*see* Bossuyt et al). 2011;127:1079-80 (Correspondence)
Moffatt MF (*see* Ege et al). 2011;127:138-44
Moffatt MF (*see* Holt et al). 2011;127:1054-62
Moffitt J (*see* Golden et al). 2011;127:852-4
Mohamed YA (*see* Miller et al). 2011;127:883-91
Molderings GJ, Homann J, Raithel M, Frieling T. Toward a global classification of mast cell activation diseases. 2011;127:1311 (Correspondence)
Monshi M (*see* Elsheikh et al). 2011;127:1543-51
Monti G, Castagno E, Liguori SA, Lupica MM, Tarasco V, Viola S, Tovo PA. Food protein–induced enterocolitis syndrome by cow's milk proteins passed through breast milk. 2011;127:679-80 (Letter to the Editor)
Moore WC (*see* Busse et al). 2011;127:130-7
Moore WC (*see* Fitzpatrick et al). 2011;127:382-9
Moore WC (*see* Holguin et al). 2011;127:1486-93
Moore WC (*see* Li et al). 2011;127:1457-65
Moqbel R (*see* Saude et al). 2011;127:757-64
Moretto A (*see* Bucca et al). 2011;127:412-9
Morgan K (*see* Brown et al). 2011;127:661-8
Morgan W (*see* Simon et al). 2011;127:550 (Correspondence)
Mori M (*see* Andersson et al). 2011;127:905-12
Morin L-L (*see* Miller et al). 2011;127:883-91
Morita H (*see* Nomura et al). 2011;127:685-8 (Letter to the Editor)
Moritz K (*see* Zimmermann et al). 2011;127:200-7
Morrison A (*see* Vaidyanathan et al). 2011;127:173-8
Morrison S (*see* Martin et al). 2011;127:1473-9
Mostoslavsky G (*see* Pessach et al). 2011;127:1400-7
Mouillot G (*see* Vince et al). 2011;127:538-41 (Letter to the Editor)
Mudway IS (*see* Mushtaq et al). 2011;127:1236-42
Mulholland EK (*see* Balloch et al). 2011;127:1080-1 (Correspondence)
Müller-Wehling K (*see* Naumann et al). 2011;127:1187-94
Muntner P (*see* Sharief et al). 2011;127:1195-202
Muro AF (*see* Kohan et al). 2011;127:439-46
Murphy-Berendts K (*see* Liss et al). 2011;127:1298-300 (Letter to the Editor)
Murray C (*see* Nicolaou et al). 2011;127:684-5 (Letter to the Editor)
Mushtaq N, Ezzati M, Hall L, Dickson I, Kirwan M, Png KMY, Mudway IS, Grigg J. Adhesion of *Streptococcus pneumoniae* to human airway epithelial cells exposed to urban particulate matter. 2011;127:1236-42
Mutschlechner S (*see* Wallner et al). 2011;127:1571-8

N

Naclerio RM (*see* Baroody et al). 2011;127:927-34
Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT. Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy. 2011;127:1622-4 (Letter to the Editor)
Nafstad P (*see* Håberg et al). 2011;127:262-4 (Letter to the Editor)
Nahum A, Dadi H, Bates A, Roifman CM. The L412F variant of Toll-like receptor 3 *(TLR3)* is associated with cutaneous candidiasis, increased susceptibility to cytomegalovirus, and autoimmunity. 2011;127:528-31 (Letter to the Editor)
Nair P, O'Byrne PM, Hargreave FE. Reply. 2011;127:834 (Correspondence)
Naisbitt DJ (*see* Elsheikh et al). 2011;127:1543-51
Naisbitt DJ (*see* Pichler et al). 2011;127:S74-81
Nakamura H (*see* Fukutomi et al). 2011;127:531-3 (Letter to the Editor)
Nakamura Y, Harama D, Shimokawa N, Hara M, Suzuki R, Tahara Y, Ishimaru K, Katoh R, Okumura K, Ogawa H, Shibata S, Nakao A. Circadian clock gene *Period2* regulates a time-of-day–dependent variation in cutaneous anaphylactic reaction. 2011;127:1038-45
Nakanishi M (*see* Sato et al). 2011;127:1595-603

Nakano H (*see* Ushio et al). 2011;127:1267-76
Nakao A (*see* Nakamura et al). 2011;127:1038-45
Nakazawa T (*see* Fukutomi et al). 2011;127:531-3 (Letter to the Editor)
Naldini L (*see* Bosticardo et al). 2011;127:1376-84
Nandy A (*see* Cromwell et al). 2011;127:865-72
Naumann A, Söderhäll C, Fölster-Holst R, Baurecht H, Harde V, Müller-Wehling K, Rodríguez E, Ruether A, Franke A, Wagenpfeil S, Novak N, Mempel M, Kalali BN, Allgaeuer M, Koch J, Gerhard M, Melén E, Wahlgren C-F, Kull I, Stahl C, Pershagen G, Lauener R, Riedler J, Doekes G, Scheynius A, Illig T, von Mutius E, Schreiber S, Kere J, Kabesch M, Weidinger S. A comprehensive analysis of the *COL29A1* gene does not support a role in eczema. 2011;127:1187-94
Nebel S (*see* Dumitru et al). 2011;127:1515-21
Nelson A (*see* Sato et al). 2011;127:1595-603
Nelson CE (*see* Huang et al). 2011;127:372-81
Nelson H (*see* Massanari et al). 2011;127:548 (Correspondence)
Nelson HS, Nolte H, Creticos P, Maloney J, Wu J, Bernstein DI. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. 2011;127:72-80
Nelson M (*see* McKinney et al). 2011;127:1629-32 (Letter to the Editor)
Neubauer A (*see* Valenta et al). 2011;127:860-4
Neunkirchner A (*see* Schmetterer et al). 2011;127:238-45
Newcomb DC, Boswell MG, Zhou W, Huckabee MM, Goleniewska K, Sevin CM, Khurana Hershey GK, Kolls JK, Peebles RS Jr. Human T_H17 cells express a functional IL-13 receptor and IL-13 attenuates IL-17A production. 2011;127:1006-13
Newell A, Dadi H, Goldberg R, Ngan B-Y, Grunebaum E, Roifman CM. Diffuse large B-cell lymphoma as presenting feature of Zap-70 deficiency. 2011;127:517-9 (Letter to the Editor)
Ngan B-Y (*see* Newell et al). 2011;127:517-9 (Letter to the Editor)
Nganga LW (*see* Commins et al). 2011;127:1286-93
Nguyen M (*see* Bégin et al). 2011;127:1624-6 (Letter to the Editor)
Nichols KE (*see* Rezaei et al). 2011;127:1329-41
Nicklas R (*see* Spector et al). 2011;127:1641-2 (Correspondence)
Nicklas RA (*see* Golden et al). 2011;127:852-4
Nicolaou N (*see* Custovic et al). 2011;127:631-3
Nicolaou N, Murray C, Belgrave D, Poorafshar M, Simpson A, Custovic A. Quantification of specific IgE to whole peanut extract and peanut components in prediction of peanut allergy. 2011;127:684-5 (Letter to the Editor)
Nicolaou NC (*see* Custovic et al). 2011;127:390-7
Nicolas J-F (*see* Hennino et al). 2011;127:1064-7 (Letter to the Editor)
Nicolas J-F (*see* Vanbervliet et al). 2011;127:943-53
Niederberger V (*see* Valenta et al). 2011;127:860-4
Niemiec MJ (*see* Bianchi et al). 2011;127:1243-52
Niespodziana K (*see* Valenta et al). 2011;127:860-4
Niespodziana K, Focke-Tejkl M, Linhart B, Civaj V, Blatt K, Valent P, van Hage M, Grönlund H, Valenta R. A hypoallergenic cat vaccine based on Fel d 1–derived peptides fused to hepatitis B PreS. 2011;127:1562-70
Nilsen RM (*see* Håberg et al). 2011;127:262-4 (Letter to the Editor)
Nishida K (*see* Ushio et al). 2011;127:1267-76
Nishizaki K (*see* Okano et al). 2011;127:277-9 (Letter to the Editor)
Nitschke M (*see* Kasperkiewicz et al). 2011;127:267-70 (Letter to the Editor)
Niyonsaba F (*see* Ushio et al). 2011;127:1267-76
Niżankowska-Mogilnicka E (*see* Sanak et al). 2011;127:1141-9
Noble V (*see* Houliston et al). 2011;127:98-9
Noda Y (*see* Okano et al). 2011;127:277-9 (Letter to the Editor)
Nograles K (*see* Suárez-Fariñas et al). 2011;127:954-64
Nograles KE (*see* Guttman-Yassky et al). 2011;127:1110-8
Nograles KE (*see* Guttman-Yassky et al). 2011;127:1420-32
Nolan R (*see* Houliston et al). 2011;127:98-9
Nolte H (*see* Blaiss et al). 2011;127:64-71
Nolte H (*see* Nelson et al). 2011;127:72-80
Nomura I, Morita H, Hosokawa S, Hoshina H, Fukuie T, Watanabe M, Ohtsuka Y, Shoda T, Terada A, Takamasu T, Arai K, Ito Y, Ohya Y, Saito H, Matsumoto K. Four distinct subtypes of non–IgE-mediated gastrointestinal food allergies in neonates and infants, distinguished by their initial symptoms. 2011;127:685-8 (Letter to the Editor)
Norbury G (*see* Slatter et al). 2011;127:533-5 (Letter to the Editor)
Northstone K (*see* Brown et al). 2011;127:661-8
Notarangelo LD (*see* Massaad et al). 2011;127:998-1005
Notarangelo LD (*see* Massaad et al). 2011;127:998-1005
Notarangelo LD (*see* Pessach et al). 2011;127:1344-50
Notarangelo LD (*see* Pessach et al). 2011;127:1400-7
Novak N (*see* De Benedetto et al). 2011;127:773-86
Novak N (*see* Naumann et al). 2011;127:1187-94
Nowak-Węgrzyn A (*see* Chawla et al). 2011;127:680-2 (Letter to the Editor)
Nowak-Węgrzyn A (*see* Martos et al). 2011;127:990-7
Nowak-Węgrzyn A, Sampson HA. Future therapies for food allergies. 2011;127:558-73
Nurmagambetov TA (*see* Barnett et al). 2011;127:145-52
Nurmatov U, Devereux G, Sheikh A. Nutrients and foods for the primary prevention of asthma and allergy: Systematic review and meta-analysis. 2011;127:724-35
Nutman TB (*see* Santiago et al). 2011;127:479-86
Nydegger R (*see* Thamrin et al). 2011;127:1494-502
Nystad W (*see* Håberg et al). 2011;127:262-4 (Letter to the Editor)

O

O'Mahony L (*see* Palomares et al). 2011;127:1541-2 (Editorial)
O'Byrne PM (*see* Nair et al). 2011;127:834 (Correspondence)
O'Hehir RE (*see* Prickett et al). 2011;127:608-15

Ober C (*see* Alvarado Arnez et al). 2011;127:279-82 (Letter to the Editor)
Oberhuber C (*see* Le et al). 2011;127:677-9 (Letter to the Editor)
Oettgen HC (*see* Arias et al). 2011;127:1552-61
Oettgen HC (*see* Mathias et al). 2011;127:795-805
Ogawa H (*see* Nakamura et al). 2011;127:1038-45
Ogawa H (*see* Ushio et al). 2011;127:1267-76
Ohmori K (*see* Jung et al). 2011;127:420-9
Ohta K (*see* Brożek et al). 2011;127:1643-5 (Correspondence)
Ohtsuka Y (*see* Nomura et al). 2011;127:685-8 (Letter to the Editor)
Ohya Y (*see* Nomura et al). 2011;127:685-8 (Letter to the Editor)
Oida K (*see* Jung et al). 2011;127:420-9
Okamoto N (*see* Jung et al). 2011;127:420-9
Okano M, Fujiwara T, Higaki T, Makihara S, Haruna T, Noda Y, Kanai K, Kariya S, Yasueda H, Nishizaki K. Characterization of pollen antigen–induced IL-31 production by PBMCs in patients with allergic rhinitis. 2011;127:277-9 (Letter to the Editor)
Oksenhendler E (*see* Vince et al). 2011;127:538-41 (Letter to the Editor)
Okumura K (*see* Nakamura et al). 2011;127:1038-45
Okumura K (*see* Ushio et al). 2011;127:1267-76
Olszowiec-Chlebna M (*see* Majak et al). 2011;127:1294-9 (Letter to the Editor)
Oppenheimer J (*see* Chipps et al). 2011;127:1640-1 (Correspondence)
Oppenheimer J (*see* Golden et al). 2011;127:852-4
Oppenheimer J (*see* Spector et al). 2011;127:1641-2 (Correspondence)
Opstelten D-JE (*see* van der Aar et al). 2011;127:1532-40
Orange JS, Glessner JT, Resnick E, Sullivan KE, Lucas M, Ferry B, Kim CE, Hou C, Wang F, Chiavacci R, Kugathasan S, Sleasman JW, Baldassano R, Perez EE, Chapel H, Cunningham-Rundles C, Hakonarson H. Genome-wide association identifies diverse causes of common variable immunodeficiency. 2011;127:1360-7
Ordovas-Montanes J (*see* Pessach et al). 2011;127:1400-7
Osborne N (*see* Martin et al). 2011;127:1473-9
Osborne NJ, Koplin JJ, Martin PE, Gurrin LC, Lowe AJ, Matheson MC, Ponsonby A-L, Wake M, Tang MLK, Dharmage SC, Allen KJ. Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants. 2011;127:668-76
O'Mahony L (*see* Akdis et al). 2011;127:701-21
O'Mahony L (*see* Fujita et al). 2011;127:1612-21
Owens G, MacGinnitie A. Higher-ovalbumin-content influenza vaccines are well tolerated in children with egg allergy. 2011;127:264-5 (Letter to the Editor)
Ownby DR (*see* Joseph et al). 2011;127:1203-10
Ownby DR (*see* Wegienka et al). 2011;127:287-8 (Correspondence)

P

Paccani SR, Benagiano M, Savino MT, Finetti F, Tonello F, D'Elios MM, Baldari CT. The adenylate cyclase toxin of *Bacillus anthracis* is a potent promoter of T_H17 cell development. 2011;127:1635-7 (Letter to the Editor)
Pacquement H (*see* Lugo Reyes et al). 2011;127:543-4 (Letter to the Editor)
Palmer CNA (*see* Brown et al). 2011;127:661-8
Palomares O (*see* Akdis et al). 2011;127:701-21
Palomares O (*see* Vereda et al). 2011;127:1304-7 (Letter to the Editor)
Palomares O, O'Mahony L, Akdis CA. The many routes of dendritic cells to ensure immune regulation. 2011;127:1541-2 (Editorial)
Pals ST (*see* Kuijpers et al). 2011;127:1411-4 (Letter to the editor)
Paradis J (*see* Bégin et al). 2011;127:1624-6 (Letter to the Editor)
Paradis L (*see* Bégin et al). 2011;127:1624-6 (Letter to the Editor)
Parent M-É (*see* El-Zein et al). 2011;127:1081 (Correspondence)
Park BK (*see* Elsheikh et al). 2011;127:1543-51
Park BK (*see* Pichler et al). 2011;127:S74-81
Park I-H (*see* Pessach et al). 2011;127:1400-7
Paruchuri S (*see* Laidlaw et al). 2011;127:815-22
Pascoe E (*see* Houliston et al). 2011;127:98-9
Pasmans SGMA (*see* Brown et al). 2011;127:661-8
Passalacqua G (*see* Bousquet et al). 2011;127:49-56
Passalacqua G (*see* Canonica et al). 2011;127:44-5
Patel D (*see* Corren et al). 2011;127:398-405
Paul E (*see* Chen et al). 2011;127:1414-7 (Letter to the Editor)
Paul IM (*see* Wang et al). 2011:127:161-6
Peckham D (*see* Elsheikh et al). 2011;127:1543-51
Peden DB, Bush RK. Advances in environmental and occupational respiratory disease in 2010. 2011;127:696-700
Peebles RS Jr (*see* Newcomb et al). 2011;127:1006-13
Peeters KABM (*see* van Hoffen et al). 2011;127:100-1 (Letter to the Editor)
Pekkanen J (*see* Roduit et al). 2011;127:179-85
Penugonda M (*see* Busse et al). 2011;127:130-7
Penugonda M (*see* Fitzpatrick et al). 2011;127:1604-11
Penugonda M (*see* Sorkness et al). 2011;127:1073-4 (Letter to the Editor)
Peralta M (*see* Vince et al). 2011;127:538-41 (Letter to the Editor)
Perez EE (*see* Orange et al). 2011;127:1360-7
Perry TT (*see* Varshney et al). 2011;127:654-60
Pershagen G (*see* Naumann et al). 2011;127:1187-94
Pershagen G (*see* Rosenlund et al). 2011;127:1219-25
Perzanowski MS (*see* Commins et al). 2011;127:1286-93
Pessach IM, Notarangelo LD. Gene therapy for primary immunodeficiencies: Looking ahead, toward gene correction. 2011;127:1344-50
Pessach IM, Ordovas-Montanes J, Zhang S-Y, Casanova J-L, Giliani S, Gennery AR, Al-Herz W, Manos PD, Schlaeger TM, Park I-H, Rucci F, Agarwal S, Mostoslavsky G, Daley GQ, Notarangelo LD. Induced pluripotent stem cells: A novel frontier in the study of human primary immunodeficiencies. 2011;127:1400-7
Petermann S (*see* Dreschler et al). 2011;127:487-94
Peters SP (*see* Busse et al). 2011;127:130-7

Peters SP (*see* Fitzpatrick et al). 2011;127:382-9
Peters SP (*see* Holguin et al). 2011;127:1486-93
Peters SP (*see* Huang et al). 2011;127:372-81
Peters SP (*see* Li et al). 2011;127:1457-65
Petersen M (*see* McKinney et al). 2011;127:1629-32 (Letter to the Editor)
Peterson EL (*see* Joseph et al). 2011;127:1203-10
Pfender N (*see* Hofmann et al). 2011;127:265-7 (Letter to the Editor)
Phillips BR (*see* Simon et al). 2011;127:550 (Correspondence)
Phillips EJ, Chung W-H, Mockenhaupt M, Roujeau J-C, Mallal SA. Drug hypersensitivity: Pharmacogenetics and clinical syndromes. 2011;127:S60-6
Phipatanakul W (*see* Gaffin et al). 2011;127:292-3 (Correspondence)
Picard C (*see* Lugo Reyes et al). 2011;127:543-4 (Letter to the Editor)
Pichler U (*see* Wallner et al). 2011;127:1571-8
Pichler WJ (*see* Elsheikh et al). 2011;127:1543-51
Pichler WJ (*see* Romano et al). 2011;127:S59
Pichler WJ, Naisbitt DJ, Park BK. Immune pathomechanism of drug hypersensitivity reactions. 2011;127:S74-81
Pickl WF (*see* Schmetterer et al). 2011;127:238-45
Pineda F (*see* Alonzi et al). 2011;127:1627-9 (Letter to the Editor)
Pipper CB (*see* Bisgaard et al). 2011;127:1155-64
Pityn PJ, Anderson J. Personal sampling of small mold spores using slit cassettes. 2011;127:1063-4 (Letter to the Editor)
Platts-Mills TAE (*see* Commins et al). 2011;127:1286-93
Png KMY (*see* Mushtaq et al). 2011;127:1236-42
Pochan SL (*see* Commins et al). 2011;127:1286-93
Poddighe D (*see* Mathias et al). 2011;127:795-805
Poliani PL (*see* Bosticardo et al). 2011;127:1376-84
Pons L (*see* Kim et al). 2011;127:640-6
Pons L (*see* Kulis et al). 2011;127:81-8
Pons L (*see* Varshney et al). 2011;127:654-60
Ponsonby A-L (*see* Osborne et al). 2011;127:668-76
Poorafshar M (*see* Nicolaou et al). 2011;127:684-5 (Letter to the Editor)
Portnoy J (*see* Spector et al). 2011;127:1641-2 (Correspondence)
Portnoy JM (*see* Golden et al). 2011;127:852-4
Postma DS (*see* Melgert et al). 2011;127:830-3 (Letter to the Editor)
Postma DS (*see* Savenije et al). 2011;127:1505-12
Postma DS (*see* Savenije et al). 2011;127:750-6
Postma DS (*see* Wijga et al). 2011;127:275-7 (Letter to the Editor)
Potocki L (*see* Chinen et al). 2011;127:1579-86
Prem N (*see* Geroldinger-Simic et al). 2011;127:616-22
Prenner BM, Lanier BQ, Bernstein DI, Shekar T, Teper A. Reply. 2011;127:289 (Correspondence)
Prescott SL (*see* Reece et al). 2011;127:447-53
Prescott SL (*see* Tulic et al). 2011;127:470-8
Price D, Martin RJ, Barnes N, Dorinsky P, Israel E, Roche N, Chisholm A, Hillyer EV, Kemp L, Lee AJ, von Ziegenweidt J, Colice G. Reply. 2011;127:835 (Correspondence)
Prickett SR, Voskamp AL, Dacumos-Hill A, Symons K, Rolland JM, O'Hehir RE. Ara h 2 peptides containing dominant CD4$^+$ T-cell epitopes: Candidates for a peanut allergy therapeutic. 2011;127:602-15
Putnam PE (*see* Blanchard et al). 2011;127:208-17

Q

Qin W (*see* Ma et al). 2011;127:1447-56
Qu X (*see* Fan et al). 2011;127:521-2 (Letter to the Editor)
Quaked N (*see* Akdis et al). 2011;127:701-21

R

Rachid R, Leslie D, Schneider L, Twarog F. Hypersensitivity to systemic corticosteroids: An infrequent but potentially life-threatening condition. 2011;127:524-8 (Letter to the Editor)
Radigan L (*see* Chinen et al). 2011;127:1579-86
Raeiszadeh M (*see* Marashi et al). 2011;127:1385-93
Rafaels NM (*see* De Benedetto et al). 2011;127:773-86
Rafaels NM (*see* Leung et al). 2011;127:965-73
Rahbar A (*see* Marashi et al). 2011;127:1385-93
Raithel M (*see* Molderings et al). 2011;127:1311 (Correspondence)
Rajuan N (*see* Katz et al). 2011;127:647-53
Rajuan N (*see* Katz et al). 2011;127:839-40 (Correspondence)
Ramesh N (*see* Massaad et al). 2011;127:998-1005
Rand CS (*see* Clerisme-Beaty et al). 2011;127:406-11
Randolph C (*see* Golden et al). 2011;127:852-4
Randolph C (*see* Spector et al). 2011;127:1641-2 (Correspondence)
Ratanamaneechat S (*see* Busse et al). 2011;127:130-7
Razi CH, Harmancı K. Reply. 2011;127:1078-9 (Correspondence)
Rebholz CE (*see* Marquis et al). 2011;127:270-2 (Letter to the Editor)
Reddel HK (*see* Thamrin et al). 2011;127:1494-502
Reddy S (*see* Accetta et al). 2011;127:535-8 (Letter to the Editor)
Reece P, Thanendran A, Crawford L, Tulic MK, Thabane L, Prescott SL, Sehmi R, Denburg JA. Maternal allergy modulates cord blood hematopoietic progenitor Toll-like receptor expression and function. 2011;127:447-53
Reed CE. Reply. 2011;127:1639 (Correspondence)
Réguerre Y (*see* Lugo Reyes et al). 2011;127:543-4 (Letter to the Editor)
Regush S (*see* Saude et al). 2011;127:757-64
Reich K (*see* Kasperkiewicz et al). 2011;127:267-70 (Letter to the Editor)
Reichenbach J (*see* Bianchi et al). 2011;127:1243-52
Reijmerink NE (*see* Savenije et al). 2011;127:750-6
Reinhardt D (*see* Koletzko et al). 2011;127:836-8 (Correspondence)
Reisdorph NA (*see* Broccardo et al). 2011;127:186-93
Reisman RE (*see* Golden et al). 2011;127:852-4
Reiter H (*see* Kränke et al). 2011;127:1645 (Correspondence)
Remes S (*see* Roduit et al). 2011;127:179-85
Rennard SI (*see* Sato et al). 2011;127:1595-603
Resnick E (*see* Orange et al). 2011;127:1360-7
Resti M (*see* Azzari et al). 2011;127:1394-9

Rezaei N, Hedayat M, Aghamohammadi A, Nichols KE. Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies. 2011;127:1329-41
Rhyner C (*see* Akdis et al). 2011;127:701-21
Rhyner C (*see* Fujita et al). 2011;127:1612-21
Ribeiro M (*see* Seth et al). 2011;127:272-5 (Letter to the Editor)
Ricciardi C (*see* Bhan et al). 2011;127:1302-4 (Letter to the Editor)
Richman T (*see* Tulic et al). 2011;127:470-8
Rieber EP (*see* Hänsel et al). 2011;127:787-94
Riedler J (*see* Naumann et al). 2011;127:1187-94
Riedler J (*see* Roduit et al). 2011;127:179-85
Rieger CHL (*see* Simões et al). 2011;127:293 (Correspondence)
Ring J (*see* Gilles et al). 2011;127:454-61
Ring J (*see* Simons et al). 2011;127:587-93
Risse P-A (*see* Chang et al). 2011;127:1046-53
Rivière J-P (*see* Lugo Reyes et al). 2011;127:543-4 (Letter to the Editor)
Roberts G (*see* Brown et al). 2011;127:661-8
Roberts GC (*see* DunnGalvin et al). 2011;127:633-22
Robins S (*see* Roussel et al). 2011;127:1632-4 (Letter to the Editor)
Robinson CL (*see* Baumann et al). 2011;127:875-82
Robinson D (*see* DeLong et al). 2011;127:1211-18
Roche N (*see* Price et al). 2011;127:835-6 (Correspondence)
Rodríguez E (*see* Naumann et al). 2011;127:1187-94
Rodríguez R (*see* Vereda et al). 2011;127:1304-7 (Letter to the Editor)
Rodriguez-Bada JL (*see* Rondón et al). 2011;127:1069-71 (Letter to the Editor)
Rodriguez-Jimenez B (*see* Blanchard et al). 2011;127:208-17
Rodríguez-Martínez CE (*see* Castro-Rodriguez et al). 2011;127:1082-3 (Correspondence)
Roduit C, Wohlgensinger J, Frei R, Bitter S, Bieli C, Loeliger S, Büchele G, Riedler J, Dalphin J-C, Remes S, Roponen M, Pekkanen J, Kabesch M, Schaub B, von Mutius E, Braun-Fahrländer C, Lauener R. Prenatal animal contact and gene expression of innate immunity receptors at birth are associated with atopic dermatitis. 2011;127:179-85
Roifman CM (*see* Grunebaum et al). 2011;127:1417-9 (Letter to the Editor)
Roifman CM (*see* Nahum et al). 2011;127:528-31 (Letter to the Editor)
Roifman CM (*see* Newell et al). 2011;127:517-9 (Letter to the Editor)
Rolla G (*see* Bucca et al). 2011;127:412-9
Rolland JM (*see* Prickett et al). 2011;127:608-15
Romano A (*see* Alonzi et al). 2011;127:1627-9 (Letter to the Editor)
Romano A, Gaeta F, Valluzzi RL, Caruso C, Rumi G, Bousquet PJ. Reply. 2011;127:1638 (Correspondence)
Romano A, Pichler WJ, Blanca M. Preface. 2011;127:S59
Romano A, Torres MJ, Castells M, Sanz ML, Blanca M. Diagnosis and management of drug hypersensitivity reactions. 2011;127:S67-73
Romaschin A (*see* Seth et al). 2011;127:272-5 (Letter to the Editor)
Romero K (*see* Baumann et al). 2011;127:875-82
Roncarolo MG (*see* Bosticardo et al). 2011;127:1376-84
Rondón C, Blanca-López N, Aranda A, Herrera R, Rodriguez-Bada JL, Canto G, Mayorga C, Torres MJ, Campo P, Blanca M. Local allergic rhinitis: Allergen tolerance and immunologic changes after preseasonal immunotherapy with grass pollen. 2011;127:1069-71 (Letter to the Editor)
Ronmark E (*see* Commins et al). 2011;127:1286-93
Roponen M (*see* Roduit et al). 2011;127:179-85
Rosc C (*see* Kasperkiewicz et al). 2011;127:267-70 (Letter to the Editor)
Rose Y (*see* Lugo Reyes et al). 2011;127:543-4 (Letter to the Editor)
Rosenberg JL. Lack of pretreatment cost-effectiveness and side effects of omalizumab versus prednisone/montelukast on tolerability of immunotherapy. 2011;127:548 (Correspondence)
Rosenlund H, Kull I, Pershagen G, Wolk A, Wickman M, Bergström A. Fruit and vegetable consumption in relation to allergy: Disease-related modification of consumption? 2011;127:1219-25
Rosner BA (*see* Lange et al). 2011;127:734-40
Ross TM (*see* Busse et al). 2011;127:130-7
Roth N (*see* Simon et al). 2011;127:194-9
Rothenberg ME, Bousquet J. News Beyond Our Pages. 2011;127:1-2, 297-8, 423-4, 553-4, 841-2, 1085-6, 1317-8
Rothenberg ME (*see* Blanchard et al). 2011;127:208-17
Rothenberg ME (*see* Broide et al). 2011;127:689-95
Rothers J (*see* Custovic et al). 2011;127:390-7
Roujeau J-C (*see* Phillips et al). 2011;127:S60-6
Rousseau M-C (*see* El-Zein et al). 2011;127:1081 (Correspondence)
Rousseau S (*see* Chang et al). 2011;127:1046-53
Rousseau S (*see* Roussel et al). 2011;127:1632-4 (Letter to the Editor)
Roussel L (*see* Chang et al). 2011;127:1046-53
Roussel L, Robins S, Schachter A, Bérubé J, Hamid Q, Rousseau S. Steroids and extracellular signal-regulated kinase 1/2 activity suppress activating transcription factor 3 expression in patients with severe asthma. 2011;127:1632-4 (Letter to the Editor)
Routes J (*see* Accetta et al). 2011;127:535-8 (Letter to the Editor)
Rouzaire P (*see* Vanbervliet et al). 2011;127:943-53
Rowe BH (*see* Saude et al). 2011;127:757-64
Rozières A (*see* Hennino et al). 2011;127:1064-7 (Letter to the Editor)
Rozières A (*see* Vanbervliet et al). 2011;127:943-53
Rucci F (*see* Pessach et al). 2011;127:1400-7
Rudders SA (*see* Clark et al). 2011;127:682-3 (Letter to the Editor)
Ruether A (*see* Naumann et al). 2011;127:1187-94
Rumi G (*see* Romano et al). 2011;127:1638 (Correspondence)
Russell FM (*see* Balloch et al). 2011;127:1080-1 (Correspondence)
Rutgers B (*see* Melgert et al). 2011;127:831-3 (Letter to the Editor)
Ryan D (*see* Costa et al). 2011;127:920-6

S

Sabin BR, Saltoun CA, Avila PC. Advances in upper airway diseases and allergen immunotherapy. 2011;127:342-50

Saito A (*see* Fukutomi et al). 2011;127:531-3 (Letter to the Editor)

Saito H (*see* Nomura et al). 2011;127:685-8 (Letter to the Editor)

Salo PM, Calatroni A, Gergen PJ, Hoppin JA, Sever ML, Jaramillo R, Arbes SJ Jr, Zeldin DC. Allergy-related outcomes in relation to serum IgE: Results from the National Health and Nutrition Examination Survey 2005-2006. 2011;127:1226-35

Saltoun CA (*see* Sabin et al). 2011;127:342-50

Salzer U (*see* Bacchelli et al). 2011;127:1253-9

Sampson H (*see* Thyagarajan et al). 2011;127:291-2 (Correspondence)

Sampson HA (*see* Nowak-Węgrzyn et al). 2011;127:558-73

Sampson HA (*see* Vereda et al). 2011;127:603-7

Sampson HA, Leung DYM, Burks AW, Lack G, Bahna SL, Jones SM, Wong DA. A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. 2011;127:1309-10 (Letter to the Editor)

Sanak M, Gielicz A, Bochenek G, Kaszuba M, Nižankowska-Mogilnicka E, Szczeklik A. Targeted eicosanoid lipidomics of exhaled breath condensate provide a distinct pattern in the aspirin-intolerant asthma phenotype. 2011;127:1141-7

Sanchez-Borges M (*see* Simons et al). 2011;127:587-93

Sandel MT (*see* Wood et al). 2011;127:913-9

Santiago HC, Bennuru S, Boyd A, Eberhard M, Nutman TB. Structural and immunologic cross-reactivity among filarial and mite tropomyosin: Implications for the hygiene hypothesis. 2011;127:479-86

Sanz ML (*see* Ferrer et al). 2011;127:1300-2 (Letter to the Editor)

Sanz ML (*see* Romano et al). 2011;127:S67-3

Saper V. Moderately complex US Food and Drug Administration–cleared method for human IgE antibody serology. 2011;127:547 (Correspondence)

Sato T, Liu X, Basma H, Togo S, Sugiura H, Nelson A, Nakanishi M, Kanaji N, Wang X, Kim M, Li Y, Michalski J, Farid M, Sharp JG, Rennard SI. IL-4 induces differentiation of human embryonic stem cells into fibrogenic fibroblast-like cells. 2011;127:1595-603

Saude EJ, Skappak CD, Regush S, Cook K, Ben-Zvi A, Becker A, Moqbel R, Sykes BD, Rowe BH, Adamko DJ. Metabolomic profiling of asthma: Diagnostic utility of urine nuclear magnetic resonance spectroscopy. 2011;127:757-64

Sauer AV (*see* Bosticardo et al). 2011;127:1376-84

Savenije OE, Granell R, Caudri D, Koppelman GH, Smit HA, Wijga A, de Jongste JC, Brunekreef B, Sterne JA, Postma DS, Henderson J, Kerkhof M. Comparison of childhood wheezing phenotypes in 2 birth cohorts: ALSPAC and PIAMA. 2011;127:1505-12

Savenije OEM, Kerkhof M, Reijmerink NE, Brunekreef B, de Jongste JC, Smit HA, Wijga AH, Postma DS, Koppelman GH. Interleukin-1 receptor–like 1 polymorphisms are associated with serum IL1RL1-a, eosinophils, and asthma in childhood. 2011;127:750-6

Savino MT (*see* Paccani et al). 2011;127:1635-7 (Letter to the Editor)

Sayama K (*see* Dai et al). 2011;127:806-814

Sayers I (*see* Wan et al). 2011;127:223-31

Scaramuzza S (*see* Selleri et al). 2011;127:1368-75

Scarselli A (*see* Selleri et al). 2011;127:1368-75

Schachter A (*see* Roussel et al). 2011;127:1632-4 (Letter to the Editor)

Schaffartzik A (*see* Akdis et al). 2011;127:701-21

Schäkel K (*see* Hänsel et al). 2011;127:787-94

Schatz M (*see* Krishnan et al). 2011;127:123-7

Schaub B (*see* Lluis et al). 2011;127:1587-94

Schaub B (*see* Roduit et al). 2011;127:179-85

Scheckenbach K (*see* Dumitru et al). 2011;127:1515-21

Schedel M (*see* Lluis et al). 2011;127:1587-94

Schena F (*see* Bosticardo et al). 2011;127:1376-84

Scheynius A (*see* Naumann et al). 2011;127:1187-94

Schiepan JR (*see* Busse et al). 2011;127:130-7

Schlaeger TM (*see* Pessach et al). 2011;127:1400-7

Schlievert PM (*see* Broccardo et al). 2011;127:186-93

Schmetterer KG, Haiderer D, Leb-Reichl VM, Neunkirchner A, Jahn-Schmid B, Küng HJ, Schuch K, Steinberger P, Bohle B, Pickl WF. Bet v 1–specific T-cell receptor/forkhead box protein 3 transgenic T cells suppress Bet v 1–specific T-cell effector function in an activation-dependent manner. 2011;127:238-45

Schmid-Grendelmeier P (*see* Zimmermann et al). 2011;127:200-7

Schmidt E (*see* Kasperkiewicz et al). 2011;127:267-70 (Letter to the Editor)

Schmidt-Weber C (*see* Gilles et al). 2011;127:454-61

Schmidt-Weber CB (*see* Dumitru et al). 2011;127:1515-21

Schmitt A-M (*see* Hennino et al). 2011;127:1064-7 (Letter to the Editor)

Schmitt-Kopplin P (*see* Gilles et al). 2011;127:454-61

Schmitz M (*see* Hänsel et al). 2011;127:787-94

Schneider L (*see* Rachid et al). 2011;127:524-8 (Letter to the Editor)

Schneider LC (*see* De Benedetto et al). 2011;127:773-86

Schneider LC (*see* Leung et al). 2011;127:965-73

Schneider LC (*see* Nadeau et al). 2011;127:1622-4 (Letter to the Editor)

Schneider P (*see* Bacchelli et al). 2011;127:1253-9

Schön MP (*see* Buhl et al). 2011:127:284-5 (Letter to the Editor)

Schreiber S (*see* Naumann et al). 2011;127:1187-94

Schuch K (*see* Schmetterer et al). 2011;127:238-45

Schuller D (*see* Spector et al). 2011;127:1641-2 (Correspondence)

Schuller DE (*see* Golden et al). 2011;127:852-74

Schünemann HJ (*see* Bousquet et al). 2011;127:49-56

Schünemann HJ (*see* Brożek et al). 2011;127:1643-5 (Correspondence)

Schünemann HJ (*see* Costa et al). 2011;127:920-6

Schuster V (*see* Horn et al). 2011;127:544-6 (Letter to the Editor)

Schwarz J (*see* Broccardo et al). 2011;127:186-93
Schwarz JC (*see* Wood et al). 2011;127:913-9
Scott JA (*see* Seth et al). 2011;127:272-5 (Letter to the Editor)
Scott RJ (*see* Baines et al). 2011;127:153-60
Scurati S (*see* Frati et al). 2011;127:1076-7 (Correspondence)
Scurlock AM (*see* Varshney et al). 2011;127:654-60
Scurlock AM (*see* Vickery et al). 2011;127:576-84
Sehmi R (*see* Reece et al). 2011;127:447-53
Selleri S, Brigida I, Casiraghi M, Scaramuzza S, Cappelli B, Cassani B, Ferrua F, Aker M, Slavin S, Scarselli A, Cancrini C, Marktel S, Grazia Roncarolo M, Aiuti A. *In vivo* T-cell dynamics during immune reconstitution after hematopoietic stem cell gene therapy in adenosine deaminase severe combined immune deficiency. 2011;127:1368-75
Senna GE (*see* Simons et al). 2011;127:587-93
Sensi L (*see* Frati et al). 2011;127:1076-7 (Correspondence)
Seth R, Ribeiro M, Romaschin A, Scott JA, Manno M, Scott JA, Liss GM, Tarlo SM. Occupational endotoxin exposure and a novel luminol-enhanced chemiluminescence assay of nasal lavage neutrophil activation. 2011;127:272-5 (Letter to the Editor)
Sever ML (*see* Salo et al). 2011;127:1226-35
Sevin CM (*see* Newcomb et al). 2011;127:1006-13
Shamji M (*see* Dumitru et al). 2011;127:1515-21
Shamji MH (*see* James et al). 2011;127:509-16
Sharief S, Jariwala S, Kumar J, Muntner P, Melamed ML. Vitamin D levels and food and environmental allergies in the United States: Results from the National Health and Nutrition Examination Survey 2005-2006. 2011;127:1195-202
Sharp JG (*see* Sato et al). 2011;127:1595-603
Shearer WT (*see* Chinen et al). 2011;127:336-41
Sheikh A (*see* Arnoldussen et al). 2011;127:1081-2 (Correspondence)
Sheikh A (*see* Arnoldussen et al). 2011;127:246-53
Sheikh A (*see* Kotz et al). 2011;127:623-30
Sheikh A (*see* Nurmatov et al). 2011;127:724-33
Sheikh A (*see* Simons et al). 2011;127:587-93
Shekar T (*see* Prenner et al). 2011;127:289 (Correspondence)
Shemer A (*see* Suárez-Fariñas et al). 2011;127:954-64
Shi J (*see* Fan et al). 2011;127:1312 (Correspondence)
Shi L (*see* Li et al). 2011;127:765-72
Shi Y (*see* Ma et al). 2011;127:1447-56
Shibata S (*see* Nakamura et al). 2011;127:1038-45
Shibuya A (*see* Strait et al). 2011;127:982-9
Shieh C-C (*see* Liu et al). 2011;127:1014-23
Shimokawa N (*see* Nakamura et al). 2011;127:1038-45
Shin T (*see* Jung et al). 2011;127:420-9
Shirakata Y (*see* Dai et al). 2011;127:806-814
Shoda T (*see* Nomura et al). 2011;127:685-8 (Letter to the Editor)
Shreffler W (*see* Kim et al). 2011;127:640-6
Shreffler WG. Microarrayed recombinant allergens for diagnostic testing. 2011;127:843-9
Sibanda E (*see* Arkestål et al). 2011;127:1024-8
Sibiryak DS (*see* van der Aar et al). 2011;127:1532-40
Sicherer S (*see* Thyagarajan et al). 2011;127:291-2 (Correspondence)
Sicherer SH, Leung DYM. Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2010. 2011;127:326-35
Sicherer SH. Epidemiology of food allergy. 2011;127:594-602
Sieber J. Necessity of product-specific assessments or restrictions of meta-analyses to well-designed and well-powered studies. 2011;127:1075-6 (Correspondence)
Sigelman S (*see* Busse et al). 2011;127:130-7
Silberg JL (*see* Lange et al). 2011;127:734-40
Siler U (*see* Bianchi et al). 2011;127:1243-52
Silkoff PE, Loza MJ. Exhaled nitric oxide in prednisone-dependent asthma to identify the eosinophilic positive phenotype. 2011;127:834 (Correspondence)
Siltanen M, Wehkalampi K, Hovi P, Eriksson JG, Strang-Karlsson S, Järvenpää A-L, Andersson S, Kajantie E. Preterm birth reduces the incidence of atopy in adulthood. 2011;127:935-42
Silverberg JI, Kleiman E, Lev-Tov H, Silverberg NB, Durkin HG, Joks R, Smith-Norowitz TA. Association between obesity and atopic dermatitis in childhood: A case-control study. 2011;127:1180-6
Silverberg NB (*see* Silverberg et al). 2011;127:1180-6
Silverman GA (*see* Sivaprasad et al). 2011;127:254-61
Silverman M (*see* Leonardi et al). 2011;127:1466-72
Simeone S (*see* Busse et al). 2011;127:130-7
Simões EAF, Fredrick L, Carbonell-Estrany X, Rieger CHL, Mitchell I, Groothuis JR. Reply. 2011;127:293 (Correspondence)
Simon D, Hoesli S, Roth N, Staedler S, Yousefi S, Simon H-U. Eosinophil extracellular DNA traps in skin diseases. 2011;127:194-9
Simon DM (*see* Fitzpatrick et al). 2011;127:1604-11
Simon H-U (*see* Dworski et al). 2011;127:1260-6
Simon H-U (*see* Simon et al). 2011;127:194-9
Simon MR, Chinchilli VM, Phillips BR, Sorkness CA, Lemanske RF Jr, Szefler SJ, Taussig L, Bacharier LB, Morgan W. Reply. 2011;127:550 (Correspondence)
Simone B (*see* Zimmermann et al). 2011;127:200-7
Simons FER, Ardusso LRF, Bilò MB, El-Gamal YM, Ledford DK, Ring J, Sanchez-Borges M, Senna GE, Sheikh A, Thong BY. World Allergy Organization Guidelines for the Assessment and Management of Anaphylaxis. 2011;127:587-93
Simpson A (*see* Custovic et al). 2011;127:1480-5
Simpson A (*see* Custovic et al). 2011;127:390-7
Simpson A (*see* Nicolaou et al). 2011;127:684-5 (Letter to the Editor)
Simpson CR (*see* Kotz et al). 2011;127:623-30
Simpson JL (*see* Baines et al). 2011;127:153-60
Sirvent S (*see* Vereda et al). 2011;127:1304-7 (Letter to the Editor)
Sismanopoulos N (*see* Zhang et al). 2011;127:1522-31
Sivaprasad U, Askew DJ, Ericksen MB, Gibson AM, Stier MT, Brandt EB, Bass SA, Daines MO, Chakir J, Stringer KF, Wert SE, Whitsett JA, Le Cras TD, Wills-Karp M, Silverman GA, Khurana Hershey GK. A nonredundant

role for mouse Serpinb3a in the induction of mucus production in asthma. 2011;127:254-61
Skappak CD (*see* Saude et al). 2011;127:757-64
Skoner DP (*see* Blaiss et al). 2011;127:64-71
Slatter MA, Angus B, Windebank K, Taylor A, Meaney C, Lester T, Norbury G, Hambleton S, Abinun M, Flood TJ, Cant AJ, Gennery AR. Polymorphous lymphoproliferative disorder with Hodgkin-like features in common γ-chain–deficient severe combined immunodeficiency. 2011;127:533-5 (Letter to the Editor)
Slavin S (*see* Selleri et al). 2011;127:1368-75
Sleasman JW (*see* Orange et al). 2011;127:1360-7
Slejko JF (*see* Sullivan et al). 2011;127:363-9
Sly PD (*see* Custovic et al). 2011;127:1480-5
Smart B (*see* Chipps et al). 2011;127:1640-1 (Correspondence)
Smejda K (*see* Majak et al). 2011;127:1294-6 (Letter to the Editor)
Smit HA (*see* Savenije et al). 2011;127:1505-12
Smit HA (*see* Savenije et al). 2011;127:750-6
Smit HA (*see* Wijga et al). 2011;127:275-7 (Letter to the Editor)
Smith-Norowitz TA (*see* Silverberg et al). 2011;127:1180-6
Soderberg-Naucler C (*see* Marashi et al). 2011;127:1385-93
Söderhäll C (*see* Naumann et al). 2011;127:1187-94
Soderstrom L (*see* Custovic et al). 2011;127:1480-5
Sordillo JE, Webb T, Kwan D, Kamel J, Hoffman E, Milton DK, Gold DR. Allergen exposure modifies the relation of sensitization to fraction of exhaled nitric oxide levels in children at risk for allergy and asthma. 2011;127:1165-72
Sorkness CA (*see* Simon et al). 2011;127:550 (Correspondence)
Sorkness CA (*see* Wang et al). 2011;127:161-6
Sorkness RL, Teague WG, Penugonda M, Fitzpatrick AM. Sex dependence of airflow limitation and air trapping in children with severe asthma. 2011;127:1073-4 (Letter to the Editor)
Sozanska B (*see* Ege et al). 2011;127:138-44
Spector S (*see* Chipps et al). 2011;127:1640-1 (Correspondence)
Spector S, Wallace D, Nicklas R, Portnoy J, Blessing-Moore J, Bernstein D, Cox L, Oppenheimer J, Lang D, Schuller D, Randolph C, Tilles S, Khan D. Comments on Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines. 2011;127:1641-2 (Correspondence)
Spector SL (*see* Golden et al). 2011;127:852-4
Spycher BD (*see* Leonardi et al). 2011;127:1466-72
Spycher BD (*see* Marquis et al). 2011;127:270-2 (Letter to the Editor)
Staedler S (*see* Simon et al). 2011;127:194-9
Stahl C (*see* Naumann et al). 2011;127:1187-94
Stanford RH, Yancey SW, Stempel DA. Asthma control differences between inhaled corticosteroids likely related to differences in patient severity. 2011;127:835 (Correspondence)
Starke J (*see* Hänsel et al). 2011;127:787-94
Steele P (*see* Kim et al). 2011;127:640-6
Steele P (*see* Varshney et al). 2011;127:654-60
Stein M (*see* Katz et al). 2011;127:289-90 (Correspondence)
Steinberger P (*see* Schmetterer et al). 2011;127:238-45
Steinke JW (*see* Laidlaw et al). 2011;127:815-22
Stelmach I (*see* Majak et al). 2011;127:1294-6 (Letter to the Editor)
Stelmach I (*see* Majak et al). 2011;127:286-7 (Correspondence)
Stempel DA (*see* Stanford et al). 2011;127:835 (Correspondence)
Stenke E (*see* DunnGalvin et al). 2011;127:633-9
Stephenson ST (*see* Fitzpatrick et al). 2011;127:1604-11
Stern D (*see* Custovic et al). 2011;127:390-7
Sterne JA (*see* Savenije et al). 2011;127:1505-12
Stier MT (*see* Sivaprasad et al). 2011;127:254-61
Stirling RG (*see* Chen et al). 2011;127:1414-7 (Letter to the Editor)
Stokes JR (*see* Casale et al). 2011;127:8-15
Storms W (*see* Chipps et al). 2011;127:1640-1 (Correspondence)
Strachan DP (*see* Ege et al). 2011;127:138-44
Strachan DP (*see* Wan et al). 2011;127:223-31
Strait RT, Mahler A, Hogan S, Khodoun M, Shibuya A, Finkelman FD. Ingested allergens must be absorbed systemically to induce systemic anaphylaxis. 2011;127:982-9
Strang-Karlsson S (*see* Siltanen et al). 2011;127:935-42
Streib JE (*see* Bin et al). 2011;127:430-8
Streib JE (*see* Leung et al). 2011;127:965-73
Stringer KF (*see* Sivaprasad et al). 2011;127:254-61
Strippoli M-PF (*see* Leonardi et al). 2011;127:1466-72
Strippoli M-PF (*see* Marquis et al). 2011;127:270-2 (Letter to the Editor)
Strunk R (*see* Forno et al). 2011;127:741-9
Strunk RC (*see* An et al). 2011;127:1440-6
Strunk RC (*see* Wang et al). 2011;127:161-6
Stucke EM (*see* Blanchard et al). 2011;127:208-17
Suarez F (*see* Lugo Reyes et al). 2011;127:543-4 (Letter to the Editor)
Suárez-Fariñas M, Tintle SJ, Shemer A, Chiricozzi A, Nograles K, Cardinale I, Duan S, Bowcock AM, Krueger JG, Guttman-Yassky E. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. 2011;127:954-64
Sugerman RW (*see* Wasserman et al). 2011;127:290-1 (Correspondence)
Sugiura H (*see* Sato et al). 2011;127:1595-603
Suki B (*see* Thamrin et al). 2011;127:1494-502
Sullivan KE (*see* Orange et al). 2011;127:1360-7
Sullivan PW, Ghushchyan VH, Slejko JF, Belozeroff V, Globe DR, Lin S-L. The burden of adult asthma in the United States: Evidence from the Medical Expenditure Panel Survey. 2011;127:363-9
Sumino K (*see* Busse et al). 2011;127:130-7
Sundquist J (*see* Crump et al). 2011;127:1173-9
Sundquist K (*see* Crump et al). 2011;127:1173-9
Surfus J (*see* Accetta et al). 2011;127:535-8 (Letter to the Editor)
Sutherland ER (*see* Huang et al). 2011;127:372-81
Suzuki R (*see* Nakamura et al). 2011;127:1038-45

Swenson C (*see* Bush et al). 2011;127:974-81
Sykes BD (*see* Saude et al). 2011;127:754-61
Symons K (*see* Prickett et al). 2011;127:608-15
Syverson G (*see* Accetta et al). 2011;127:535-8 (Letter to the Editor)
Szczeklik A (*see* Sanak et al). 2011;127:1141-7
Szefler SJ (*see* Leung et al). 2011;127:128-9, 361-2, 722-3, 873-4, 1131-2, 1438-9
Szefler SJ (*see* Simon et al). 2011;127:550 (Correspondence)
Szefler SJ (*see* Wang et al). 2011;127:161-6
Szefler SJ. Advances in pediatric asthma in 2010: Addressing the major issues. 2011;127:102-15

T

Tabak C (*see* Wijga et al). 2011;127:275-7 (Letter to the Editor)
Tabar AI, Arroabarren E, Echechipía S, García BE, Martin S, Alvarez-Puebla MJ. Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy. 2011;127:57-63
Tahara Y (*see* Nakamura et al). 2011;127:1038-45
Takamasu T (*see* Nomura et al). 2011;127:685-8 (Letter to the Editor)
Tanaka A (*see* Jung et al). 2011;127:420-9
Tanaka S (*see* Ushio et al). 2011;127:1267-76
Tang MLK (*see* Balloch et al). 2011;127:1080-1 (Correspondence)
Tang MLK (*see* Osborne et al). 2011;127:668-76
Taniguchi M (*see* Fukutomi et al). 2011;127:531-3 (Letter to the Editor)
Tapisiz A (*see* Türktaş et al). 2011;127:1078 (Correspondence)
Tarasco V (*see* Monti et al). 2011;127:679-80 (Letter to the Editor)
Tarlo SM (*see* Seth et al). 2011;127:275-7 (Letter to the Editor)
Taussig L (*see* Simon et al). 2011;127:550 (Correspondence)
Taussig LM (*see* Wang et al). 2011;127:161-6
Taylor A (*see* Slatter et al). 2011;127:533-5 (Letter to the Editor)
Taylor PA (*see* Leung et al). 2011;127:965-73
Teague WG (*see* Busse et al). 2011;127:130-7
Teague WG (*see* Clerisme-Beaty et al). 2011;127:406-11
Teague WG (*see* Fitzpatrick et al). 2011;127:282-4 (Letter to the Editor)
Teague WG (*see* Fitzpatrick et al). 2011;127:382-9
Teague WG (*see* Holguin et al). 2011;127:1486-93
Teague WG (*see* Li et al). 2011;127:1457-65
Teague WG (*see* Sorkness et al). 2011;127:1073-4 (Letter to the Editor)
ten Hacken NH (*see* Melgert et al). 2011;127:830-3 (Letter to the Editor)
Teper A (*see* Prenner et al). 2011;127:289 (Correspondence)
Terada A (*see* Nomura et al). 2011;127:685-8 (Letter to the Editor)
Teunissen MBM (*see* van der Aar et al). 2011;127:1532-40
Thabane L (*see* Reece et al). 2011;127:447-53
Thadhani R (*see* Bhan et al). 2011;127:1302-4 (Letter to the Editor)
Thalhamer J (*see* Wallner et al). 2011;127:1571-8
Thamm P (*see* Dreschler et al). 2011;127:487-94
Thamrin C, Zindel J, Nydegger R, Reddel HK, Chanez P, Wenzel SE, FitzPatrick S, Watt RA, Suki B, Frey U. Predicting future risk of asthma exacerbations using individual conditional probabilities. 2011;127:1494-502
Thanendran A (*see* Reece et al). 2011;127:447-53
Theoharides TC (*see* Zhang et al). 2011;127:1522-31
Thomas WR. The advent of recombinant allergens and allergen cloning. 2011;127:855-9
Thompson BR (*see* Chen et al). 2011;127:1414-7 (Letter to the Editor)
Thompson EE (*see* Alvarado Arnez et al). 2011;127:279-82 (Letter to the Editor)
Thong BY (*see* Simons et al). 2011;127:587-93
Thornton CA (*see* Tulic et al). 2011;127:470-8
Thors C (*see* Arkestål et al). 2011;127:1024-8
Thrasher AJ (*see* Bacchelli et al). 2011;127:1253-9
Thyagarajan A, Varshney P, Jones SM, Sicherer S, Wood R, Vickery BP, Sampson H, Burks AW. Reply. 2011;127:291-2 (Correspondence)
Tian L (*see* Altin et al). 2011;127:1277-85
Till SJ (*see* James et al). 2011;127:509-16
Tilles S (*see* Spector et al). 2011;127:1641-2 (Correspondence)
Tilles SA (*see* Golden et al). 2011;127:852-4
Timens W (*see* Melgert et al). 2011;127:830-3 (Letter to the Editor)
Tiñana AM (*see* Laidlaw et al). 2011;127:815-22
Tintle SJ (*see* Suárez-Fariñas et al). 2011;127:954-64
Tochino Y (*see* Kanazawa et al). 2011;127:899-904
Togias A (*see* Busse et al). 2011;127:130-7
Togias A (*see* Calderón et al). 2011;127:30-8
Togo S (*see* Sato et al). 2011;127:1595-603
Tohyama M (*see* Dai et al). 2011;127:806-14
Tokumaru S (*see* Dai et al). 2011;127:806-14
Tomassen P (*see* Bachert et al). 2011;127:1313-4 (Correspondence)
Tonello F (*see* Paccani et al). 2011;127:1635-7 (Letter to the Editor)
Torres MJ (*see* Rondón et al). 2011;127:1069-71 (Letter to the Editor)
Torres MJ (*see* Romano et al). 2011;127:S67-3
Tovo PA (*see* Monti et al). 2011;127:679-80 (Letter to the Editor)
Tracy JM (*see* Golden et al). 2011;127:852-4
Traggiai E (*see* Bosticardo et al). 2011;127:1376-84
Traidl-Hoffmann C (*see* Gilles et al). 2011;127:454-61
Trautmann A (*see* Kerstan et al). 2011;127:495-501
Treis A (*see* Fujita et al). 2011;127:1612-21
Troye-Blomberg M (*see* Arkestål et al). 2011;127:1024-8
Tsai M-Y (*see* Liu et al). 2011;127:1014-23
Tulic MK (*see* Reece et al). 2011;127:447-53
Tulic MK, Hodder M, Forsberg A, McCarthy S, Richman T, D'Vaz N, van den Biggelaar AHJ, Thornton CA, Prescott SL. Differences in innate immune function between allergic and nonallergic children: New insights into immune ontogeny. 2011;127:470-8
Türktaş I, Bakirtas A, Tapisiz A. When should we put evidence into clinical practice? 2011;127:1078 (Correspondence)

Turmel J (*see* Bougault et al). 2011;127:892-8
Twarog F (*see* Rachid et al). 2011;127:524-8 (Letter to the Editor)

U

Ueland PM (*see* Håberg et al). 2011;127:262-4 (Letter to the Editor)
Ueno T (*see* Ushio et al). 2011;127:1267-76
Umetsu DT (*see* Nadeau et al). 2011;127:1622-4 (Letter to the Editor)
Urban C (*see* Horn et al). 2011;127:544-6 (Letter to the Editor)
Urban CF (*see* Bianchi et al). 2011;127:1243-52
Ushio H, Ueno T, Kojima Y, Komatsu M, Tanaka S, Yamamoto A, Ichimura Y, Ezaki J, Nishida K, Komazawa-Sakon S, Niyonsaba F, Ishii T, Yanagawa T, Kominami E, Ogawa H, Okumura K, Nakano H. Crucial role for autophagy in degranulation of mast cells. 2011;127:1267-76

V

Vaidyanathan S, Williamson P, Clearie K, Morrison A, Lipworth B. Nasal AMP and histamine challenge within and outside the pollen season in patients with seasonal allergic rhinitis. 2011;127:173-8
Valent P (*see* Akin et al). 2011;127:1311-2 (Correspondence)
Valent P (*see* Niespodziana et al). 2011;127:1562-70
Valenta R (*see* Arkestål et al). 2011;127:1024-8
Valenta R (*see* Niespodziana et al). 2011;127:1562-70
Valenta R, Niespodziana K, Focke-Tejkl M, Marth K, Huber H, Neubauer A, Niederberger V. Recombinant allergens: What does the future hold? 2011;127:860-4
Valluzzi RL (*see* Romano et al). 2011;127:1638 (Correspondence)
van Capel TMM (*see* van der Aar et al). 2011;127:1532-40
Van De Veen W (*see* Akdis et al). 2011;127:701-21
van den Akker PC (*see* Brown et al). 2011;127:661-8
van den Biggelaar AHJ (*see* Tulic et al). 2011;127:470-8
van der Aar AMG, Sibiryak DS, Bakdash G, van Capel TMM, van der Kleij HPM, Opstelten D-JE, Teunissen MBM, Kapsenberg ML, de Jong EC. Vitamin D3 targets epidermal and dermal dendritic cells for induction of distinct regulatory T cells. 2011;127:1532-40
van der Kleij HPM (*see* van der Aar et al). 2011;127:1532-40
van der Tas CWH (*see* van Hoffen et al). 2011;127:100-1 (Letter to the Editor)
van Hage M (*see* Arkestål et al). 2011;127:1024-8
van Hage M (*see* Niespodziana et al). 2011;127:1562-70
van Hage M (*see* Vereda et al). 2011;127:603-7
van Hoffen E (*see* Le et al). 2011;127:677-9 (Letter to the Editor)
van Hoffen E, Peeters KABM, van Neerven RJJ, van der Tas CWH, Zuidmeer L, van Ieperen-van Dijk AG, Bruijnzeel-Koomen CAFM, Knol EF, van Ree R, Knulst AC. Effect of birch pollen–specific immunotherapy on birch pollen–related hazelnut allergy. 2011;127:100-1 (Letter to the Editor)
van Ieperen-van Dijk AG (*see* van Hoffen et al). 2011;127:100-1 (Letter to the Editor)
van Lier RAW (*see* Kuijpers et al). 2011;127:1411-4 (Letter to the editor)
van Neerven RJJ (*see* van Hoffen et al). 2011;127:100-1 (Letter to the Editor)
van Odijk J (*see* Vereda et al). 2011;127:603-7
van Ree R (*see* van Hoffen et al). 2011;127:100-1 (Letter to the Editor)
van Ree R (*see* Wallner et al). 2011;127:1571-8
Van Rooijen N (*see* Arias et al). 2011;127:1552-61
van Wijk RG (*see* Brożek et al). 2011;127:1643-5 (Correspondence)
Vanbervliet B (*see* Hennino et al). 2011;127:1064-7 (Letter to the Editor)
Vanbervliet B, Akdis M, Vocanson M, Rozières A, Benetière J, Rouzaire P, Akdis CA, Nicolas J-F, Hennino A. Histamine receptor H1 signaling on dendritic cells plays a key role in the IFN-γ/IL-17 balance in T cell–mediated skin inflammation. 2011;127:943-63
Vandiedonck C (*see* Holt et al). 2011;127:1054-62
Vani J (*see* Maddur et al). 2011;127:823-30
Varshney P (*see* Thyagarajan et al). 2011;127:291-2 (Correspondence)
Varshney P, Jones SM, Scurlock AM, Perry TT, Kemper A, Steele P, Hiegel A, Kamilaris J, Carlisle S, Yue X, Kulis M, Pons L, Vickery B, Burks AW. A randomized controlled study of peanut oral immunotherapy: Clinical desensitization and modulation of the allergic response. 2011;127:654-60
Vasiadi M (*see* Zhang et al). 2011;127:1522-31
Vaughn MP. Montelukast might improve compliance with subcutaneous immunotherapy treatments in patients with allergic asthma. 2011;127:286 (Correspondence)
Venegas EN (*see* Alvarado Arnez et al). 2011;127:279-82 (Letter to the Editor)
Verbinnen B (*see* Bossuyt et al). 2011;127:1079-80 (Correspondence)
Verbsky J (*see* Accetta et al). 2011;127:535-8 (Letter to the Editor)
Vereda A, Sirvent S, Villalba M, Rodríguez R, Cuesta-Herranz J, Palomares O. Improvement of mustard (*Sinapis alba*) allergy diagnosis and management by linking clinical features and component-resolved approaches. 2011;127:1304-7 (Letter to the Editor)
Vereda A, van Hage M, Ahlstedt S, Ibañez MD, Cuesta-Herranz J, van Odijk J, Wickman M, Sampson HA. Peanut allergy: Clinical and immunologic differences among patients from 3 different geographic regions. 2011;127:603-7
Verhoef A (*see* Worm et al). 2011;127:89-97
Vickery B (*see* Kim et al). 2011;127:640-6
Vickery B (*see* Varshney et al). 2011;127:654-60
Vickery BP (*see* Thyagarajan et al). 2011;127:291-2 (Correspondence)

Vickery BP, Scurlock AM, Jones SM, Burks AW. Mechanisms of immune tolerance relevant to food allergy. 2011;127:576-84
Vidyasagar S (*see* De Benedetto et al). 2011;127:773-86
Vieths S (*see* Geroldinger-Simic et al). 2011;127:616-22
Villa A (*see* Bosticardo et al). 2011;127:1376-84
Villalba M (*see* Vereda et al). 2011;127:1304-7 (Letter to the Editor)
Vince N, Boutboul D, Mouillot G, Just N, Peralta M, Casanova J-L, Conley ME, Bories J-C, Oksenhendler E, Malphettes M, Fieschi C. Defects in the CD19 complex predispose to glomerulonephritis, as well as IgG1 subclass deficiency. 2011;127:538-41 (Letter to the Editor)
Viola S (*see* Monti et al). 2011;127:679-80 (Letter to the Editor)
Virchow JC (*see* Dreschler et al). 2011;127:487-94
Visness CM (*see* Wood et al). 2011;127:913-9
Viswanathan RK (*see* Biagtan et al). 2011;127:1626-7 (Letter to the editor)
Vocanson M (*see* Vanbervliet et al). 2011;127:943-53
Vollset SE (*see* Håberg et al). 2011;127:262-4 (Letter to the Editor)
von Berg A (*see* Koletzko et al). 2011;127:836-8 (Correspondence)
von der Weid NX (*see* Marquis et al). 2011;127:270-2 (Letter to the Editor)
von Mutius E (*see* Ege et al). 2011;127:138-44
von Mutius E (*see* Lluis et al). 2011;127:1587-94
von Mutius E (*see* Naumann et al). 2011;127:1187-94
von Mutius E (*see* Roduit et al). 2011;127:179-85
von Mutius E. Trajectories of childhood wheeze. 2011;127:1513-4 (Editorial)
von Ziegenweidt J (*see* Price et al). 2011;127:835-6 (Correspondence)
Voskamp AL (*see* Prickett et al). 2011;127:608-15

W

Wachholz PA (*see* James et al). 2011;127:509-16
Wagenmann M (*see* Dumitru et al). 2011;127:1515-21
Wagenpfeil S (*see* Naumann et al). 2011;127:1187-94
Wahlgren C-F (*see* Naumann et al). 2011;127:1187-94
Wahlström J (*see* Ludvigsson et al). 2011;127:1071-3 (Letter to the Editor)
Wahn U (*see* Bousquet et al). 2011;127:49-56
Wake M (*see* Osborne et al). 2011;127:668-76
Walker SM (*see* James et al). 2011;127:509-16
Walker T (*see* Arias et al). 2011;127:1552-61
Wallace D (*see* Golden et al). 2011;127:852-4
Wallace D (*see* Spector et al). 2011;127:1641-2 (Correspondence)
Wallner M, Hauser M, Himly M, Zaborsky N, Mutschlechner S, Harrer A, Asam C, Pichler U, van Ree R, Briza P, Thalhamer J, Bohle B, Achatz G, Ferreira F. Reshaping the Bet v 1 fold modulates T_H polarization. 2011;127:1571-8
Walter Canonica G (*see* Bousquet et al). 2011;127:49-56
Walters EH (*see* Martin et al). 2011;127:1473-9
Wambre E (*see* DeLong et al). 2011;127:1211-18
Wan YI, Strachan DP, Evans DM, Henderson J, McKeever T, Holloway JW, Hall IP, Sayers I. A genome-wide association study to identify genetic determinants of atopy in subjects from the United Kingdom. 2011;127:223-31
Wang DY (*see* Li et al). 2011;127:765-72
Wang F (*see* Orange et al). 2011;127:1360-7
Wang J-Y (*see* Liu et al). 2011;127:1014-23
Wang L, Hollenbeak CS, Mauger DT, Zeiger RS, Paul IM, Sorkness CA, Lemanske RF Jr, Martinez FD, Strunk RC, Szefler SJ, Taussig LM. Cost-effectiveness analysis of fluticasone versus montelukast in children with mild-to-moderate persistent asthma in the Pediatric Asthma Controller Trial. 2011;127:161-6
Wang W-Z (*see* Liu et al). 2011;127:1014-23
Wang X (*see* Sato et al). 2011;127:1595-603
Wardlaw AJ (*see* Lötvall et al). 2011;127:355-60
Waserman S (*see* Arias et al). 2011;127:1552-61
Wasserman RL, Sugerman RW, Mireku-Akomeah N, Mansfield L, Baker JW. Office-based oral immunotherapy for food allergy is safe and effective. 2011;127:290-1 (Correspondence)
Wasserman SI (*see* Huang et al). 2011;127:372-81
Watanabe M (*see* Nomura et al). 2011;127:685-8 (Letter to the Editor)
Watt RA (*see* Thamrin et al). 2011;127:1494-502
Webb L (*see* McKinney et al). 2011;127:1629-32 (Letter to the Editor)
Webb T (*see* Sordillo et al). 2011;127:1165-72
Weber-Mzell D (*see* Horn et al). 2011;127:544-6 (Letter to the Editor)
Webster AD (*see* Marashi et al). 2011;127:1385-93
Wechsler ME (*see* Huang et al). 2011;127:372-81
Weckesser S (*see* Hofmann et al). 2011;127:265-7 (Letter to the Editor)
Wegienka G (*see* Joseph et al). 2011;127:1203-10
Wegienka G, Johnson CC, Havstad S, Ownby DR, Zoratti EM. Reply. 2011;127:287-8 (Correspondence)
Wehkalampi K (*see* Siltanen et al). 2011;127:935-42
Weidinger S (*see* De Benedetto et al). 2011;127:773-86
Weidinger S (*see* Naumann et al). 2011;127:1187-94
Weinberg A (*see* Leung et al). 2011;127:965-73
Weiss S (*see* Forno et al). 2011;127:741-9
Weiss ST (*see* Himes et al). 2011;127:1067-9 (Letter to the Editor)
Weiss ST. Bacterial components plus vitamin D: The ultimate solution to the asthma (autoimmune disease) epidemic? 2011;127:1128-30 (Editorial)
Weng HH (*see* Meltzer et al). 2011;127:167-72
Weng Z (*see* Zhang et al). 2011;127:1522-31
Wenger J (*see* Bhan et al). 2011;127:1302-4 (Letter to the Editor)
Wenzel S (*see* Busse et al). 2011;127:130-7
Wenzel SE (*see* Fitzpatrick et al). 2011;127:382-9
Wenzel SE (*see* Holguin et al). 2011;127:1486-93
Wenzel SE (*see* Li et al). 2011;127:1457-65
Wenzel SE (*see* Lötvall et al). 2011;127:355-60
Wenzel SE (*see* Meltzer et al). 2011;127:167-72
Wenzel SE (*see* Thamrin et al). 2011;127:1494-502
Wert SE (*see* Sivaprasad et al). 2011;127:254-61

Whitaker P (*see* Elsheikh et al). 2011;127:1543-51
Whitsett JA (*see* Sivaprasad et al). 2011;127:254-61
Wichmann H-E (*see* Koletzko et al). 2011;127:836-8 (Correspondence)
Wickman M (*see* Rosenlund et al). 2011;127:1219-25
Wickman M (*see* Vereda et al). 2011;127:603-7
Wiener-Kronish JP (*see* Huang et al). 2011;127:372-81
Wieringa MH (*see* Wijga et al). 2011;127:275-7 (Letter to the Editor)
Wijga A (*see* Savenije et al). 2011;127:1505-12
Wijga A, Tabak C, Postma DS, Kerkhof M, Wieringa MH, Hoekstra MO, Brunekreef B, de Jongste JC, Smit HA. Sex differences in asthma during the first 8 years of life: The Prevention and Incidence of Asthma and Mite Allergy (PIAMA) birth cohort study. 2011;127:275-7 (Letter to the Editor)
Wijga AH (*see* Savenije et al). 2011;127:750-6
Wijmenga C (*see* Brown et al). 2011;127:661-8
Williams JV (*see* Miller et al). 2011;127:883-91
Williamson P (*see* Vaidyanathan et al). 2011;127:173-8
Wills-Karp M (*see* Sivaprasad et al). 2011;127:254-61
Willumsen N (*see* Holm et al). 2011;127:1029-37
Wilson DR (*see* James et al). 2011;127:509-16
Windebank K (*see* Slatter et al). 2011;127:533-5 (Letter to the Editor)
Winkleby MA (*see* Crump et al). 2011;127:1173-9
Wise RA (*see* Baumann et al). 2011;127:875-82
Wise RA (*see* Clerisme-Beaty et al). 2011;127:406-11
Withers M (*see* Chinen et al). 2011;127:1579-86
Woehrl S (*see* Zimmermann et al). 2011;127:200-7
Wohlgensinger J (*see* Roduit et al). 2011;127:179-85
Wolk A (*see* Rosenlund et al). 2011;127:1219-25
Wong DA (*see* Sampson et al). 2011;127:1309-10 (Letter to the Editor)
Wood LG (*see* Baines et al). 2011;127:153-60
Wood LG, Garg ML, Gibson PG. A high-fat challenge increases airway inflammation and impairs bronchodilator recovery in asthma. 2011;127:1133-40
Wood R (*see* Thyagarajan et al). 2011;127:291-2 (Correspondence)
Wood RA (*see* Corren et al). 2011;127:398-405
Wood RA, Bloomberg GR, Kattan M, Conroy K, Sandel MT, Dresen A, Gergen PJ, Gold DR, Schwarz JC, Visness CM, Gern JE. Relationships among environmental exposures, cord blood cytokine responses, allergy, and wheeze at 1 year of age in an inner-city birth cohort (Urban Environment and Childhood Asthma study). 2011;127:913-25
Woodcock A (*see* Custovic et al). 2011;127:390-7
Woodcroft KJ (*see* Joseph et al). 2011;127:1203-10
Woodward K (*see* Miller et al). 2011;127:883-91
Workman LJ (*see* Commins et al). 2011;127:1286-93
Workman S (*see* Chua et al). 2011;127:1410-1 (Letter to the Editor)
Workman S (*see* Marashi et al). 2011;127:1385-93
Worm M (*see* Bousquet et al). 2011;127:49-56
Worm M, Lee H-H, Kleine-Tebbe J, Hafner RP, Laidler P, Healey D, Buhot C, Verhoef A, Maillère B, Kay AB, Larché M. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. 2011;127:89-97
Woyke T (*see* Huang et al). 2011;127:372-81
Wright AL (*see* Custovic et al). 2011;127:390-7
Wruck L (*see* Broccardo et al). 2011;127:186-93
Wu J (*see* Nelson et al). 2011;127:72-80
Würtzen PA (*see* Holm et al). 2011;127:1029-37

X

Xia W (*see* Fan et al). 2011;127:1312 (Correspondence)
Xian W (*see* Li et al). 2011;127:765-72
Xie Y (*see* Ma et al). 2011;127:1447-56
Xing W (*see* Laidlaw et al). 2011;127:815-22
Xing W (*see* Mathias et al). 2011;127:795-805
Xu G (*see* Fan et al). 2011;127:1312 (Correspondence)
Xu G (*see* Fan et al). 2011;127:521-2 (Letter to the Editor)
Xu R (*see* Fan et al). 2011;127:1312 (Correspondence)
Xu Y (*see* Cakebread et al). 2011;127:1148-54

Y

Yamamoto A (*see* Ushio et al). 2011;127:1267-76
Yanagawa T (*see* Ushio et al). 2011;127:1267-76
Yancey SW (*see* Stanford et al). 2011;127:835 (Correspondence)
Yang A (*see* Ma et al). 2011;127:1447-56
Yang L (*see* Dai et al). 2011;127:806-14
Yang P-W (*see* Liu et al). 2011;127:1014-23
Yao R (*see* Blaiss et al). 2011;127:64-71
Yasueda H (*see* Fukutomi et al). 2011;127:531-3 (Letter to the Editor)
Yasueda H (*see* Okano et al). 2011;127:277-9 (Letter to the Editor)
Ye J (*see* Bhan et al). 2011;127:1302-4 (Letter to the Editor)
Yegin A (*see* Corren et al). 2011;127:398-405
Yen C-L (*see* Liu et al). 2011;127:1014-23
Yildirim-Toruner C, Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. 2011;127:303-12
Yonas M (*see* Holguin et al). 2011;127:1486-93
Yoshida T (*see* De Benedetto et al). 2011;127:773-86
Yousefi S (*see* Dworski et al). 2011;127:1260-6
Yousefi S (*see* Simon et al). 2011;127:194-9
Yue X (*see* Varshney et al). 2011;127:654-60

Z

Zaborsky N (*see* Wallner et al). 2011;127:1571-8
Zaccaro DJ (*see* Busse et al). 2011;127:130-7
Zaccaro DJ (*see* Leung et al). 2011;127:965-73
Zahner C (*see* Dumitru et al). 2011;127:1515-21
Zarember KA (*see* Kang et al). 2011;127:1319-26
Zeiger RS (*see* Wang et al). 2011;127:161-6
Zeldin DC (*see* Salo et al). 2011;127:1226-35
Zeller S (*see* Akdis et al). 2011;127:701-21
Zelniker T (*see* Geroldinger-Simic et al). 2011;127:616-22
Zhang B, Alysandratos K-D, Angelidou A, Asadi S, Sismanopoulos N, Delivanis D-A, Weng Z, Miniati A,

Vasiadi M, Katsarou-Katsari A, Miao B, Leeman SE, Kalogeromitros D, Theoharides TC. Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: Relevance to atopic dermatitis. 2011;127:1522-31
Zhang K (*see* De Benedetto et al). 2011;127:773-86
Zhang KK (*see* Li et al). 2011;127:765-72
Zhang L (*see* Chinen et al). 2011;127:1579-86
Zhang N (*see* Bachert et al). 2011;127:1313-4 (Correspondence)
Zhang S-Y (*see* Pessach et al). 2011;127:1400-7
Zhang X (*see* Gilles et al). 2011;127:454-61
Zhang Y (*see* Holt et al). 2011;127:1054-64
Zhao B (*see* Ma et al). 2011;127:1447-56
Zhao Y (*see* Brown et al). 2011;127:661-8
Zhou W (*see* Newcomb et al). 2011;127:1006-13
Zhu J (*see* Corren et al). 2011;127:398-405
Zillikens D (*see* Kasperkiewicz et al). 2011;127:267-70 (Letter to the Editor)
Zimmermann C (*see* Dumitru et al). 2011;127:1515-21
Zimmermann M (*see* Akdis et al). 2011;127:701-21
Zimmermann M, Koreck A, Meyer N, Basinski T, Meiler F, Simone B, Woehrl S, Moritz K, Eiwegger T, Schmid-Grendelmeier P, Kemeny L, Akdis CA. TNF-like weak inducer of apoptosis (TWEAK) and TNF-α cooperate in the induction of keratinocyte apoptosis. 2011;127:200-7
Zindel J (*see* Thamrin et al). 2011;127:1494-502
Zoratti E (*see* Joseph et al). 2011;127:1203-10
Zoratti EM (*see* Wegienka et al). 2011;127:287-8 (Correspondence)
Zuberbier T (*see* Bousquet et al). 2011;127:49-56
Zuberbier T (*see* Brożek et al). 2011;127:1643-5 (Correspondence)
Zuidmeer L (*see* van Hoffen et al). 2011;127:100-1 (Letter to the Editor)
Zuo K (*see* Fan et al). 2011;127:521-2 (Letter to the Editor)

Subject index*

The index to the abstracts of the scientific sessions of the annual meeting of the American Academy of Allergy, Asthma and Immunology is located in the February issue, Supplement 1.

A

Abstracts
Program and abstracts of papers to be presented during scientific sessions. American Academy of Allergy, Asthma and Immunology 2011 annual meeting, March 18-22, 2011. 2011;127:AB1-AB412

Adrenergic beta-antagonists
Asthma in the elderly: β-Adrenergic receptor blockers may worsen, β-receptor agonists relieve (with caveats) (Caviglia). 2011;127:1639 (Correspondence)
Asthma in the elderly: β-Adrenergic receptor blockers may worsen, β-receptor agonists relieve (with caveats) (Reed). 2011;127:1639 (Letter reply)

Adverse drug reactions; *see* Drug hypersensitivity

Agammaglobulinemia
Longitudinal decline in lung function in patients with primary immunoglobulin deficiencies (Chen et al). 2011;127:1414-7 (Letter to the editor)

Airway hyperresponsiveness
Airway hyperresponsiveness in elite swimmers: Is it a transient phenomenon? (Bougault et al). 2011;127:892-8
Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma (Huang et al). 2011;127:372-81
Identification of a novel regulator of mucus production in patients with asthma (Leung and Szefler). 2011;127:129 (The editors' choice)
The bronchial microbiome and airway hyperresponsiveness in asthmatic patients (Leung and Szefler). 2011;127:361 (The editors' choice)

Airway inflammation
A high-fat challenge increases airway inflammation and impairs bronchodilator recovery in asthma (Wood et al). 2011;127:1133-40
Allergens, television, and airway inflammation in children with and without allergy (Leung and Szefler). 2011;127:1131 (The editors' choice)
Progressive airflow limitation is a feature of children with severe asthma (F[illegible]patrick and Teague). 2011;127:282-4 (Letter to the editor)

Airway remodeling
Claudin-1 expression in airway smooth muscle exacerbates airway remodeling in asthmatic subjects (Fujita et al). 2011;127:1612-21
The extra domain A of fibronectin is essential for allergen-induced airway fibrosis and hyperresponsiveness in mice (Kohan et al). 2011;127:439-46

Albuterol
Beclomethasone and albuterol rescue medication for asthma exacerbation (Rothenberg and Bousquet). 2011;127:1317-8 (News beyond our pages)

Allergen challenge; *see* Food challenge

Allergenicity; *see* Sensitization

Allergens; *see also specific allergens*
A hypoallergenic cat vaccine based on Fel d 1–derived peptides fused to hepatitis B PreS (Niespodziana et al). 2011;127:1562-70
Future forms of immunotherapy (Casale and Stokes). 2011;127:8-15
Microarrayed recombinant allergens for diagnostic testing (Shreffler). 2011;127:843-9
Necessity of product-specific assessments or restrictions of meta-analyses to well-designed and well-powered studies (Sieber). 2011;127:1075-6 (Correspondence)
Peanut allergy: clinical and immunologic differences among patients from 3 different geographic regions (Vereda et al). 2011;127:603-7
Recombinant allergens for specific immunotherapy (Cromwell et al). 2011;127:865-72 (Current perspectives)
The advent of recombinant allergens and allergen cloning (Thomas). 2011;127:855-9 (Current perspectives)

Allergies; *see also* Food hypersensitivity; *specific allergens*
Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2010 (Sicherer and Leung). 2011;127:326-35
Advances in mechanisms of asthma, allergy, and immunology in 2010 (Broide et al). 2011;127:689-95
Allergen exposure modifies the relation of sensitization to fraction of exhaled nitric oxide levels in children at risk for allergy and asthma (Sordillo et al). 2011;127:1165-72
Allergy Archives (Frankland). 48, 80, 115, 180, 2011;127:43
Allergy-related outcomes in relation to serum IgE: results from the National Health and Nutrition Examination Survey 2005-2006 (Salo et al). 2011;127:1226-35

*January, part 1, pp. 1-296; part 2, pp. S1-S58; February, part 1, pp. 297-552; part 2, pp. AB1-AB412; March, part 1, pp. 553-840; part 2, pp. S59-S84; April, pp. 841-1084; May, pp. 1085-1316; June, pp. 1317-1714.

BCG vaccination and allergy: a systematic review and meta-analysis (Arnoldussen et al). 2011;127: 246-53
Calcitonin gene-related peptide– and vascular endothelial growth factor–positive inflammatory cells in late-phase allergic skin reactions in atopic subjects (Kay). 2011;127:232-7
Can oral pathogens influence allergic disease? (Arbes and Matsui). 2011;127:1119-27 (Rostrum)
Comments on a recent meta-analysis: BCG vaccination and allergic conditions (El-Zein et al). 2011;127:1081 (Correspondence)
Comments on a recent meta-analysis: BCG vaccination and allergic conditions (Arnoldussen et al). 2011;127:1081-2 (Letter reply)
Crucial role for autophagy in degranulation of mast cells (Ushio et al). 2011;127:1267-76
Decreased T-cell receptor signaling through CARD11 differentially compromises forkhead box protein 3–positive regulatory versus T_H2 effector cells to cause allergy (Altin et al). 2011;127:1277-85
Differences in innate immune function between allergic and nonallergic children: new insights into immune ontogeny (Tulic et al). 2011;127:470-8
Efficacy and safety of immunotherapy for allergies to *Alternaria alternata* in children (Kuna et al). 2011;127:502-8
Facilitated antigen presentation and its inhibition by blocking IgG antibodies depends on IgE repertoire complexity (Holm et al). 2011;127:1029-37
Fruit and vegetable consumption in relation to allergy: disease-related modification of consumption? (Rosenlund et al). 2011;127:1219-25
Future forms of immunotherapy (Casale and Stokes). 2011;127:8-15
Gestational age at birth and risk of allergic rhinitis in young adulthood (Crump et al). 2011;127:1173-9
Gut microbiota, probiotics, and vitamin D: interrelated exposures influencing allergy, asthma, and obesity? (Ly et al). 2011;127:1087-94
Identifying seasonal variation in allergic rhinoconjunctivitis (Flynn). 2011;127:1314-5 (Correspondence)
Impaired allergy diagnostics among parasite-infected patients caused by IgE antibodies to the carbohydrate epitope galactose-α1,3-galactose (Arkestål et al). 2011;127:1024-8
Influence of gastrointestinal commensal bacteria on the immune responses that mediate allergy and asthma (McLoughlin and Mills). 2011;127: 1097-107
Inhibition of differentiation, amplification, and function of human T_H17 cells by intravenous immunoglobulin (Maddur et al). 2011;127:823-30
Nutrients and foods for the primary prevention of asthma and allergy: systematic review and meta-analysis (Nurmatov et al). 2011;127:724-33
Recombinant allergens: What does the future hold? (Valenta et al). 2011;127:860-4 (Current perspectives)
Rhinoconjunctival sensitization to hydrolyzed wheat protein in facial soap can induce wheat-dependent exercise-induced anaphylaxis (Fukutomi et al). 2011;127:531-3 (Letter to the editor)
Structural and immunologic cross-reactivity among filarial and mite tropomyosin: implications for the hygiene hypothesis (Santiago et al). 2011;127: 479-86
The European Union at the forefront of the fight against allergy (Rothenberg and Bousquet). 2011;127:554 (News beyond our pages)
Vitamin D levels and food and environmental allergies in the United States: results from the National Health and Nutrition Examination Survey 2005-2006 (Sharief et al). 2011;127:1195-202

Allergy and immunology (specialty)
Advances in basic and clinical immunology in 2010 (Chinen and Shearer). 2011;127:336-41

American Academy of Allergy, Asthma and Immunology (AAAAI); *see also* Abstracts; Practice parameters
A special thank-you to our reviewers. 2011;127: 299-302

Aminopeptidases
Unexpected effect of inhibiting TLA_4H (Rothenberg and Bousquet). 2011;127:2 (News beyond our pages)

Anaphylaxis
Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2010 (Sicherer and Leung). 2011;127: 326-35
Allergen immunotherapy: a practice parameter third update (Cox et al). 2011;127:S1-S58 (Practice parameter)
Circadian clock gene *Period2* regulates a time-of-day–dependent variation in cutaneous anaphylactic reaction (Nakamura et al). 2011;127: 1038-45
Distinct immune effector pathways contribute to the full expression of peanut-induced anaphylactic reactions in mice (Arias et al). 2011;127: 1553-62.e1
Epidemiology of food allergy (Sicherer). 2011;127: 594-602 (Current perspectives)
Frequency of US emergency department visits for food-related acute allergic reactions (Clark et al). 2011;127:682-3 (Letter to the editor)
IgE-mediated systemic anaphylaxis and impaired tolerance to food antigens in mice with enhanced IL-4 receptor signaling (Mathias et al). 2011;127: 795-805
Ingested allergens must be absorbed systemically to induce systemic anaphylaxis (Strait et al). 2011;127:982-9
Neutrophils and IgG are required in active and passive anaphylaxis in mice (Rothenberg and

Bousquet). 2011;127:1317-8 (News beyond our pages)
Prevention of severe food allergy should focus on the blood and not the gut (Leung and Szefler). 2011;127:873 (The editors' choice)
Rhinoconjunctival sensitization to hydrolyzed wheat protein in facial soap can induce wheat-dependent exercise-induced anaphylaxis (Fukutomi et al). 2011;127:531-3 (Letter to the editor)
Stinging insect hypersensitivity: a practice parameter update 2011 (Golden et al). 2011;127:852-4 (Practice parameter)
The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1,3-galactose (Commins et al). 2011;127:1286-93
Tick bites: a common cause of IgE antibodies to alpha-gal (Leung and Szefler). 2011;127:1131 (The editors' choice)
World Allergy Organization anaphylaxis guidelines: summary (Simons et al). 2011;127:587-93 (Practice paper)

Angiogenesis
Angiogenesis linked to IL-25–mediated asthma (Rothenberg and Bousquet). 2011;127:553-4 (News beyond our pages)

Animals, domestic; *see also* Farming-related exposure
A hypoallergenic cat vaccine based on Fel d 1–derived peptides fused to hepatitis B PreS (Niespodziana et al). 2011;127:1562-70
Allergen-specific IgG antibody levels modify the relationship between allergen-specific IgE and wheezing in childhood (Custovic et al). 2011;127:1480-5
Allergens, television, and airway inflammation in children with and without allergy (Leung and Szefler). 2011;127:1131 (The editors' choice)
Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy (Worm et al). 2011;127:89-97
Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge (Corren et al). 2011;127:398-405
Prenatal animal contact and gene expression of innate immunity receptors at birth are associated with atopic dermatitis (Roduit et al). 2011;127:179-85
Prenatal animal contact may prevent atopic dermatitis (Leung and Szefler). 2011;127:128 (The editors' choice)
Quality of life and pets (Brenna). 2011;127:287 (Correspondence)
Quality of life and pets (Wegienka et al). 2011;127:287-8 (Letter reply)
The risk of wheezing decreases with increasing allergen-specific IgG antibody levels (Leung and Szefler). 2011;127:1438-9 (The editors' choice)

Antibiotics; *see also specific antibiotics*
More evidence implicating antibiotics in the development of pediatric asthma (Rothenberg and Bousquet). 2011;127:553 (News beyond our pages)

Antigen presentation
Facilitated antigen presentation and its inhibition by blocking IgG antibodies depends on IgE repertoire complexity (Holm et al). 2011;127:1029-37
Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies (James et al). 2011;127:509-16

Antigens
Insights into the helminth-allergy interface through allergen cross-reactivity (Leung and Szefler). 2011;127:362 (The editors' choice)

Antihistamines
Clinical utility of the Chronic Urticaria Index (Biagtan et al). 2011;127:1626-7 (Letter to the editor)

Apoptosis
TNF-like weak inducer of apoptosis (TWEAK) and TNF-α cooperate in the induction of keratinocyte apoptosis (Zimmermann et al). 2011;127:200-7
Two new families with X-linked inhibitor of apoptosis deficiency and a review of all 26 published cases (Horn et al). 2011;127:544-6 (Letter to the editor)

Aspergillosis
Restoration of anti-*Aspergillus* defense by neutrophil extracellular traps in human chronic granulomatous disease after gene therapy is calprotectin-dependent (Bianchi et al). 2011;127:1243-52

Aspirin
Targeted eicosanoid lipidomics of exhaled breath condensate provide a distinct pattern in the aspirin-intolerant asthma phenotype (Sanak et al). 2011;127:1141-7

Asthma
A call for action: comparative effectiveness research in asthma (Krishnan et al). 2011;127:123-7 (Rostrum)
A high-fat challenge increases airway inflammation and impairs bronchodilator recovery in asthma (Wood et al). 2011;127:1133-40
A new mediator of inflammation of the lung (Rothenberg and Bousquet). 2011;127:297 (News beyond our pages)
A nonredundant role for mouse Serpinb3a in the induction of mucus production in asthma (Sivaprasad et al). 2011;127:254-61
A physiologic signature for asthma (Rothenberg and Bousquet). 2011;127:553 (News beyond our pages)
Advances in adult asthma diagnosis and treatment and HEDQ in 2010 (Apter). 2011;127:116-22
Advances in mechanisms of asthma, allergy, and immunology in 2010 (Broide et al). 2011;127:689-95
Allele-specific transcription of the asthma-associated PHD finger protein 11 gene *(PHF11)* modulated by

octamer-binding transcription factor 1 (Oct-1) (Holt et al). 2011;127:1054-62
Angiogenesis linked to IL-25–mediated asthma (Rothenberg and Bousquet). 2011;127:553-4 (News beyond our pages)
Anti–IL-13 evaluated in mild asthma (Rothenberg and Bousquet). 2011;127:297-8 (News beyond our pages)
Assessing the reproducibility of asthma genome-wide association studies in a general clinical population (Himes et al). 2011;127:1067-9 (Letter to the editor)
Asthma-associated polymorphisms in 17q21 influence cord blood *ORMDL3* and *GSDMA* gene expression and IL-17 secretion (Lluis et al). 2011;127:1587-94
Asthma control differences between inhaled corticosteroids likely related to differences in patient severity (Stanford et al). 2011;127:835 (Correspondence)
Asthma control differences between inhaled corticosteroids likely related to differences in patient severity (Price et al). 2011;127:835-6 (Letter reply)
Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome (Lötvall et al). 2011;127:355-60 (Rostrum)
Asthma in the elderly: β-Adrenergic receptor blockers may worsen, β-receptor agonists relieve (with caveats) (Caviglia). 2011;127:1639 (Correspondence)
Asthma in the elderly: β-Adrenergic receptor blockers may worsen, β-receptor agonists relieve (with caveats) (Reed). 2011;127:1639 (Letter reply)
Bacterial components plus vitamin D: the ultimate solution to the asthma (autoimmune disease) epidemic? (Weiss). 2011;127:1128-30 (Editorial)
Beclomethasone and albuterol rescue medication for asthma exacerbation (Rothenberg and Bousquet). 2011;127:1317-8 (News beyond our pages)
Celiac disease confers a 1.6-fold increased risk of asthma: a nationwide population-based cohort study (Ludvigsson et al). 2011;127:1071-3 (Letter to the editor)
Childhood eczema and rhinitis predict atop · but not nonatopic adult asthma: a prospective cohort study over 4 decades (Martin et al). 2011;127: 1473-9.e1
Chronic cough and irritable larynx (Bucca et al). 2011;127:412-9
Claudin-1 expression in airway smooth muscle exacerbates airway remodeling in asthmatic subjects (Fujita et al). 2011;127: 1612-21.e8
Comments on Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (Spector et al). 2011;127:1641-2 (Correspondence)
Comments on Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (Brożek et al). 2011;127:1643-5 (Letter reply)
Costs of asthma in the United States: 2002-2007 (Barnett and Nurmagambetov). 2011;127:145-52
Daily symptom monitoring reduces oral corticosteroid doses in patients with refractory asthma (Rothenberg and Bousquet). 2011;127:1317-8 (News beyond our pages)
Differences in recommendations between the Allergic Rhinitis and its Impact on Asthma Update 2010 and US Rhinitis Practice Parameters (Chipps et al). 2011;127:1640-1.e1 (Correspondence)
Effects of distance from a heavily transited avenue on asthma and atopy in a periurban shantytown in Lima, Peru (Baumann et al). 2011;127:875-82
Enhancing patients' expectations of asthma medication might improve medication adherence (Leung and Szefler). 2011;127:361 (The editors' choice)
Eosinophil and neutrophil extracellular DNA traps in human allergic asthmatic airways (Dworski et al). 2011;127:1260-6
Exhaled nitric oxide in prednisone-dependent asthma to identify the eosinophilic positive phenotype (Silkoff and Loza). 2011;127:834 (Correspondence)
Exhaled nitric oxide in prednisone-dependent asthma to identify the eosinophilic positive phenotype (Nair et al). 2011;127:834 (Letter reply)
Exogenous IFN-β has antiviral and anti-inflammatory properties in primary bronchial epithelial cells from asthmatic subjects exposed to rhinovirus (Cakebread et al). 2011;127:1148-54
Genome-wide interaction analysis for asthma and environmental exposure to farming (Leung and Szefler). 2011;127:129 (The editors' choice)
Gut microbiota, probiotics, and vitamin D: interrelated exposures influencing allergy, asthma, and obesity? (Ly et al). 2011;127:1087-94
Human T_H17 cells express a functional IL-13 receptor and IL-13 attenuates IL-17A production (Newcomb et al). 2011;127:1006-13
Identification of a novel regulator of mucus production in patients with asthma (Leung and Szefler). 2011;127:129 (The editors' choice)
IL1RL1 gene: role in asthma, eosinophilia, and serum IL1RL1-a levels (Leung and Szefler). 2011;127: 723 (The editors' choice)
Importance of hedgehog interacting protein and other lung function genes in asthma (Li et al). 2011;127: 1457-65
Increased nasal IL-5 levels act as a predisposing factor of asthma in southern China (Fan et al). 2011;127: 1312-3 (Correspondence)
Increased nasal IL-5 levels act as a predisposing factor of asthma in southern China (Bachert et al). 2011;127:1313-4 (Letter reply)

Influence of gastrointestinal commensal bacteria on the immune responses that mediate allergy and asthma (McLoughlin and Mills). 2011;127: 1097-107

Mast cell–associated alveolar inflammation in patients with atopic uncontrolled asthma (Andersson et al). 2011;127:905-12

Metabolic dysfunction associated with asthma and obesity (Rothenberg and Bousquet). 2011;127:841 (News beyond our pages)

Montelukast might improve compliance with subcutaneous immunotherapy treatments in patients with allergic asthma (Vaughn). 2011;127: 286 (Correspondence)

Montelukast might improve compliance with subcutaneous immunotherapy treatments in patients with allergic asthma (Majak and Stelmach). 2011;127:286 (Letter reply)

More alternative activation of macrophages in lungs of asthmatic patients (Melgert et al). 2011;127:831-3 (Letter to the editor)

Novel findings for a functional role of asthma-associated polymorphisms in the 17q21 locus (Leung and Szefler). 2011;127:1438-9 (The editors' choice)

Obesity and asthma: an association modified by age of asthma onset (Holguin et al). 2011;127:1486-93

Paracetamol, nonsteroidal anti-inflammatory drugs, and risk of asthma in adult survivors of childhood cancer (Marquis et al). 2011;127:270-2 (Letter to the editor)

Potential roles of pentosidine in age-related and disease-related impairment of pulmonary functions in patients with asthma (Kanazawa et al). 2011;127:899-904

Predicting asthma exacerbations: peak expiratory flow revisited (Fuhlbrigge). 2011;127:1503-4 (Editorial)

Predicting future risk of asthma exacerbations using individual conditional probabilities (Thamrin et al). 2011;127:1494-1502

Severe asthma phenotype driven by IL-17A (Rothenberg and Bousquet). 2011;127:2 (News beyond our pages)

Sputum gene expression profiles define transcriptional phenotypes of asthma (Leung and Szefler). 2011;127:128 (The editors' choice)

Steroids and extracellular signal-regulated kinase 1/2 activity suppress activating transcription factor 3 expression in patients with severe asthma (Roussel et al). 2011;127:1632-5 (Letter to the editor)

Surveillance of the cost of asthma in the 21st century (Gergen). 2011;127:370-1 (Editorial)

Targeted eicosanoid lipidomics of exhaled breath condensate provide a distinct pattern in the aspirin-intolerant asthma phenotype (Sanak et al). 2011;127:1141-7

T_H17 cytokines induce human airway smooth muscle cell migration (Chang et al). 2011;127:1046-53

The Asthma Predictive Index: not a useful tool in clinical practice (Brand). 2011;127:293-4 (Correspondence)

The bronchial microbiome and airway hyperresponsiveness in asthmatic patients (Leung and Szefler). 2011;127:361 (The editors' choice)

The burden of adult asthma in the United States: evidence from the Medical Expenditure Panel Survey (Sullivan et al). 2011;127:363-9

The extra domain A of fibronectin is essential for allergen-induced airway fibrosis and hyperresponsiveness in mice (Kohan et al). 2011;127:439-46

The Madison Avenue effect: how drug presentation style influences adherence and outcome in patients with asthma (Clerisme-Beaty et al). 2011;127: 406-11

The march towards asthma in the first 4 decades (Leung and Szefler). 2011;127:1438-9 (The editors' choice)

The Severe Asthma Research Program (SARP) (Rothenberg and Bousquet). 2011;127:1085-6 (News beyond our pages)

Transcriptional phenotypes of asthma defined by gene expression profiling of induced sputum samples (Baines et al). 2011;127:153-60

Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbation (Meltzer et al). 2011;127:167-72

Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccine (Busse et al). 2011;127:130-7

When should we put evidence into clinical practice? (Türktas et al). 2011;127:1078 (Correspondence)

When should we put evidence into clinical practice? (Razi and Harmanci). 2011;127:1078-9 (Letter reply)

Asthma, adolescent

Asthma control also for teenagers (Rothenberg and Bousquet). 2011;127:298 (News beyond our pages)

Asthma, pediatric

A lower prevalence of asthma among patients with chronic rhinosinusitis in southern China (Fan et al). 2011;127:520-2 (Letter to the editor)

Advances in pediatric asthma in 2010: addressing the major issues (Szefler). 2011;127:102-15

Allergen exposure modifies the relation of sensitization to fraction of exhaled nitric oxide levels in children at risk for allergy and asthma (Sordillo et al). 2011;127:1165-72

Comparison of childhood wheezing phenotypes in 2 birth cohorts: ALSPAC and PIAMA (Savenije et al). 2011;127:1502-12

Cost-effectiveness analysis of fluticasone versus montelukast in children with mild-to-moderate

persistent asthma in the Pediatric Asthma Controller Trial (Wang et al). 2011;127:161-6
Decreased response to inhaled steroids in overweight and obese asthmatic children (Forno et al). 2011;127:741-9
Elevation of IgE in children with sickle cell disease is associated with doctor diagnosis of asthma and increased morbidity (An et al). 2011;127:1440-6
Endotyping early childhood asthma by quantitative symptom assessment (Bisgaard et al). 2011;127:1155-64
First results from the Urban Environment and Childhood Asthma study (Leung and Szefler). 2011;127:873 (The editors' choice)
Forced expiratory flow between 25% and 75% of vital capacity may be a marker of bronchial impairment in allergic rhinitis (Ciprandi and Cirillo). 2011;127:549 (Correspondence), 2011;127:550-1 (Letter reply)
Forced expiratory flow between 25% and 75% of vital capacity may be a marker of bronchial impairment in allergic rhinitis (Simon et al). 2011;127:550 (Letter reply)
Gene-environment interaction for childhood asthma and exposure to farming in Central Europe (Ege et al). 2011;127:138-44
Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program (Fitzpatrick et al). 2011;127:382-9
Interleukin-1 receptor–like 1 polymorphisms are associated with serum IL1RL1-a, eosinophils, and asthma in childhood (Savenije et al). 2011;127:750-6
Maternal folate levels in pregnancy and asthma in children at age 3 years (Håberg et al). 2011;127:262-4 (Letter to the editor)
Metabolomic profiling of asthma: diagnostic utility of urine nuclear magnetic resonance spectroscopy (Saude et al). 2011;127:757-64
More evidence implicating antibiotics in the development of pediatric asthma (Rothenberg and Bousquet). 2011;127:553 (News beyond our pages)
Nutrients and foods for the primary prevention of asthma and allergy: systematic review and meta-analysis (Nurmatov et al). 2011;127:724-33
Obese/overweight asthmatic children have decreased response to inhaled steroids (Leung and Szefler). 2011;127:722 (The editors' choice)
Obesity and asthma: an association modified by age of asthma onset (Holguin et al). 2011;127:1486-93
Omalizumab add-on therapy improves asthma outcomes in children (Rothenberg and Bousquet). 2011;127:1317-8 (News beyond our pages)
Parental psychosocial stress and asthma morbidity in Puerto Rican twins (Lange et al). 2011;127:734-40
Progressive airflow limitation is a feature of children with severe asthma (Fitzpatrick and Teague). 2011;127:282-4 (Letter to the editor)
Sex dependence of airflow limitation and air trapping in children with severe asthma (Sorkness et al). 2011;127:1073-4 (Letter to the editor)
Sex differences in asthma during the first 8 years of life: the Prevention and Incidence of Asthma and Mite Allergy (PIAMA) birth cohort study (Wijga et al). 2011;127:275-7 (Letter to the editor)
The asthma predictive index remains a useful tool to predict asthma in young children with recurrent wheeze in clinical practice (Castro-Rodriguez et al). 2011;127:1082-3 (Correspondence)
The magnetic power of urine in the diagnosis of asthma (Leung and Szefler). 2011;127:722 (The editors' choice)
Thiol redox disturbances in children with severe asthma are associated with posttranslational modification of the transcription factor nuclear factor (erythroid-derived 2)–like 2 (Fitzpatrick et al). 2011;127:1604-11
To wheeze or not to wheeze—that is NOT the question (Leung and Szefler). 2011;127:1132 (The editors' choice)
Trajectories of childhood wheeze (von Mutius). 2011;127:1513-4 (Editorial)
Unraveling mechanisms of severe asthma in childhood (Leung and Szefler). 2011;127:1438-9 (The editors' choice)
Validation of the Asthma Predictive Index and comparison with simpler clinical prediction rules (Leonardi et al). 2011;127:1466-72
Vitamin D supplementation in children may prevent asthma exacerbation triggered by acute respiratory infection (Majak et al). 2011;127:1294-6 (Letter to the editor)

Athletes; *see* Exercise

Atopy

A genome-wide association study to identify genetic determinants of atopy in subjects from the United Kingdom (Wan et al). 2011;127:223-31
Altered T-cell receptor signaling in the pathogenesis of allergic disease (Datta and Milner). 2011;127:351-4 (Rostrum)
Association between obesity and atopic dermatitis in childhood: a case-control study (Silverberg et al). 2011;127:1180-6
BCG vaccination and allergy: a systematic review and meta-analysis (Arnoldussen et al). 2011;127:246-53
Celiac disease confers a 1.6-fold increased risk of asthma: a nationwide population-based cohort study (Ludvigsson et al). 2011;127:1071-3 (Letter to the editor)
Effect of day care attendance on sensitization and atopic wheezing differs by Toll-like receptor 2

genotype in 2 population-based birth cohort studies (Custovic et al). 2011;127:390-7
Effects of distance from a heavily transited avenue on asthma and atopy in a periurban shantytown in Lima, Peru (Baumann et al). 2011;127:875-82
Maternal allergy modulates cord blood hematopoietic progenitor Toll-like receptor expression and function (Reece et al). 2011;127:447-53
Preterm birth protects against atopy in adult life (Leung and Szefler). 2011;127:874 (The editors' choice)
Preterm birth reduces the incidence of atopy in adulthood (Siltanen et al). 2011;127:935-42
Relationships among environmental exposures, cord blood cytokine responses, allergy, and wheeze at 1 year of age in an inner-city birth cohort (Urban Environment and Childhood Asthma study) (Wood et al). 2011;127:913-9
The effect of prophylactic palivizumab on recurrent wheezing in children with an atopic family history (Gaffin et al). 2011;127:292-3 (Correspondence)
The effect of prophylactic palivizumab on recurrent wheezing in children with an atopic family history (Simões et al). 2011;127:293 (Letter reply)

Atopy patch tests
$CD8^+$T cells are recruited early to allergen exposure sites in atopy patch test reactions in human atopic dermatitis (Hennino et al). 2011;127:1064-7 (Letter to the editor)

Autoimmune diseases
Bacterial components plus vitamin D: the ultimate solution to the asthma (autoimmune disease) epidemic? (Weiss). 2011;127:1128-30 (Editorial)
Current and novel therapeutics in the treatment of systemic lupus erythematosus (Yildirim-Toruner and Diamond). 2011;127:303-12
Plastic IL-17 cells (Rothenberg and Bousquet). 2011;127:1317-8 (News beyond our pages)
The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders (Ballow). 2011;127:315-23
The L412F variant of Toll-like receptor 3 *(TLR3)* is associated with cutaneous candidiasis, increased susceptibility to cytomegalovirus, and autoimmunity (Nahum et al). 2011;127:528-31 (Letter to the editor)

Autophagy
Crucial role for autophagy in degranulation of mast cells (Ushio et al). 2011;127:1267-76

B

B lymphocytes
Lessons from Smith-Magenis syndrome: low transmembrane activator and calcium modulator and cyclophilin ligand interactor expression leads to B-cell dysfunction (Leung and Szefler). 2011;127:1438-9 (The editors' choice)
The C76R transmembrane activator and calcium modulator cyclophilin ligand interactor mutation disrupts antibody production and B-cell homeostasis in heterozygous and homozygous mice (Bacchelli et al). 2011;127:1253-9
Transmembrane activator and CAML interactor (TACI) haploinsufficiency results in B-cell dysfunction in patients with Smith-Magenis syndrome (Chinen et al). 2011;127:1579-86

Bacillus anthracis
The adenylate cyclase toxin of *Bacillus anthracis* is a potent promoter of T_H17 cell development (Paccani et al). 2011;127:1636-7 (Letter to the editor)

Bacteria; *see also* Intestinal microflora
Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma (Huang et al). 2011;127:372-81
Can oral pathogens influence allergic disease? (Arbes and Matsui). 2011;127:1119-27 (Rostrum)
The bronchial microbiome and airway hyperresponsiveness in asthmatic patients (Leung and Szefler). 2011;127:361 (The editors' choice)

BCG vaccination
BCG vaccination and allergy: a systematic review and meta-analysis (Arnoldussen et al). 2011;127:246-53
Comments on a recent meta-analysis: BCG vaccination and allergic conditions (El-Zein et al). 2011;127:1081 (Correspondence)
Comments on a recent meta-analysis: BCG vaccination and allergic conditions (Arnoldussen et al). 2011;127:1081-2 (Letter reply)

Beclomethasone
Beclomethasone and albuterol rescue medication for asthma exacerbation (Rothenberg and Bousquet). 2011;127:1317-8 (News beyond our pages)

Bet v 1 allergen
Reshaping the Bet v 1 fold modulates T_H polarization (Wallner et al). 2011;127:1571-8.e9

Biological markers
Advances in pediatric asthma in 2010: addressing the major issues (Szefler). 2011;127:102-15
Tetramers offer a new approach for monitoring patients with peanut allergy receiving immunotherapy (Leung and Szefler). 2011;127:1132 (The editors' choice)
The European Union at the forefront of the fight against allergy (Rothenberg and Bousquet). 2011;127:554 (News beyond our pages)

Birch pollen allergy
Birch pollen-related food allergy: clinical aspects and the role of allergen-specific IgE and IgG_4 antibodies (Geroldinger-Simic et al). 2011;127:616-22

Effect of birch pollen-specific immunotherapy on birch pollen-related hazelnut allergy (van Hoffen et al). 2011;127:100-1 (Letter to the editor)
Freezing does not alter antigenic properties of fresh fruits for skin testing in patients with birch tree pollen–induced oral allergy syndrome (Bégin et al). 2011;127:1624-6.e3 (Letter to the editor)

Breast-feeding
Food protein–induced enterocolitis syndrome by cow's milk proteins passed through breast milk (Monti et al). 2011;127:679-80 (Letter to the editor)
Supplementation with cow's milk at birth is not recommended (Koletzko et al). 2011;127:836-8 (Correspondence)
Supplementation with cow's milk at birth is not recommended (Katz et al). 2011;127:839-40 (Letter reply)

Bronchoconstriction
Toll-like receptor 7 agonists are potent and rapid bronchodilators in guinea pigs (Kaufman et al). 2011;127:462-9

Bronchodilator agents
A taste for relaxation (Rothenberg and Bousquet). 2011;127:1 (News beyond our pages)

C

Calcitonin gene-related peptide
Calcitonin gene-related peptide– and vascular endothelial growth factor–positive inflammatory cells in late-phase allergic skin reactions in atopic subjects (Kay). 2011;127:232-7

Candidiasis
New host defense mechanisms against *Candida* species clarify the basis of clinical phenotypes (Hanna and Etzoni). 2011;127:1433-7 (Current perspectives)

Cathelicidins
Circulating levels of 25-hydroxyvitamin D and human cathelicidin in healthy adults (Bhan et al). 2011;127:1302-4 (Letter to the editor)

Cats; *see* Animals, domestic

CD19
Defects in the CD19 complex predispose to glomerulonephritis, as well as IgG1 subclass deficiency (Vince et al). 2011;127:538-41 (Letter to the editor)

Celiac disease
Celiac disease confers a 1.6-fold increased risk of asthma: a nationwide population-based cohort study (Ludvigsson et al). 2011;127:1071-3 (Letter to the editor)

Cephalosporins
Penicillin allergy might not be very common in subjects with cephalosporin allergy (Macy). 2011;127:1638 (Correspondence)
Penicillin allergy might not be very common in subjects with cephalosporin allergy (Romano et al). 2011;127:1638-9 (Letter reply)

Chagas disease
Sequence variation in the *IL4* gene and resistance to *Trypanosoma cruzi* infection in Bolivians (Alvarado Arnez et al). 2011;127:279-82 (Letter to the editor)

Churg-Strauss syndrome
IL-25 implicated in Churg-Strauss syndrome (Rothenberg and Bousquet). 2011;127:297 (News beyond our pages)

Circadian rhythm
Circadian clock gene *Period2* regulates a time-of-day–dependent variation in cutaneous anaphylactic reaction (Nakamura et al). 2011;127:1038-45

Claudins
Claudin-1 expression in airway smooth muscle exacerbates airway remodeling in asthmatic subjects (Fujita et al). 2011;127:1612-21.e8

Clinical trials
A call for action: comparative effectiveness research in asthma (Krishnan et al). 2011;127:123-7 (Rostrum)
How representative are clinical study patients with allergic rhinitis in primary care? (Costa et al). 2011;127:920-6
The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA2LEN) article (Bousquet et al). 2011;127:49-56

Cloning
The advent of recombinant allergens and allergen cloning (Thomas). 2011;127:855-9 (Current perspectives)

Colds, common; *see* Rhinovirus

Common variable immunodeficiency
Common variable immunodeficiency and hemophagocytic features associated with a *FAS* gene mutation. 2011;127:1411-4 (Letter to the editor)
Common variable immunodeficiency presenting as herpes simplex virus encephalitis (Borish et al). 2011;127:541-3 (Letter to the editor)
Genome-wide association identifies diverse causes of common variable immunodeficiency (Orange et al). 2011;127:1360-7
Inflammation in common variable immunodeficiency is associated with a distinct $CD8^+$ response to cytomegalovirus (Marashi et al). 2011;127:1385-93
The case of *TACI* C104R: mutation or polymorphism? (Leung and Szefler). 2011;127:1132 (The editors' choice)
The C76R transmembrane activator and calcium modulator cyclophilin ligand interactor mutation

disrupts antibody production and B-cell homeostasis in heterozygous and homozygous mice (Bacchelli et al). 2011;127:1253-9

Complement

N1H1 severity in middle-aged adults (Rothenberg and Bousquet). 2011;127:842 (News beyond our pages)

CONSORT criteria

The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA2LEN) article (Bousquet et al). 2011;127:49-56

Continuing Medical Education. 2011;127:16-7, 28-9, 313-4, 324-5, 574-5, 585-6, 850-1, 1095-6, 1108-9, 1327-8, 1342-3

Corrections

A population-based study on peanut, tree nut, fish, shellfish, and sesame allergy prevalence in Canada (Ben-Shoshan et al) (2010;125:1327-35). 2011;127:840

Allergen immunotherapy: a practice parameter third update (Cox et al) (2011;127:S1-S58). 2011;127:840

Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond (Calderón et al) (2011;127:30-8). 2011;127:859

Association of Atopic Dermatitis (AD) Severity to Milk and Egg Allergy Outcomes in a Cohort of Atopic, Food Allergic Children (COFAR) (Scurlock) (2011;127:AB36). 2011;127:1315

House dust mite sublingual immunotherapy: results of a US trial (Bush et al) (2011;127:974-81). 2011;127:1561

Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome (Cox et al) (2010;125:1336-43). 2011;127:840

Mepolizumab does not alter levels of eosinophils, T cells, and mast cells in the duodenal mucosa in eosinophilic esophagitis (Conus et al) (2010;126:175-7). 2011;127:833

Correspondence; *see also* Letters to the editor

Age- and serotype-dependent antibody response to pneumococcal polysaccharides (Bossuyt et al). 2011;127:1079-80 (Correspondence)

Age- and serotype-dependent antibody response to pneumococcal polysaccharides (Balloch et al). 2011;127:1080-1 (Letter reply)

Asthma control differences between inhaled corticosteroids likely related to differences in patient severity (Stanford et al). 2011;127:835 (Correspondence)

Asthma control differences between inhaled corticosteroids likely related to differences in patient severity (Price et al). 2011;127:835-6 (Letter reply)

Asthma in the elderly: β-Adrenergic receptor blockers may worsen, β-receptor agonists relieve (with caveats) (Caviglia). 2011;127:1639 (Correspondence)

Asthma in the elderly: β-Adrenergic receptor blockers may worsen, β-receptor agonists relieve (with caveats) (Reed). 2011;127:1639 (Letter reply)

Comments on a recent meta-analysis: BCG vaccination and allergic conditions (El-Zein et al). 2011;127:1081 (Correspondence)

Comments on a recent meta-analysis: BCG vaccination and allergic conditions (Arnoldussen et al). 2011;127:1081-2 (Letter reply)

Comments on Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (Spector et al). 2011;127:1641-2 (Correspondence)

Comments on Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (Brożek et al). 2011;127:1643-5 (Letter reply)

Differences in recommendations between the Allergic Rhinitis and its Impact on Asthma Update 2010 and US Rhinitis Practice Parameters (Chipps et al). 2011;127:1640-1.e1 (Correspondence)

Dose-dependence of sublingual immunotherapy shown by meta-analysis (Frati et al). 2011;127:1076-7 (Correspondence)

Dose-dependence of sublingual immunotherapy shown by meta-analysis (Di Lorenzo and Di Bona). 2011;127:1077-8 (Letter reply)

Exhaled nitric oxide in prednisone-dependent asthma to identify the eosinophilic positive phenotype (Silkoff and Loza). 2011;127:834 (Correspondence)

Exhaled nitric oxide in prednisone-dependent asthma to identify the eosinophilic positive phenotype (Nair et al). 2011;127:834 (Letter reply)

Fluticasone furoate nasal spray is the only intranasal corticosteroid to reduce the ocular symptoms of seasonal allergic rhinitis consistently (Keith and Lee). 2011;127:288-9 (Correspondence)

Fluticasone furoate nasal spray is the only intranasal corticosteroid to reduce the ocular symptoms of seasonal allergic rhinitis consistently (Prenner et al). 2011;127:289 (Letter reply)

Forced expiratory flow between 25% and 75% of vital capacity may be a marker of bronchial impairment in allergic rhinitis (Ciprandi and Cirillo). 2011;127:549 (Correspondence), 2011;127:550-1 (Letter reply)

Forced expiratory flow between 25% and 75% of vital capacity may be a marker of bronchial impairment in allergic rhinitis (Simon et al). 2011;127:550 (Letter reply)

How to improve the safety of adrenaline (epinephrine) autoinjectors (Kränke et al). 2011;127:1646 (Correspondence)

Identifying seasonal variation in allergic rhinoconjunctivitis (Flynn). 2011;127:1314-5 (Correspondence)

Increased nasal IL-5 levels act as a predisposing factor of asthma in southern China (Fan et al). 2011;127: 1312-3 (Correspondence)
Increased nasal IL-5 levels act as a predisposing factor of asthma in southern China (Bachert et al). 2011;127:1313-4 (Letter reply)
Lack of pretreatment cost-effectiveness and side effects of omalizumab versus prednisone/montelukast on tolerability of immunotherapy (Rosenberg). 2011;127:548 (Correspondence)
Lack of pretreatment cost-effectiveness and side effects of omalizumab versus prednisone/montelukast on tolerability of immunotherapy (Massanari et al). 2011;127:548-9 (Letter reply)
Moderately complex US Food and Drug Administration–cleared method for human IgE antibody serology (Saper). 2011;127:547 (Correspondence)
Moderately complex US Food and Drug Administration–cleared method for human IgE antibody serology (Hamilton). 2011;127:547-8 (Letter reply)
Montelukast might improve compliance with subcutaneous immunotherapy treatments in patients with allergic asthma (Vaughn). 2011;127: 286 (Correspondence)
Montelukast might improve compliance with subcutaneous immunotherapy treatments in patients with allergic asthma (Majak and Stelmach). 2011;127:286 (Letter reply)
Necessity of product-specific assessments or restrictions of meta-analyses to well-designed and well-powered studies (Sieber). 2011;127:1075-6 (Correspondence)
Office-based oral immunotherapy for food allergy is safe and effective (Wasserman et al). 2011;127: 290-1 (Correspondence)
Office-based oral immunotherapy for food allergy is safe and effective (Thyagarajan et al). 2011;127: 291-2 (Letter reply)
Oral immunotherapy: ready for prime time? (Katz et al). 2011;127:289-90 (Correspondence)
Penicillin allergy might not be very common in subjects with cephalosporin allergy (Macy). 2011;127:1638 (Correspondence)
Penicillin allergy might not be very common in subjects with cephalosporin allergy (Romano et al). 2011;127:1638-9 (Letter reply)
Quality of life and pets (Brenna). 2011;127:287 (Correspondence)
Quality of life and pets (Wegienka et al). 2011;127: 287-8 (Letter reply)
Salbutamol inhaler misuse resulting in skin burn (Bonniaud et al). 2011;127:295 (Correspondence)
Supplementation with cow's milk at birth is not recommended (Koletzko et al). 2011;127:836-8 (Correspondence)
Supplementation with cow's milk at birth is not recommended (Katz et al). 2011;127:839-40 (Letter reply)
The Asthma Predictive Index: not a useful tool in clinical practice (Brand). 2011;127:293-4 (Correspondence)
The asthma predictive index remains a useful tool to predict asthma in young children with recurrent wheeze in clinical practice (Castro-Rodriguez et al). 2011;127:1082-3 (Correspondence)
The effect of prophylactic palivizumab on recurrent wheezing in children with an atopic family history (Gaffin et al). 2011;127:292-3 (Correspondence)
The effect of prophylactic palivizumab on recurrent wheezing in children with an atopic family history (Simões et al). 2011;127:293 (Letter reply)
Toward a global classification of mast cell activation diseases (Molderings et al). 2011;127:1311 (Correspondence)
Toward a global classification of mast cell activation diseases (Akin et al). 2011;127:1311-2 (Letter reply)
When should we put evidence into clinical practice? (Türktas et al). 2011;127:1078 (Correspondence)
When should we put evidence into clinical practice? (Razi and Harmanci). 2011;127:1078-9 (Letter reply)

Corticosteroids; *see also specific corticosteroids*
Advances in adult asthma diagnosis and treatment and HEDQ in 2010 (Apter). 2011;127:116-22
Asthma control differences between inhaled corticosteroids likely related to differences in patient severity (Stanford et al). 2011;127:835 (Correspondence)
Asthma control differences between inhaled corticosteroids likely related to differences in patient severity (Price et al). 2011;127:835-6 (Letter reply)
Daily symptom monitoring reduces oral corticosteroid doses in patients with refractory asthma (Rothenberg and Bousquet). 2011;127:1317-8 (News beyond our pages)
Decreased response to inhaled steroids in overweight and obese asthmatic children (Forno et al). 2011;127:741-9
Hypersensitivity to systemic corticosteroids: an infrequent but potentially life-threatening condition (Rachid et al). 2011;127:524-8 (Letter to the editor)
New evidence of lack of inhaled corticosteroid effects on the fetus (Rothenberg and Bousquet). 2011;127: 1 (News beyond our pages)
Obese/overweight asthmatic children have decreased response to inhaled steroids (Leung and Szefler). 2011;127:722 (The editors' choice)
Run-in oral steroids improve topical nasal steroid response (Rothenberg and Bousquet). 2011;127: 1317-8 (News beyond our pages)

Steroids and extracellular signal-regulated kinase 1/2 activity suppress activating transcription factor 3 expression in patients with severe asthma (Roussel et al). 2011;127:1632 (Letter to the editor)

Cost-benefit analysis; *see also* Health care costs

Cost-effectiveness analysis of fluticasone versus monte!ukast in children with mild-to-moderate persistent asthma in the Pediatric Asthma Controller Trial (Wang et al). 2011;127:161-6

Disease-modifying effect and economic implications of sublingual immunotherapy (Canonica and Passalacqua). 2011;127:44-5 (Editorial)

Health economics of allergen-specific immunotherapy in the United States (Lockey and Hankin). 2011;127:39-43 (Editorial)

Surveillance of the cost of asthma in the 21st century (Gergen). 2011;127:370-1 (Editorial)

The burden of adult asthma in the United States: evidence from the Medical Expenditure Panel Survey (Sullivan et al). 2011;127:363-9

Cough

Chronic cough and irritable larynx (Bucca et al). 2011;127:412-9

Cross-reactivity

Improvement of mustard *(Sinapis alba)* allergy diagnosis and management by linking clinical features and component-resolved approaches (Vereda et al). 2011;127:1304-7 (Letter to the editor)

Insights into the helminth-allergy interface through allergen cross-reactivity (Leung and Szefler). 2011;127:362 (The editors' choice)

Peanut allergy: clinical and immunologic differences among patients from 3 different geographic regions (Vereda et al). 2011;127:603-7

Single–tree nut immunotherapy attenuates allergic reactions in mice with hypersensitivity to multiple tree nuts (Kulis et al). 2011;127:81-8

Cystic fibrosis (CF)

Enhanced antigenicity leads to altered immunogenicity in sulfamethoxazole-hypersensitive patients with cystic fibrosis (Elsheikh et al). 2011;127:1543-51

Cytokines

A physiologic signature for asthma (Rothenberg and Bousquet). 2011;127:553 (News beyond our pages)

A striking local esophageal cytokine expression profile in eosinophilic esophagitis (Blanchard et al). 2011;127:208-17

Arraying eosinophilic esophagitis (Leung and Szefler). 2011;127:128 (The editors' choice)

Characterization of an IL-1 family cytokine (Rothenberg and Bousquet). 2011;127:2 (News beyond our pages)

Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases (Akdis et al). 2011;127:701-21 (Current perspectives)

Severe asthma phenotype driven by IL-17A (Rothenberg and Bousquet). 2011;127:2 (News beyond our pages)

Cytomegalovirus

Inflammation in common variable immunodeficiency is associated with a distinct $CD8^+$ response to cytomegalovirus (Marashi et al). 2011;127: 1385-93

D

Day care attendance

Effect of day care attendance on sensitization and atopic wheezing differs by Toll-like receptor 2 genotype in 2 population-based birth cohort studies (Custovic et al). 2011;127:390-7

Effect of day care on asthma development differs by *TLR2* genotype (Leung and Szefler). 2011;127:361 (The editors' choice)

Dendritic cells

Histamine receptor H1 signaling on dendritic cells plays a key role in the IFN-γ/IL-17 balance in T cell-mediated skin inflammation (Vanbervliet et al). 2011;127:943-53

Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong T_H17/T_H1T-cell responses (Hänsel et al). 2011;127:787-94

Immune pathomechanism of drug hypersensitivity reactions (Pichler et al). 2011;127:S74-S81

Impact of immunotherapy on blood dendritic cells in patients with *Hymenoptera* venom allergy (Dreschler et al). 2011;127:487-94

Peroxisome proliferator–activated receptor γ-mediated suppression of dendritic cell function prevents the onset of atopic dermatitis in NC/Tnd mice (Jung et al). 2011;127:420-9

Pollen metabolome analysis reveals adenosine as a major regulator of dendritic cell-primed T_H cell responses (Gilles et al). 2011;127:454-61

The many routes of dendritic cells to ensure immune regulation (Palomares et al). 2011;127:1541-2 (Editorial)

Vitamin D3 targets epidermal and dermal dendritic cells for induction of distinct regulatory T cells (van der Aar et al). 2011;127:1532-40

Dermatitis

Drug hypersensitivity: pharmacogenetics and clinical syndromes (Phillips et al). 2011;127:S60-S66

Dermatitis, atopic

A comprehensive analysis of the *COL29A1* gene does not support a role in eczema (Naumann et al). 2011;127:1187-94

Association between obesity and atopic dermatitis in childhood: a case-control study (Silverberg et al). 2011;127:1180-6

$CD8^+$T cells are recruited early to allergen exposure sites in atopy patch test reactions in human atopic

dermatitis (Hennino et al). 2011;127:1064-7 (Letter to the editor)
Comparative proteomic profiling of patients with atopic dermatitis based on history of eczema herpeticum infection and *Staphylococcus aureus* colonization (Broccardo et al). 2011;127:186-93
Contrasting pathogenesis of atopic dermatitis and psoriasis—part I: clinical and pathologic concepts (Guttman-Yassky et al). 2011;127:1110-8 (Current perspectives)
Contrasting pathogenesis of atopic dermatitis and psoriasis—part II: Immune cell subsets and therapeutic concepts (Guttman-Yassky et al). 2011;127:1420-32 (Current perspectives)
Deficient expression of the transcription factor Sp1 might increase the propensity of patients with atopic dermatitis to disseminated viral skin infection (Leung and Szefler). 2011;127:362 (The editors' choice)
Histamine receptor H1 signaling on dendritic cells plays a key role in the IFN-γ/IL-17 balance in T cell-mediated skin inflammation (Vanbervliet et al). 2011;127:943-53
Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-γ response (Leung et al). 2011;127:965-73
Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: relevance to atopic dermatitis (Zhang et al). 2011;127:1522-31.e8
IgE-independent house dust mite allergen–induced skin inflammation (Leung and Szefler). 2011;127:723 (The editors' choice)
Improvement of treatment-refractory atopic dermatitis by immunoadsorption: a pilot study (Kasperkiewicz et al). 2011;127:267-70 (Letter to the editor)
Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy (Brown et al). 2011;127:661-7
Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities (Suárez-Fariñas et al). 2011;127:954-64
Nonlesional atopic dermatitis skin reveals an abnormal phenotype (Leung and Szefler). 2011;127:874 (The editors' choice)
Peroxisome proliferator–activated receptor γ-mediated suppression of dendritic cell function prevents the onset of atopic dermatitis in NC/Tnd mice (Jung et al). 2011;127:420-9
Prenatal animal contact and gene expression of innate immunity receptors at birth are associated with atopic dermatitis (Roduit et al). 2011;127:179-85
Prenatal animal contact may prevent atopic dermatitis (Leung and Szefler). 2011;127:128 (The editors' choice)
Specificity protein 1 is pivotal in the skin's antiviral response (Bin et al). 2011;127:430-8
The 2-hit theory for epidermal barrier disruption in atopic dermatitis (Leung and Szefler). 2011;127:723 (The editors' choice)
Tight junction defects in patients with atopic dermatitis (De Benedetto et al). 2011;127:773-86

Desensitization
A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response (Varshney et al). 2011;127:654-60
Diagnosis and management of drug hypersensitivity reactions (Romano et al). 2011;127:S67-S73
Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy (Nadeau et al). 2011;127:1622-4 (Letter to the editor)
Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization (Kim et al). 2011;127:640-6

Desloratadine
Petasol butenoate complex (Ze 339) relieves allergic rhinitis–induced nasal obstruction more effectively than desloratadine (Dumitru et al). 2011;127:1515-21

Dexamethasone
Alleviating allergic airway diseases by means of short-term administration of IL-2 and dexamethasone (Ma et al). 2011;127:1447-56
Dexamethasone regulation of thymic stromal lymphopoietin receptor expression on mast cells and their precursors (Allakhverdi et al). 2011;127:523-4 (Letter to the editor)

Diagnostic techniques and procedures; *see also specific techniques*
Diagnosing IgE-mediated hypersensitivity to sesame by an immediate-reading "contact test" with sesame oil (Alonzi et al). 2011;127:1627-9 (Letter to the editor)
Diagnosis and management of drug hypersensitivity reactions (Romano et al). 2011;127:S67-S73
Microarrayed recombinant allergens for diagnostic testing (Shreffler). 2011;127:843-9
Moderately complex US Food and Drug Administration–cleared method for human IgE antibody serology (Saper). 2011;127:547 (Correspondence)
Moderately complex US Food and Drug Administration–cleared method for human IgE antibody serology (Hamilton). 2011;127:547-8 (Letter reply)
Peanut allergy: overestimated in epidemiology or underdiagnosed in primary care? (Custovic and Nicolaou). 2011;127:631-2 (Editorial)
The Asthma Predictive Index: not a useful tool in clinical practice (Brand). 2011;127:293-4 (Correspondence)
The magnetic power of urine in the diagnosis of asthma (Leung and Szefler). 2011;127:722 (The editors' choice)

DiGeorge syndrome
Induction of tolerance to parental parathyroid grafts using allogeneic thymus tissue in patients with DiGeorge anomaly (Chinn and Markert). 2011;127:1351-5 (Current perspectives)
DNA; *see also* Gene expression
Eosinophil and neutrophil extracellular DNA traps in human allergic asthmatic airways (Dworski et al). 2011;127:1260-6
Eosinophil extracellular DNA traps in skin diseases (Simon et al). 2011;127:194-9
Dogs; *see* Animals, domestic
Drug hypersensitivity; *see also specific drugs*
Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2010 (Sicherer and Leung). 2011;127:326-35
Asthma in the elderly: β-Adrenergic receptor blockers may worsen, β-receptor agonists relieve (with caveats) (Caviglia). 2011;127:1639 (Correspondence)
Asthma in the elderly: β-Adrenergic receptor blockers may worsen, β-receptor agonists relieve (with caveats) (Reed). 2011;127:1639 (Letter reply)
Diagnosis and management of drug hypersensitivity reactions (Romano et al). 2011;127:S67-S73
Drug hypersensitivity: pharmacogenetics and clinical syndromes (Phillips et al). 2011;127:S60-S66
Enhanced antigenicity leads to altered immunogenicity in sulfamethoxazole-hypersensitive patients with cystic fibrosis (Elsheikh et al). 2011;127:1543-51
Factors associated with severe versus mild immunotherapy-related systemic reactions: a case-referent study (Liss et al). 2011;127:1298-300 (Letter to the editor)
Hypersensitivity to systemic corticosteroids: an infrequent but potentially life-threatening condition (Rachid et al). 2011;127:524-8 (Letter to the editor)
Immune pathomechanism of drug hypersensitivity reactions (Pichler et al). 2011;127:S74-S81
Long-term follow-up of patients with hypersensitivity to nonsteroidal anti-inflammatory drugs reveals shortcomings in compliance and care (Buhl et al). 2011;127:284-5 (Letter to the editor)
Penicillin allergy might not be very common in subjects with cephalosporin allergy (Macy). 2011;127:1638 (Correspondence)
Penicillin allergy might not be very common in subjects with cephalosporin allergy (Romano et al). 2011;127:1638-9 (Letter reply)
Preface (to Highlights of the 4th Drug Hypersensitivity Meeting) (Romano et al). 2011;127:S59
The role of penicillin in benign skin rashes in childhood: a prospective study based on drug rechallenge (Caubet et al). 2011;127:218-22
Drug safety
How to improve the safety of adrenaline (epinephrine) autoinjectors (Kränke et al). 2011;127:1646 (Correspondence)
Salbutamol inhaler misuse resulting in skin burn (Bonniaud et al). 2011;127:295 (Correspondence)
Drug therapy; *see* Patient compliance
Dust mite allergen; *see* Mites

E

Eczema; *see also* Dermatitis, atopic
A comprehensive analysis of the *COL29A1* gene does not support a role in eczema (Naumann et al). 2011;127:1187-94
Childhood eczema and rhinitis predict atopic but not nonatopic adult asthma: a prospective cohort study over 4 decades (Martin et al). 2011;127:1473-9.e1
Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-γ response (Leung et al). 2011;127:965-73
The march towards asthma in the first 4 decades (Leung and Szefler). 2011;127:1438-9 (The editors' choice)
Editorials
Bacterial components plus vitamin D: the ultimate solution to the asthma (autoimmune disease) epidemic? (Weiss). 2011;127:1128-30
Disease-modifying effect and economic implications of sublingual immunotherapy (Canonica and Passalacqua). 2011;127:44-5
Food allergy: Are we getting closer to a cure? (Leung). 2011;127:555-7
Health economics of allergen-specific immunotherapy in the United States (Lockey and Hankin). 2011;127:39-43
Induced pluripotent stem cells and primary immunodeficiencies: a new frontier reached, a new world beyond? (Gaspar). 2011;127:1408-9
One hundred years of allergen immunotherapy: time to ring the changes (Durham and Leung). 2011;127:3-7
Patient characteristics associated with allergen immunotherapy initiation and adherence (Hankin and Lockey). 2011;127:46-8
Peanut allergy: overestimated in epidemiology or underdiagnosed in primary care? (Custovic and Nicolaou). 2011;127:631-2
Predicting asthma exacerbations: peak expiratory flow revisited (Fuhlbrigge). 2011;127:1503-4
Surveillance of the cost of asthma in the 21st century (Gergen). 2011;127:370-1
The many routes of dendritic cells to ensure immune regulation (Palomares et al). 2011;127:1541-2
Trajectories of childhood wheeze (von Mutius). 2011;127:1513-4
Egg hypersensitivity
Heated egg white proteins are more susceptible to gastrointestinal degradation (Leung and Szefler). 2011;127:873 (The editors' choice)

Higher-ovalbumin-content influenza vaccines are well tolerated in children with egg allergy (Owens and MacGinnitie). 2011;127:264-5 (Letter to the editor)
Mechanisms underlying differential food allergy response to heated egg (Martos et al). 2011;127: 990-7
Ovalbumin content of 2010-2011 influenza vaccines (McKinney et al). 2011;127:1629-32 (Letter to the editor)

Eicosanoids
Targeted eicosanoid lipidomics of exhaled breath condensate provide a distinct pattern in the aspirin-intolerant asthma phenotype (Sanak et al). 2011;127:1141-7

Emergency medical services
Frequency of US emergency department visits for food-related acute allergic reactions (Clark et al). 2011;127:682-3 (Letter to the editor)

Encephalitis, herpes simplex
Common variable immunodeficiency presenting as herpes simplex virus encephalitis (Borish et al). 2011;127:541-3 (Letter to the editor)

Endothelial growth factors
Calcitonin gene-related peptide– and vascular endothelial growth factor–positive inflammatory cells in late-phase allergic skin reactions in atopic subjects (Kay). 2011;127:232-7

Endotoxins
Occupational endotoxin exposure and a novel luminol-enhanced chemiluminescence assay of nasal lavage neutrophil activation (Seth et al). 2011;127:272-5 (Letter to the editor)

Endotypes
Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome (Lötvall et al). 2011;127:355-60 (Rostrum)
Endotyping early childhood asthma by quantitative symptom assessment (Bisgaard et al). 2011;127: 1155-64

Enterocolitis
Food protein–induced enterocolitis syndrome by cow's milk proteins passed through breast milk (Monti et al). 2011;127:679-80 (Letter to the editor)
The prevalence and natural course of food protein–induced enterocolitis syndrome to cow's milk: a large-scale, prospective population-based study (Katz et al). 2011;127:647-53

Environmental exposure; *see also* Farming-related exposure; Hygiene hypothesis; Occupational exposure
Advances in environmental and occupational respiratory disease in 2010 (Peden and Bush). 2011;127:696-700
Allergen exposure modifies the relation of sensitization to fraction of exhaled nitric oxide levels in children at risk for allergy and asthma (Sordillo et al). 2011;127:1165-72
First results from the Urban Environment and Childhood Asthma study (Leung and Szefler). 2011;127:873 (The editors' choice)
Personal sampling of small mold spores using slit cassettes (Pityn and Anderson). 2011;127:1063-4 (Letter to the editor)
Relationships among environmental exposures, cord blood cytokine responses, allergy, and wheeze at 1 year of age in an inner-city birth cohort (Urban Environment and Childhood Asthma study) (Wood et al). 2011;127:913-9

Eosinophilia
Drug hypersensitivity: pharmacogenetics and clinical syndromes (Phillips et al). 2011;127:S60-S66
IL-25 implicated in Churg-Strauss syndrome (Rothenberg and Bousquet). 2011;127:297 (News beyond our pages)
IL1RL1 gene: role in asthma, eosinophilia, and serum IL1RL1-a levels (Leung and Szefler). 2011;127: 723 (The editors' choice)

Eosinophilic esophagitis
A striking local esophageal cytokine expression profile in eosinophilic esophagitis (Blanchard et al). 2011;127:208-17
Arraying eosinophilic esophagitis (Leung and Szefler). 2011;127:128 (The editors' choice)
Expression of mast cell–associated genes is upregulated in adult eosinophilic esophagitis and responds to steroid or dietary therapy (Hsu Blatman et al). 2011;127:1307-8 (Letter to the editor)

Eosinophils
Eosinophil and neutrophil extracellular DNA traps in human allergic asthmatic airways (Dworski et al). 2011;127:1260-6
Eosinophil extracellular DNA traps in skin diseases (Simon et al). 2011;127:194-9
Exhaled nitric oxide in prednisone-dependent asthma to identify the eosinophilic positive phenotype (Silkoff and Loza). 2011;127:834 (Correspondence)
Exhaled nitric oxide in prednisone-dependent asthma to identify the eosinophilic positive phenotype (Nair et al). 2011;127:834 (Letter reply)
Interleukin-1 receptor–like 1 polymorphisms are associated with serum IL1RL1-a, eosinophils, and asthma in childhood (Savenije et al). 2011;127: 750-6

Epinephrine
How to improve the safety of adrenaline (epinephrine) autoinjectors (Kränke et al). 2011;127:1646 (Correspondence)

Epithelial cells
Adhesion of *Streptococcus pneumoniae* to human airway epithelial cells exposed to urban particulate matter (Mushtaq et al). 2011;127:1236-42
Role of p63/p73 in epithelial remodeling and their response to steroid treatment in nasal polyposis (Li et al). 2011;127:765-72

European Union
The European Union at the forefront of the fight against allergy (Rothenberg and Bousquet). 2011;127:554 (News beyond our pages)

Exercise
Airway hyperresponsiveness in elite swimmers: Is it a transient phenomenon? (Bougault et al). 2011;127:892-8
Allergens, television, and airway inflammation in children with and without allergy (Leung and Szefler). 2011;127:1131 (The editors' choice)
Rhinoconjunctival sensitization to hydrolyzed wheat protein in facial soap can induce wheat-dependent exercise-induced anaphylaxis (Fukutomi et al). 2011;127:531-3 (Letter to the editor)

F

Farming-related exposure
Gene-environment interaction for childhood asthma and exposure to farming in Central Europe (Ege et al). 2011;127:138-44
Genome-wide interaction analysis for asthma and environmental exposure to farming (Leung and Szefler). 2011;127:129 (The editors' choice)

***FAS* gene mutation**
Common variable immunodeficiency and hemophagocytic features associated with a *FAS* gene mutation. 2011;127:1411-4 (Letter to the editor)

Fatty acids
A high-fat challenge increases airway inflammation and impairs bronchodilator recovery in asthma (Wood et al). 2011;127:1133-40

Fc epsilon receptors (FcεRI); *see* Receptors, Fc

Fetal development; *see* Pregnancy/prenatal exposure

Fibroblasts
IL-4 induces differentiation of human embryonic stem cells into fibrogenic fibroblast-like cells (Sato et al). 2011;127:1595-603

Fibrosis
The extra domain A of fibronectin is essential for allergen-induced airway fibrosis and hyperresponsiveness in mice (Kohan et al). 2011;127:439-46

Filaggrin
Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy (Brown et al). 2011;127:661-7
Skin drives the immune system nuts (Leung and Szefler). 2011;127:722 (The editors' choice)
The 2-hit theory for epidermal barrier disruption in atopic dermatitis (Leung and Szefler). 2011;127:723 (The editors' choice)

Fluticasone propionate
Cost-effectiveness analysis of fluticasone versus montelukast in children with mild-to-moderate persistent asthma in the Pediatric Asthma Controller Trial (Wang et al). 2011;127:161-6
Fluticasone furoate nasal spray is the only intranasal corticosteroid to reduce the ocular symptoms of seasonal allergic rhinitis consistently (Keith and Lee). 2011;127:288-9 (Correspondence)
Fluticasone furoate nasal spray is the only intranasal corticosteroid to reduce the ocular symptoms of seasonal allergic rhinitis consistently (Prenner et al). 2011;127:289 (Letter reply)
Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis (Baroody et al). 2011;127:927-34
Run-in oral steroids improve topical nasal steroid response (Rothenberg and Bousquet). 2011;127:1317-8 (News beyond our pages)

Folic acid
Maternal folate levels in pregnancy and asthma in children at age 3 years (Håberg et al). 2011;127:262-4 (Letter to the editor)

Food challenge
A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy (Sampson et al). 2011;127:1309-10 (Letter to the editor)
Highly accurate prediction of food challenge outcome using routinely available clinical data (DunnGalvin et al). 2011;127:633-9
Peanut allergy: overestimated in epidemiology or underdiagnosed in primary care? (Custovic and Nicolaou). 2011;127:631-2 (Editorial)
Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants (Osborne et al). 2011;127:668-76

Food hypersensitivity; *see also specific foods*
Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2010 (Sicherer and Leung). 2011;127:326-35
Birch pollen-related food allergy: clinical aspects and the role of allergen-specific IgE and IgG_4 antibodies (Geroldinger-Simic et al). 2011;127:616-22
Can early introduction of food reduce the risk of food allergy? (Leung and Szefler). 2011;127:1131 (The editors' choice)
Diagnosing IgE-mediated hypersensitivity to sesame by an immediate-reading "contact test" with sesame oil (Alonzi et al). 2011;127:1627-9 (Letter to the editor)
Differences in the allergenicity of 6 different kiwifruit cultivars analyzed by prick-to-prick testing, open food challenges, and ELISA (Le et al). 2011;127:677-9 (Letter to the editor)
Early complementary feeding and risk of food sensitization in a birth cohort (Joseph et al). 2011;127:1203-10
Epidemiology of food allergy (Sicherer). 2011;127:594-602 (Current perspectives)

Food allergy: Are we getting closer to a cure? (Leung). 2011;127:555-7 (Overview editorial)
Four distinct subtypes of non–IgE-mediated gastrointestinal food allergies in neonates and infants, distinguished by their initial symptoms (Nomura et al). 2011;127:685-8 (Letter to the editor)
Frequency of US emergency department visits for food-related acute allergic reactions (Clark et al). 2011;127:682-3 (Letter to the editor)
Future therapies for food allergies (Nowak-Wëgrzyn and Sampson). 2011;127:558-73
Highly accurate prediction of food challenge outcome using routinely available clinical data (DunnGalvin et al). 2011;127:633-9
IgE-mediated systemic anaphylaxis and impaired tolerance to food antigens in mice with enhanced IL-4 receptor signaling (Mathias et al). 2011;127: 795-805
Improvement of mustard *(Sinapis alba)* allergy diagnosis and management by linking clinical features and component-resolved approaches (Vereda et al). 2011;127:1304-7 (Letter to the editor)
Ingested allergens must be absorbed systemically to induce systemic anaphylaxis (Strait et al). 2011;127:982-9
Location, location, location: when vitamin A supports inflammation (Rothenberg and Bousquet). 2011;127:841-2 (News beyond our pages)
Management of post–liver transplant–associated IgE-mediated food allergy in children (Maarof et al). 2011;127:1296-8 (Letter to the editor)
Mechanisms of immune tolerance relevant to food allergy (Vickery et al). 2011;127:576-84
Office-based oral immunotherapy for food allergy is safe and effective (Wasserman et al). 2011;127: 290-1 (Correspondence)
Office-based oral immunotherapy for food allergy is safe and effective (Thyagarajan et al). 2011;127: 291-2 (Letter reply)
Oral immunotherapy: ready for prime time? (Katz et al). 2011;127:289-90 (Correspondence)
Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants (Osborne et al). 2011;127:668-76
Prevention of severe food allergy should focus on the blood and not the gut (Leung and Szefler). 2011;127:873 (The editors' choice)
Shea butter contains no IgE-binding soluble proteins (Chawla et al). 2011;127:680-2 (Letter to the editor)

Foxp3

Bet v 1–specific T-cell receptor/forkhead box protein 3 transgenic T cells suppress Bet v 1–specific T-cell effector function in an activation-dependent manner (Schmetterer et al). 2011;127:238-45
Customized regulatory T cells for immunomodulation of allergen-specific T cells (Leung and Szefler). 2011;127:129 (The editors' choice)
Decreased T-cell receptor signaling through CARD11 differentially compromises forkhead box protein 3–positive regulatory versus T_H2 effector cells to cause allergy (Altin et al). 2011;127:1277-85
Mechanisms of immune tolerance relevant to food allergy (Vickery et al). 2011;127:576-84

G

Gastrointestinal tract; *see also* Intestinal microflora

Four distinct subtypes of non–IgE-mediated gastrointestinal food allergies in neonates and infants, distinguished by their initial symptoms (Nomura et al). 2011;127:685-8 (Letter to the editor)
Heated egg white proteins are more susceptible to gastrointestinal degradation (Leung and Szefler). 2011;127:873 (The editors' choice)
Mechanisms underlying differential food allergy response to heated egg (Martos et al). 2011;127: 990-7
Prevention of severe food allergy should focus on the blood and not the gut (Leung and Szefler). 2011;127:873 (The editors' choice)

Gene-environment interactions

Gene-environment interaction for childhood asthma and exposure to farming in Central Europe (Ege et al). 2011;127:138-44
Genome-wide interaction analysis for asthma and environmental exposure to farming (Leung and Szefler). 2011;127:129 (The editors' choice)
Prenatal animal contact and gene expression of innate immunity receptors at birth are associated with atopic dermatitis (Roduit et al). 2011;127:179-85
Prenatal animal contact may prevent atopic dermatitis (Leung and Szefler). 2011;127:128 (The editors' choice)

Gene expression

Allele-specific transcription of the asthma-associated PHD finger protein 11 gene *(PHF11)* modulated by octamer-binding transcription factor 1 (Oct-1) (Holt et al). 2011;127:1054-62
Asthma-associated polymorphisms in 17q21 influence cord blood *ORMDL3* and *GSDMA* gene expression and IL-17 secretion (Lluis et al). 2011;127:1587-94
Expression of mast cell–associated genes is upregulated in adult eosinophilic esophagitis and responds to steroid or dietary therapy (Hsu Blatman et al). 2011;127:1307-8 (Letter to the editor)

Gene expression profiling

Sputum gene expression profiles define transcriptional phenotypes of asthma (Leung and Szefler). 2011;127:128 (The editors' choice)
Transcriptional phenotypes of asthma defined by gene expression profiling of induced sputum samples (Baines et al). 2011;127:153-60

Gene therapy
A close look at immune reconstitution after gene therapy (Leung and Szefler). 2011;127:1438-9 (The editors' choice)
Gene therapy for primary adaptive immune deficiencies (Fischer et al). 2011;127:1356-9 (Current perspectives)
Gene therapy for primary immunodeficiencies: looking ahead, toward gene correction (Pessach and Notarangelo). 2011;127:1344-50 (Current perspectives)
Lentiviral-mediated gene therapy leads to improvement of B-cell functionality in a murine model of Wiskott-Aldrich syndrome (Bosticardo et al). 2011;127:1376-84
Purine metabolism, immune reconstitution, and abdominal adipose tumor after gene therapy for adenosine deaminase deficiency (Grunebaum et al). 2011;127:1417-9 (Letter to the editor)
Restoration of anti-*Aspergillus* defense by neutrophil extracellular traps in human chronic granulomatous disease after gene therapy is calprotectin-dependent (Bianchi et al). 2011;127:1243-52
Genetic markers
Advances in pediatric asthma in 2010: addressing the major issues (Szefler). 2011;127:102-15
Genetics
A comprehensive analysis of the *COL29A1* gene does not support a role in eczema (Naumann et al). 2011;127:1187-94
A genome-wide association study to identify genetic determinants of atopy in subjects from the United Kingdom (Wan et al). 2011;127:223-31
Advances in adult asthma diagnosis and treatment and HEDQ in 2010 (Apter). 2011;127:116-22
Assessing the reproducibility of asthma genome-wide association studies in a general clinical population (Himes et al). 2011;127:1067-9 (Letter to the editor)
Effect of day care attendance on sensitization and atopic wheezing differs by Toll-like receptor 2 genotype in 2 population-based birth cohort studies (Custovic et al). 2011;127:390-7
Effect of day care on asthma development differs by *TLR2* genotype (Leung and Szefler). 2011;127:361 (The editors' choice)
Genome-wide association identifies diverse causes of common variable immunodeficiency (Orange et al). 2011;127:1360-7
NanoWIP wipes *WAS/XLT* mutations (Leung and Szefler). 2011;127:874 (The editors' choice)
Novel findings for a functional role of asthma-associated polymorphisms in the 17q21 locus (Leung and Szefler). 2011;127:1438-9 (The editors' choice)
Preface (to Highlights of the 4th Drug Hypersensitivity Meeting) (Romano et al). 2011;127:S59
Skin drives the immune system nuts (Leung and Szefler). 2011;127:722 (The editors' choice)
The case of *TACI* C104R: mutation or polymorphism? (Leung and Szefler). 2011;127:1132 (The editors' choice)
Glomerulonephritis
Defects in the CD19 complex predispose to glomerulonephritis, as well as IgG1 subclass deficiency (Vince et al). 2011;127:538-41 (Letter to the editor)
Glucocorticoids
Role of p63/p73 in epithelial remodeling and their response to steroid treatment in nasal polyposis (Li et al). 2011;127:765-72
Systemic glucocorticosteroids affect cutaneous immune response (Rothenberg and Bousquet). 2011;127:298 (News beyond our pages)
Glutathione
Unraveling mechanisms of severe asthma in childhood (Leung and Szefler). 2011;127:1438-9 (The editors' choice)
Granulomatous disease, chronic
Chronic granulomatous disease: overview and hematopoietic stem cell transplantation (Kang et al). 2011;127:1319-26
Hodgkin lymphoma in 2 children with chronic granulomatous disease (Lugo Reyes et al). 2011;127:543-4 (Letter to the editor)
Restoration of anti-*Aspergillus* defense by neutrophil extracellular traps in human chronic granulomatous disease after gene therapy is calprotectin-dependent (Bianchi et al). 2011;127:1243-52
Grass allergens
Dose-dependence of sublingual immunotherapy shown by meta-analysis (Frati et al). 2011;127:1076-7 (Correspondence)
Dose-dependence of sublingual immunotherapy shown by meta-analysis (Di Lorenzo and Di Bona). 2011;127:1077-8 (Letter reply)
Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults (Nelson et al). 2011;127:72-80
Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents (Blaiss et al). 2011;127:64-71
Local allergic rhinitis: allergen tolerance and immunologic changes after preseasonal immunotherapy with grass pollen (Rondón et al). 2011;127:1069-71 (Letter to the editor)
Guidelines; *see also* Practice parameters
Comments on Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (Spector et al). 2011;127:1641-2 (Correspondence)
Comments on Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (Brożek et al). 2011;127:1643-5 (Letter reply)

Differences in recommendations between the Allergic Rhinitis and its Impact on Asthma Update 2010 and US Rhinitis Practice Parameters (Chipps et al). 2011;127:1640-1.e1 (Correspondence)
Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program (Fitzpatrick et al). 2011;127:382-9
How representative are clinical study patients with allergic rhinitis in primary care? (Costa et al). 2011;127:920-6
One hundred years of allergen immunotherapy: time to ring the changes (Durham and Leung). 2011;127: 3-7 (Overview editorial)
World Allergy Organization anaphylaxis guidelines: summary (Simons et al). 2011;127:587-93 (Practice paper)

H

Hay fever
Fluticasone furoate nasal spray is the only intranasal corticosteroid to reduce the ocular symptoms of seasonal allergic rhinitis consistently (Keith and Lee). 2011;127:288-9 (Correspondence)
Fluticasone furoate nasal spray is the only intranasal corticosteroid to reduce the ocular symptoms of seasonal allergic rhinitis consistently (Prenner et al). 2011;127:289 (Letter reply)
Identifying seasonal variation in allergic rhinoconjunctivitis (Flynn). 2011;127:1314-5 (Correspondence)
Nasal AMP and histamine challenge within and outside the pollen season in patients with seasonal allergic rhinitis (Vaidyanathan et al). 2011;127: 173-8
Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis (Baroody et al). 2011;127:927-34
Health care costs
Costs of asthma in the United States: 2002-2007 (Barnett and Nurmagambetov). 2011;127:145-52
Healthcare disparities
Patient characteristics associated with allergen immunotherapy initiation and adherence (Hankin and Lockey). 2011;127:46-8 (Editorial)
Hedgehog proteins
Importance of hedgehog interacting protein and other lung function genes in asthma (Li et al). 2011;127: 1457-65
Helminth antigens
Insights into the helminth-allergy interface through allergen cross-reactivity (Leung and Szefler). 2011;127:362 (The editors' choice)
Hematopoietic stem cell transplantation
A close look at immune reconstitution after gene therapy (Leung and Szefler). 2011;127:1438-9 (The editors' choice)
Chronic granulomatous disease: overview and hematopoietic stem cell transplantation (Kang et al). 2011;127:1319-26
In vivo T-cell dynamics during immune reconstitution after hematopoietic stem cell gene therapy in adenosine deaminase severe combined immune deficiency (Selleri et al). 2011;127:1368-75
Herpesviridae infections
Comparative proteomic profiling of patients with atopic dermatitis based on history of eczema herpeticum infection and *Staphylococcus aureus* colonization (Broccardo et al). 2011;127:186-93
Histamine
Nasal AMP and histamine challenge within and outside the pollen season in patients with seasonal allergic rhinitis (Vaidyanathan et al). 2011;127: 173-8
Histamine receptors; *see* Receptors, histamine
History of medicine
Allergy Archives (Frankland). 48, 80, 115, 180, 2011;127:43
One hundred years of allergen immunotherapy: time to ring the changes (Durham and Leung). 2011;127: 3-7 (Overview editorial)
HLA Antigens
Preface (to Highlights of the 4th Drug Hypersensitivity Meeting) (Romano et al). 2011;127:S59
Hodgkin lymphoma
Hodgkin lymphoma in 2 children with chronic granulomatous disease (Lugo Reyes et al). 2011;127:543-4 (Letter to the editor)
Hygiene hypothesis; *see also* Farming-related exposure
Can oral pathogens influence allergic disease? (Arbes and Matsui). 2011;127:1119-27 (Rostrum)
Quality of life and pets (Brenna). 2011;127:287 (Correspondence)
Quality of life and pets (Wegienka et al). 2011;127: 287-8 (Letter reply)
Structural and immunologic cross-reactivity among filarial and mite tropomyosin: implications for the hygiene hypothesis (Santiago et al). 2011;127: 479-86
Hymenoptera
Added value of IgE detection to rApi m 1 and rVes v 5 in patients with *Hymenoptera* venom allergy (Hofmann et al). 2011;127:265-7 (Letter to the editor)
Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond (Calderón et al). 2011;127:30-8 (Current perspectives)
Honeybee venom immunotherapy in children using a 50-μg maintenance dose (Houliston et al). 2011;127:98-9 (Letter to the editor)
Impact of immunotherapy on blood dendritic cells in patients with *Hymenoptera* venom allergy (Dreschler et al). 2011;127:487-94
Wasp venom immunotherapy induces activation and homing of $CD4^+CD25^+$ forkhead box protein

3–positive regulatory T cells controlling T_H1 responses (Kerstan et al). 2011;127:495-501

Hyper-IgE syndrome; *see* Job's syndrome

I

IgE

Added value of IgE detection to rApi m 1 and rVes v 5 in patients with *Hymenoptera* venom allergy (Hofmann et al). 2011;127:265-7 (Letter to the editor)

Allele-specific transcription of the asthma-associated PHD finger protein 11 gene *(PHF11)* modulated by octamer-binding transcription factor 1 (Oct-1) (Holt et al). 2011;127:1054-62

Allergen-specific IgG antibody levels modify the relationship between allergen-specific IgE and wheezing in childhood (Custovic et al). 2011;127:1480-5

Allergy-related outcomes in relation to serum IgE: results from the National Health and Nutrition Examination Survey 2005-2006 (Salo et al). 2011;127:1226-35

Birch pollen-related food allergy: clinical aspects and the role of allergen-specific IgE and IgG_4 antibodies (Geroldinger-Simic et al). 2011;127:616-22

Elevation of IgE in children with sickle cell disease is associated with doctor diagnosis of asthma and increased morbidity (An et al). 2011;127:1440-6

Facilitated antigen presentation and its inhibition by blocking IgG antibodies depends on IgE repertoire complexity (Holm et al). 2011;127:1029-37

Food allergy: Are we getting closer to a cure? (Leung). 2011;127:555-7 (Overview editorial)

Highly accurate prediction of food challenge outcome using routinely available clinical data (DunnGalvin et al). 2011;127:633-9

Impaired allergy diagnostics among parasite-infected patients caused by IgE antibodies to the carbohydrate epitope galactose-α1,3-galactose (Arkestål et al). 2011;127:1024-8

Ingested allergens must be absorbed systemically to induce systemic anaphylaxis (Strait et al). 2011;127:982-9

Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies (James et al). 2011;127:509-16

Moderately complex US Food and Drug Administration–cleared method for human IgE antibody serology (Saper). 2011;127:547 (Correspondence)

Moderately complex US Food and Drug Administration–cleared method for human IgE antibody serology (Hamilton). 2011;127:547-8 (Letter reply)

Quantification of specific IgE to whole peanut extract and peanut components in prediction of peanut allergy (Nicolaou et al). 2011;127:684-5 (Letter to the editor)

IgG

Neutrophils and IgG are required in active and passive anaphylaxis in mice (Rothenberg and Bousquet). 2011;127:1317-8 (News beyond our pages)

Pathogen-specific IgG antibody levels in immunodeficient patients receiving immunoglobulin replacement do not provide additional benefit to therapeutic management over total serum IgG (Chua et al). 2011;127:1410-1 (Letter to the editor)

The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders (Ballow). 2011;127:315-23

The risk of wheezing decreases with increasing allergen-specific IgG antibody levels (Leung and Szefler). 2011;127:1438-9 (The editors' choice)

IgG deficiency

Defects in the CD19 complex predispose to glomerulonephritis, as well as IgG1 subclass deficiency (Vince et al). 2011;127:538-41 (Letter to the editor)

Immune regulation

The many routes of dendritic cells to ensure immune regulation (Palomares et al). 2011;127:1541-2 (Editorial)

Immune response

Age- and serotype-dependent antibody response to pneumococcal polysaccharides (Bossuyt et al). 2011;127:1079-80 (Correspondence)

Age- and serotype-dependent antibody response to pneumococcal polysaccharides (Balloch et al). 2011;127:1080-1 (Letter reply)

Allergen-specific immunotherapy: regulatory T cells account for a well-balanced immune response (Leung and Szefler). 2011;127:362 (The editors' choice)

Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities (Suárez-Fariñas et al). 2011;127:954-64

Reshaping the Bet v 1 fold modulates T_H polarization (Wallner et al). 2011;127:1571-8.e9

Systemic glucocorticosteroids affect cutaneous immune response (Rothenberg and Bousquet). 2011;127:298 (News beyond our pages)

The adenylate cyclase toxin of *Bacillus anthracis* is a potent promoter of T_H17 cell development (Paccani et al). 2011;127:1636-7 (Letter to the editor)

The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders (Ballow). 2011;127:315-23

Immune tolerance

Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy (Worm et al). 2011;127:89-97

Mechanisms of allergen-specific immunotherapy (Akdis and Akdis). 2011;127:18-27
Mechanisms of immune tolerance relevant to food allergy (Vickery et al). 2011;127:576-84
Wasp venom immunotherapy induces activation and homing of $CD4^+CD25^+$ forkhead box protein 3–positive regulatory T cells controlling T_H1 responses (Kerstan et al). 2011;127:495-501

Immunity, innate
Advances in basic and clinical immunology in 2010 (Chinen and Shearer). 2011;127:336-41
Differences in innate immune function between allergic and nonallergic children: new insights into immune ontogeny (Tulic et al). 2011;127:470-8

Immunization
Higher-ovalbumin-content influenza vaccines are well tolerated in children with egg allergy (Owens and MacGinnitie). 2011;127:264-5 (Letter to the editor)
Inhaled vaccine shows persistent local and systemic immunization(Rothenberg and Bousquet). 2011;127:297 (News beyond our pages)
Ovalbumin content of 2010-2011 influenza vaccines (McKinney et al). 2011;127:1629-32 (Letter to the editor)
Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccine (Busse et al). 2011;127:130-7

Immunodeficiency; *see* Common variable immunodeficiency; Immunologic deficiency syndromes; Severe combined immunodeficiency

Immunoglobulins, intravenous
Inhibition of differentiation, amplification, and function of human T_H17 cells by intravenous immunoglobulin (Maddur et al). 2011;127:823-30
The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders (Ballow). 2011;127:315-23

Immunologic deficiency syndromes; *see also specific* syndromes
A close look at immune reconstitution after gene therapy (Leung and Szefler). 2011;127:1438-9 (The editors' choice)
Advances in basic and clinical immunology in 2010 (Chinen and Shearer). 2011;127:336-41
Gene therapy for primary adaptive immune deficiencies (Fischer et al). 2011;127:1356-9 (Current perspectives)
Gene therapy for primary immunodeficiencies: looking ahead, toward gene correction (Pessach and Notarangelo). 2011;127:1344-50 (Current perspectives)
Genome-wide association identifies diverse causes of common variable immunodeficiency (Orange et al). 2011;127:1360-7
Induced pluripotent stem cells: a novel frontier in the study of human primary immunodeficiencies (Pessach et al). 2011;127:1400-7.e4
Induced pluripotent stem cells and primary immunodeficiencies: a new frontier reached, a new world beyond? (Gaspar). 2011;127:1408-9 (Editorial)
Lentiviral-mediated gene therapy leads to improvement of B-cell functionality in a murine model of Wiskott-Aldrich syndrome (Bosticardo et al). 2011;127:1376-84
Longitudinal decline in lung function in patients with primary immunoglobulin deficiencies (Chen et al). 2011;127:1414-7 (Letter to the editor)
Pathogen-specific IgG antibody levels in immunodeficient patients receiving immunoglobulin replacement do not provide additional benefit to therapeutic management over total serum IgG (Chua et al). 2011;127:1410-1 (Letter to the editor)
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies (Rezaei et al). 2011;127:1329-41
Purine metabolism, immune reconstitution, and abdominal adipose tumor after gene therapy for adenosine deaminase deficiency (Grunebaum et al). 2011;127:1417-9 (Letter to the editor)
The case of *TACI* C104R: mutation or polymorphism? (Leung and Szefler). 2011;127:1132 (The editors' choice)
Two new families with X-linked inhibitor of apoptosis deficiency and a review of all 26 published cases (Horn et al). 2011;127:544-6 (Letter to the editor)

Immunology (specialty); *see* Allergy and immunology (specialty)

Immunomodulation
Bet v 1–specific T-cell receptor/forkhead box protein 3 transgenic T cells suppress Bet v 1–specific T-cell effector function in an activation-dependent manner (Schmetterer et al). 2011;127:238-45
Customized regulatory T cells for immunomodulation of allergen-specific T cells (Leung and Szefler). 2011;127:129 (The editors' choice)
Pollen metabolome analysis reveals adenosine as a major regulator of dendritic cell-primed T_H cell responses (Gilles et al). 2011;127:454-61

Immunosorbent techniques
Improvement of treatment-refractory atopic dermatitis by immunoadsorption: a pilot study (Kasperkiewicz et al). 2011;127:267-70 (Letter to the editor)

Immunotherapy
A hypoallergenic cat vaccine based on Fel d 1–derived peptides fused to hepatitis B PreS (Niespodziana et al). 2011;127:1562-70
Advances in upper airway diseases and allergen immunotherapy (Sabin et al). 2011;127:342-50

Allergen immunotherapy: a practice parameter third update (Cox et al). 2011;127:S1-S58 (Practice parameter)
Allergen-specific immunotherapy: regulatory T cells account for a well-balanced immune response (Leung and Szefler). 2011;127:362 (The editors' choice)
Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond (Calderón et al). 2011;127:30-8 (Current perspectives)
Ara h 2 peptides containing dominant $CD4^+$T-cell epitopes: candidates for a peanut allergy therapeutic (Prickett et al). 2011;127:608-15
Ara h 1–reactive T cells in individuals with peanut allergy (DeLong et al). 2011;127:1211-8
Effect of birch pollen-specific immunotherapy on birch pollen-related hazelnut allergy (van Hoffen et al). 2011;127:100-1 (Letter to the editor)
Efficacy and safety of immunotherapy for allergies to *Alternaria alternata* in children (Kuna et al). 2011;127:502-8
Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults (Nelson et al). 2011;127:72-80
Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents (Blaiss et al). 2011;127:64-71
Food allergy: Are we getting closer to a cure? (Leung). 2011;127:555-7 (Overview editorial)
Future forms of immunotherapy (Casale and Stokes). 2011;127:8-15
Future therapies for food allergies (Nowak-Wĕgrzyn and Sampson). 2011;127:558-73
Health economics of allergen-specific immunotherapy in the United States (Lockey and Hankin). 2011;127:39-43 (Editorial)
Honeybee venom immunotherapy in children using a 50-μg maintenance dose (Houliston et al). 2011;127:98-9 (Letter to the editor)
Impact of immunotherapy on blood dendritic cells in patients with *Hymenoptera* venom allergy (Dreschler et al). 2011;127:487-94
Lack of pretreatment cost-effectiveness and side effects of omalizumab versus prednisone/montelukast on tolerability of immunotherapy (Rosenberg). 2011;127:548 (Correspondence)
Lack of pretreatment cost-effectiveness and side effects of omalizumab versus prednisone/montelukast on tolerability of immunotherapy (Massanari et al). 2011;127:548-9 (Letter reply)
Local allergic rhinitis: allergen tolerance and immunologic changes after preseasonal immunotherapy with grass pollen (Rondón et al). 2011;127:1069-71 (Letter to the editor)
Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies (James et al). 2011;127:509-16
Mechanisms of allergen-specific immunotherapy (Akdis and Akdis). 2011;127:18-27
One hundred years of allergen immunotherapy: time to ring the changes (Durham and Leung). 2011;127:3-7 (Overview editorial)
Patient characteristics associated with allergen immunotherapy initiation and adherence (Hankin and Lockey). 2011;127:46-8 (Editorial)
Recombinant allergens: What does the future hold? (Valenta et al). 2011;127:860-4 (Current perspectives)
Recombinant allergens for specific immunotherapy (Cromwell et al). 2011;127:865-72 (Current perspectives)
Single–tree nut immunotherapy attenuates allergic reactions in mice with hypersensitivity to multiple tree nuts (Kulis et al). 2011;127:81-8
Tetramers offer a new approach for monitoring patients with peanut allergy receiving immunotherapy (Leung and Szefler). 2011;127:1132 (The editors' choice)
The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA2LEN) article (Bousquet et al). 2011;127:49-56
Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy (Tabar et al). 2011;127:57-63

Immunotherapy, oral

A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response (Varshney et al). 2011;127:654-60
Office-based oral immunotherapy for food allergy is safe and effective (Wasserman et al). 2011;127:290-1 (Correspondence)
Office-based oral immunotherapy for food allergy is safe and effective (Thyagarajan et al). 2011;127:291-2 (Letter reply)
Oral immunotherapy: ready for prime time? (Katz et al). 2011;127:289-90 (Correspondence)

Immunotherapy, peptide

Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy (Worm et al). 2011;127:89-97

Immunotherapy, subcutaneous allergen

Factors associated with severe versus mild immunotherapy-related systemic reactions: a case-referent study (Liss et al). 2011;127:1298-300 (Letter to the editor)

Immunotherapy, sublingual (SLIT)

Disease-modifying effect and economic implications of sublingual immunotherapy (Canonica and Passalacqua). 2011;127:44-5 (Editorial)

Dose-dependence of sublingual immunotherapy shown by meta-analysis (Frati et al). 2011;127: 1076-7 (Correspondence)
Dose-dependence of sublingual immunotherapy shown by meta-analysis (Di Lorenzo and Di Bona). 2011;127:1077-8 (Letter reply)
House dust mite sublingual immunotherapy: results of a US trial (Bush et al). 2011;127:974-81 Corrections 2011;127:1561
Necessity of product-specific assessments or restrictions of meta-analyses to well-designed and well-powered studies (Sieber). 2011;127:1075-6 (Correspondence)
Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization (Kim et al). 2011;127:640-6

Infant nutrition; *see also* Breast-feeding
Can early introduction of food reduce the risk of food allergy? (Leung and Szefler). 2011;127:1131 (The editors' choice)
Early complementary feeding and risk of food sensitization in a birth cohort (Joseph et al). 2011;127:1203-10
Supplementation with cow's milk at birth is not recommended (Koletzko et al). 2011;127:836-8 (Correspondence)
Supplementation with cow's milk at birth is not recommended (Katz et al). 2011;127:839-40 (Letter reply)

Infants; *see also* Asthma, pediatric; Premature birth
Four distinct subtypes of non–IgE-mediated gastrointestinal food allergies in neonates and infants, distinguished by their initial symptoms (Nomura et al). 2011;127:685-8 (Letter to the editor)
Host and viral factors associated with severity of human rhinovirus–associated infant respiratory tract illness (Miller et al). 2011;127:883-91
Neonatal screening for severe combined immunodeficiency caused by an adenosine deaminase defect: a reliable and inexpensive method using tandem mass spectrometry (Azzari et al). 2011;127:1394-9
Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants (Osborne et al). 2011;127:668-76

Infections; *see also specific infections*
Age- and serotype-dependent antibody response to pneumococcal polysaccharides (Bossuyt et al). 2011;127:1079-80 (Correspondence)
Age- and serotype-dependent antibody response to pneumococcal polysaccharides (Balloch et al). 2011;127:1080-1 (Letter reply)
Chronic granulomatous disease: overview and hematopoietic stem cell transplantation (Kang et al). 2011;127:1319-26
Circulating levels of 25-hydroxyvitamin D and human cathelicidin in healthy adults (Bhan et al). 2011;127:1302-4 (Letter to the editor)
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies (Rezaei et al). 2011;127:1329-41
Sequence variation in the *IL4* gene and resistance to *Trypanosoma cruzi* infection in Bolivians (Alvarado Arnez et al). 2011;127:279-82 (Letter to the editor)
The L412F variant of Toll-like receptor 3 *(TLR3)* is associated with cutaneous candidiasis, increased susceptibility to cytomegalovirus, and autoimmunity (Nahum et al). 2011;127:528-31 (Letter to the editor)

Inflammation; *see also* Airway inflammation
A new mediator of inflammation of the lung (Rothenberg and Bousquet). 2011;127:297 (News beyond our pages)
Advances in mechanisms of asthma, allergy, and immunology in 2010 (Broide et al). 2011;127: 689-95
Good and bad twins: IL-22 and IL-17A (Rothenberg and Bousquet). 2011;127:554 (News beyond our pages)
Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong T_H17/T_H1T-cell responses (Hänsel et al). 2011;127:787-94
Inflammation in common variable immunodeficiency is associated with a distinct $CD8^+$ response to cytomegalovirus (Marashi et al). 2011;127: 1385-93
Leukocyte nicotinamide adenine dinucleotide phosphate-reduced oxidase is required for isocyanate-induced lung inflammation (Liu et al). 2011;127:1014-23
Mast cell–associated alveolar inflammation in patients with atopic uncontrolled asthma (Andersson et al). 2011;127:905-12
Mite allergen is a danger signal for the skin via activation of inflammasome in keratinocytes (Dai et al). 2011;127:806-14

Influenza
N1H1 severity in middle-aged adults (Rothenberg and Bousquet). 2011;127:842 (News beyond our pages)
Ovalbumin content of 2010-2011 influenza vaccines (McKinney et al). 2011;127:1629-32 (Letter to the editor)

Influenza vaccine
Higher-ovalbumin-content influenza vaccines are well tolerated in children with egg allergy (Owens and MacGinnitie). 2011;127:264-5 (Letter to the editor)
Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccine (Busse et al). 2011;127:130-7

Inhalers; *see* Nebulizers and inhalers

Inner-city health; *see* Urban health

Insect bites and stings; *see also Hymenoptera;* Ticks
Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and

insects in 2010 (Sicherer and Leung). 2011;127: 326-35
Stinging insect hypersensitivity: a practice parameter update 2011 (Golden et al). 2011;127:852-4 (Practice parameter)

Insulin resistance
Metabolic dysfunction associated with asthma and obesity (Rothenberg and Bousquet). 2011;127:841 (News beyond our pages)

Insurance coverage
The burden of adult asthma in the United States: evidence from the Medical Expenditure Panel Survey (Sullivan et al). 2011;127:363-9

Interferons
Exogenous IFN-β has antiviral and anti-inflammatory properties in primary bronchial epithelial cells from asthmatic subjects exposed to rhinovirus (Cakebread et al). 2011;127:1148-54
Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-γ response (Leung et al). 2011;127:965-73
Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases (Akdis et al). 2011;127:701-21 (Current perspectives)

Interleukins; *see also* Receptors, interleukin
IL1RL1 gene: role in asthma, eosinophilia, and serum IL1RL1-a levels (Leung and Szefler). 2011;127: 723 (The editors' choice)
Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases (Akdis et al). 2011;127:701-21 (Current perspectives)

Interleukin-1 (IL-1)
Characterization of an IL-1 family cytokine (Rothenberg and Bousquet). 2011;127:2 (News beyond our pages)

Interleukin-2 (IL-2)
Alleviating allergic airway diseases by means of short-term administration of IL-2 and dexamethasone (Ma et al). 2011;127:1447-56

Interleukin-4 (IL-4)
IL-4 induces differentiation of human embryonic stem cells into fibrogenic fibroblast-like cells (Sato et al). 2011;127:1595-603
Sequence variation in the *IL4* gene and resistance to *Trypanosoma cruzi* infection in Bolivians (Alvarado Arnez et al). 2011;127:279-82 (Letter to the editor)

Interleukin-5 (IL-5)
Arraying eosinophilic esophagitis (Leung and Szefler). 2011;127:128 (The editors' choice)
Increased nasal IL-5 levels act as a predisposing factor of asthma in southern China (Fan et al). 2011;127: 1312-3 (Correspondence)
Increased nasal IL-5 levels act as a predisposing factor of asthma in southern China (Bachert et al). 2011;127:1313-4 (Letter reply)
Location, location, location: when vitamin A supports inflammation (Rothenberg and Bousquet). 2011;127:841-2 (News beyond our pages)

Interleukin-10 (IL-10)
Defective IL-10 signaling characteristic of hyper-IgE syndrome (Rothenberg and Bousquet). 2011;127: 841 (News beyond our pages)

Interleukin-13 (IL-13)
A striking local esophageal cytokine expression profile in eosinophilic esophagitis (Blanchard et al). 2011;127:208-17
Anti–IL-13 evaluated in mild asthma (Rothenberg and Bousquet). 2011;127:297-8 (News beyond our pages)
Human T_H17 cells express a functional IL-13 receptor and IL-13 attenuates IL-17A production (Newcomb et al). 2011;127:1006-13

Interleukin-17 (IL-17)
Asthma-associated polymorphisms in 17q21 influence cord blood *ORMDL3* and *GSDMA* gene expression and IL-17 secretion (Lluis et al). 2011;127:1587-94
Good and bad twins: IL-22 and IL-17A (Rothenberg and Bousquet). 2011;127:554 (News beyond our pages)
New host defense mechanisms against *Candida* species clarify the basis of clinical phenotypes (Hanna and Etzoni). 2011;127:1433-7 (Current perspectives)
New T_H2 cell line described (Rothenberg and Bousquet). 2011;127:1-2 (News beyond our pages)
Plastic IL-17 cells (Rothenberg and Bousquet). 2011;127:1317-8 (News beyond our pages)
Severe asthma phenotype driven by IL-17A (Rothenberg and Bousquet). 2011;127:2 (News beyond our pages)

Interleukin-22 (IL-22)
Good and bad twins: IL-22 and IL-17A (Rothenberg and Bousquet). 2011;127:554 (News beyond our pages)

Interleukin-25 (IL-25)
IL-25 implicated in Churg-Strauss syndrome (Rothenberg and Bousquet). 2011;127:297 (News beyond our pages)

Interleukin-31 (IL-31)
Characterization of pollen antigen–induced IL-31 production by PBMCs in patients with allergic rhinitis (Okano et al). 2011;127:277-9 (Letter to the editor)

Internet
Daily symptom monitoring reduces oral corticosteroid doses in patients with refractory asthma (Rothenberg and Bousquet). 2011;127:1317-8 (News beyond our pages)

Intestinal microflora
Bacterial components plus vitamin D: the ultimate solution to the asthma (autoimmune disease) epidemic? (Weiss). 2011;127:1128-30 (Editorial)
Gut microbiota, probiotics, and vitamin D: interrelated exposures influencing allergy, asthma, and obesity? (Ly et al). 2011;127:1087-94
Influence of gastrointestinal commensal bacteria on the immune responses that mediate allergy and

asthma (McLoughlin and Mills). 2011;127: 1097-107

IVIG; *see* Immunoglobulins, intravenous

J

Job's syndrome

Defective IL-10 signaling characteristic of hyper-IgE syndrome (Rothenberg and Bousquet). 2011;127: 841 (News beyond our pages)

Journal of Allergy and Clinical Immunology

A special thank-you to our reviewers. 2011;127: 299-302

K

Keratinocytes

IgE-independent house dust mite allergen–induced skin inflammation (Leung and Szefler). 2011;127: 723 (The editors' choice)

Mite allergen is a danger signal for the skin via activation of inflammasome in keratinocytes (Dai et al). 2011;127:806-14

Tight junction defects in patients with atopic dermatitis (De Benedetto et al). 2011;127:773-86

TNF-like weak inducer of apoptosis (TWEAK) and TNF-α cooperate in the induction of keratinocyte apoptosis (Zimmermann et al). 2011;127:200-7

Kiwifruit

Differences in the allergenicity of 6 different kiwifruit cultivars analyzed by prick-to-prick testing, open food challenges, and ELISA (Le et al). 2011;127: 677-9 (Letter to the editor)

L

Lactobacillus*; *see Probiotics

Langerhans cells; *see* Dendritic cells

Laryngeal diseases

Chronic cough and irritable larynx (Bucca et al). 2011;127:412-9

Letters to the editor; *see also* Correspondence

A lower prevalence of asthma among patients with chronic rhinosinusitis in southern China (Fan et al). 2011;127:520-2

A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy (Sampson et al). 2011;127:1309-10

Added value of IgE detection to rApi m 1 and rVes v 5 in patients with *Hymenoptera* venom allergy (Hofmann et al). 2011;127:265-7

Assessing the reproducibility of asthma genome-wide association studies in a general clinical population (Himes et al). 2011;127:1067-9

$CD8^+$T cells are recruited early to allergen exposure sites in atopy patch test reactions in human atopic dermatitis (Hennino et al). 2011;127:1064-7

Celiac disease confers a 1.6-fold increased risk of asthma: a nationwide population-based cohort study (Ludvigsson et al). 2011;127:1071-3

Characterization of pollen antigen–induced IL-31 production by PBMCs in patients with allergic rhinitis (Okano et al). 2011;127:277-9

Circulating levels of 25-hydroxyvitamin D and human cathelicidin in healthy adults (Bhan et al). 2011;127:1302-4

Clinical utility of the Chronic Urticaria Index (Biagtan et al). 2011;127:1626-7

Common variable immunodeficiency and hemophagocytic features associated with a *FAS* gene mutation. 2011;127:1411-4

Common variable immunodeficiency presenting as herpes simplex virus encephalitis (Borish et al). 2011;127:541-3

Defects in the CD19 complex predispose to glomerulonephritis, as well as IgG1 subclass deficiency (Vince et al). 2011;127:538-41

Dexamethasone regulation of thymic stromal lymphopoietin receptor expression on mast cells and their precursors (Allakhverdi et al). 2011;127: 523-4

Diagnosing IgE-mediated hypersensitivity to sesame by an immediate-reading "contact test" with sesame oil (Alonzi et al). 2011;127:1627-9

Differences in the allergenicity of 6 different kiwifruit cultivars analyzed by prick-to-prick testing, open food challenges, and ELISA (Le et al). 2011;127: 677-9

Diffuse large B-cell lymphoma as presenting feature of Zap-70 deficiency (Newell et al). 2011;127:517-20

Effect of birch pollen-specific immunotherapy on birch pollen-related hazelnut allergy (van Hoffen et al). 2011;127:100-1

Expression of mast cell–associated genes is upregulated in adult eosinophilic esophagitis and responds to steroid or dietary therapy (Hsu Blatman et al). 2011;127:1307-8

Factors associated with severe versus mild immunotherapy-related systemic reactions: a case-referent study (Liss et al). 2011;127:1298-300

Food protein–induced enterocolitis syndrome by cow's milk proteins passed through breast milk (Monti et al). 2011;127:679-80

Four distinct subtypes of non–IgE-mediated gastrointestinal food allergies in neonates and infants, distinguished by their initial symptoms (Nomura et al). 2011;127:685-8

Freezing does not alter antigenic properties of fresh fruits for skin testing in patients with birch tree pollen–induced oral allergy syndrome (Bégin et al). 2011;127:1624-6.e3

Frequency of US emergency department visits for food-related acute allergic reactions (Clark et al). 2011;127:682-3

Higher-ovalbumin-content influenza vaccines are well tolerated in children with egg allergy (Owens and MacGinnitie). 2011;127:264-5

Hodgkin lymphoma in 2 children with chronic granulomatous disease (Lugo Reyes et al). 2011;127:543-4

Honeybee venom immunotherapy in children using a 50-μg maintenance dose (Houliston et al). 2011;127:98-9

Human phagocyte defect caused by a *Rac2* mutation detected by means of neonatal screening for T-cell lymphopenia (Accetta et al). 2011;127:535-8

Hypersensitivity to systemic corticosteroids: an infrequent but potentially life-threatening condition (Rachid et al). 2011;127:524-8

Improvement of mustard *(Sinapis alba)* allergy diagnosis and management by linking clinical features and component-resolved approaches (Vereda et al). 2011;127:1304-7

Improvement of treatment-refractory atopic dermatitis by immunoadsorption: a pilot study (Kasperkiewicz et al). 2011;127:267-70

Local allergic rhinitis: allergen tolerance and immunologic changes after preseasonal immunotherapy with grass pollen (Rondón et al). 2011;127:1069-71

Long-term follow-up of patients with hypersensitivity to nonsteroidal anti-inflammatory drugs reveals shortcomings in compliance and care (Buhl et al). 2011;127:284-5

Longitudinal decline in lung function in patients with primary immunoglobulin deficiencies (Chen et al). 2011;127:1414-7

Management of post–liver transplant–associated IgE-mediated food allergy in children (Maarof et al). 2011;127:1296-8

Maternal folate levels in pregnancy and asthma in children at age 3 years (Håberg et al). 2011;127:262-4

More alternative activation of macrophages in lungs of asthmatic patients (Melgert et al). 2011;127:831-3

Occupational endotoxin exposure and a novel luminol-enhanced chemiluminescence assay of nasal lavage neutrophil activation (Seth et al). 2011;127:272-5

Omalizumab is effective in nonautoimmune urticaria (Ferrer et al). 2011;127:1300-2

Ovalbumin content of 2010-2011 influenza vaccines (McKinney et al). 2011;127:1629-32

Paracetamol, nonsteroidal anti-inflammatory drugs, and risk of asthma in adult survivors of childhood cancer (Marquis et al). 2011;127:270-2

Pathogen-specific IgG antibody levels in immunodeficient patients receiving immunoglobulin replacement do not provide additional benefit to therapeutic management over total serum IgG (Chua et al). 2011;127:1410-1

Personal sampling of small mold spores using slit cassettes (Pityn and Anderson). 2011;127:1063-4

Polymorphous lymphoproliferative disorder with Hodgkin-like features in common γ-chain–deficient severe combined immunodeficiency (Slatter et al). 2011;127:533-5

Progressive airflow limitation is a feature of children with severe asthma (Fitzpatrick and Teague). 2011;127:282-4

Purine metabolism, immune reconstitution, and abdominal adipose tumor after gene therapy for adenosine deaminase deficiency (Grunebaum et al). 2011;127:1417-9

Quantification of specific IgE to whole peanut extract and peanut components in prediction of peanut allergy (Nicolaou et al). 2011;127:684-5

Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy (Nadeau et al). 2011;127:1622-4

Rhinoconjunctival sensitization to hydrolyzed wheat protein in facial soap can induce wheat-dependent exercise-induced anaphylaxis (Fukutomi et al). 2011;127:531-3

Sequence variation in the *IL4* gene and resistance to *Trypanosoma cruzi* infection in Bolivians (Alvarado Arnez et al). 2011;127:279-82

Sex dependence of airflow limitation and air trapping in children with severe asthma (Sorkness et al). 2011;127:1073-4

Sex differences in asthma during the first 8 years of life: the Prevention and Incidence of Asthma and Mite Allergy (PIAMA) birth cohort study (Wijga et al). 2011;127:275-7

Shea butter contains no IgE-binding soluble proteins (Chawla et al). 2011;127:680-2

Steroids and extracellular signal-regulated kinase 1/2 activity suppress activating transcription factor 3 expression in patients with severe asthma (Roussel et al). 2011;127:1632-5

The adenylate cyclase toxin of *Bacillus anthracis* is a potent promoter of T_H17 cell development (Paccani et al). 2011;127:1636-7

The L412F variant of Toll-like receptor 3 *(TLR3)* is associated with cutaneous candidiasis, increased susceptibility to cytomegalovirus, and autoimmunity (Nahum et al). 2011;127:528-31

Two new families with X-linked inhibitor of apoptosis deficiency and a review of all 26 published cases (Horn et al). 2011;127:544-6

Vitamin D supplementation in children may prevent asthma exacerbation triggered by acute respiratory infection (Majak et al). 2011;127:1294-6

Leukocytes

Leukocyte nicotinamide adenine dinucleotide phosphate-reduced oxidase is required for isocyanate-induced lung inflammation (Liu et al). 2011;127:1014-23

Leukotriene A_4 hydrolase

Unexpected effect of inhibiting TLA_4H (Rothenberg and Bousquet). 2011;127:2 (News beyond our pages)

Lipid transfer protein
Ara h 2 peptides containing dominant CD4$^+$T-cell epitopes: candidates for a peanut allergy therapeutic (Prickett et al). 2011;127:608-15
Quantification of specific IgE to whole peanut extract and peanut components in prediction of peanut allergy (Nicolaou et al). 2011;127:684-5 (Letter to the editor)
Lung function; *see also* Respiratory function tests
Comparison of childhood wheezing phenotypes in 2 birth cohorts: ALSPAC and PIAMA (Savenije et al). 2011;127:1502-12
Importance of hedgehog interacting protein and other lung function genes in asthma (Li et al). 2011;127:1457-65
Longitudinal decline in lung function in patients with primary immunoglobulin deficiencies (Chen et al). 2011;127:1414-7 (Letter to the editor)
Potential roles of pentosidine in age-related and disease-related impairment of pulmonary functions in patients with asthma (Kanazawa et al). 2011;127:899-904
Predicting future risk of asthma exacerbations using individual conditional probabilities (Thamrin et al). 2011;127:1494-502
Progressive airflow limitation is a feature of children with severe asthma (Fitzpatrick and Teague). 2011;127:282-4 (Letter to the editor)
Lupus erythematosus, systemic
Current and novel therapeutics in the treatment of systemic lupus erythematosus (Yildirim-Toruner and Diamond). 2011;127:303-12
Lymphoma
Diffuse large B-cell lymphoma as presenting feature of Zap-70 deficiency (Newell et al). 2011;127:517-20 (Letter to the editor)
Lymphoproliferative disorders
Polymorphous lymphoproliferative disorder with Hodgkin-like features in common γ-chain–deficient severe combined immunodeficiency (Slatter et al). 2011;127:533-5 (Letter to the editor)

M

Macrophages, alveolar
More alternative activation of macrophages in lungs of asthmatic patients (Melgert et al). 2011;127:831-3 (Letter to the editor)
Malignancies
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies (Rezaei et al). 2011;127:1329-41
Purine metabolism, immune reconstitution, and abdominal adipose tumor after gene therapy for adenosine deaminase deficiency (Grunebaum et al). 2011;127:1417-9 (Letter to the editor)
Markers, biological or clinical; *see* Biological markers
Mast cells
Characterization of a novel human mast cell line that responds to stem cell factor and expresses functional FcεRI (Laidlaw et al). 2011;127:815-22
Circadian clock gene *Period2* regulates a time-of-day–dependent variation in cutaneous anaphylactic reaction (Nakamura et al). 2011;127:1038-45
Crucial role for autophagy in degranulation of mast cells (Ushio et al). 2011;127:1267-76
Dexamethasone regulation of thymic stromal lymphopoietin receptor expression on mast cells and their precursors (Allakhverdi et al). 2011;127:523-4 (Letter to the editor)
Distinct immune effector pathways contribute to the full expression of peanut-induced anaphylactic reactions in mice (Arias et al). 2011;127:1553-62.e1
Expression of mast cell–associated genes is upregulated in adult eosinophilic esophagitis and responds to steroid or dietary therapy (Hsu Blatman et al). 2011;127:1307-8 (Letter to the editor)
Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: relevance to atopic dermatitis (Zhang et al). 2011;127:1522-31
Mast cell–associated alveolar inflammation in patients with atopic uncontrolled asthma (Andersson et al). 2011;127:905-12
Mastocytosis
Toward a global classification of mast cell activation diseases (Molderings et al). 2011;127:1311 (Correspondence)
Toward a global classification of mast cell activation diseases (Akin et al). 2011;127:1311-2 (Letter reply)
Medication adherence; *see* Patient compliance
Meta-analysis
Comments on a recent meta-analysis: BCG vaccination and allergic conditions (El-Zein et al). 2011;127:1081 (Correspondence)
Comments on a recent meta-analysis: BCG vaccination and allergic conditions (Arnoldussen et al). 2011;127:1081-2 (Letter reply)
Dose-dependence of sublingual immunotherapy shown by meta-analysis (Frati et al). 2011;127:1076-7 (Correspondence)
Dose-dependence of sublingual immunotherapy shown by meta-analysis (Di Lorenzo and Di Bona). 2011;127:1077-8 (Letter reply)
Necessity of product-specific assessments or restrictions of meta-analyses to well-designed and well-powered studies (Sieber). 2011;127:1075-6 (Correspondence)
Metabolomics
Metabolomic profiling of asthma: diagnostic utility of urine nuclear magnetic resonance spectroscopy (Saude et al). 2011;127:757-64

Milk hypersensitivity
Food protein–induced enterocolitis syndrome by cow's milk proteins passed through breast milk (Monti et al). 2011;127:679-80 (Letter to the editor)
Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy (Nadeau et al). 2011;127:1622-4 (Letter to the editor)
Supplementation with cow's milk at birth is not recommended (Koletzko et al). 2011;127:836-8 (Correspondence)
Supplementation with cow's milk at birth is not recommended (Katz et al). 2011;127:839-40 (Letter reply)
The prevalence and natural course of food protein–induced enterocolitis syndrome to cow's milk: a large-scale, prospective population-based study (Katz et al). 2011;127:647-53

Mites
House dust mite sublingual immunotherapy: results of a US trial (Bush et al). 2011;127:974-81
Corrections 2011;127:1561
IgE-independent house dust mite allergen–induced skin inflammation (Leung and Szefler). 2011;127:723 (The editors' choice)
Mite allergen is a danger signal for the skin via activation of inflammasome in keratinocytes (Dai et al). 2011;127:806-14
Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy (Tabar et al). 2011;127:57-63

Molds
Efficacy and safety of immunotherapy for allergies to *Alternaria alternata* in children (Kuna et al). 2011;127:502-8
Personal sampling of small mold spores using slit cassettes (Pityn and Anderson). 2011;127:1063-4 (Letter to the editor)

Monoclonal antibodies; *see also specific monoclonal antibodies*
Anti–IL-13 evaluated in mild asthma (Rothenberg and Bousquet). 2011;127:297-8 (News beyond our pages)
Future therapies for food allergies (Nowak-Węgrzyn and Sampson). 2011;127:558-73

Montelukast
Cost-effectiveness analysis of fluticasone versus montelukast in children with mild-to-moderate persistent asthma in the Pediatric Asthma Controller Trial (Wang et al). 2011;127:161-6
Montelukast might improve compliance with subcutaneous immunotherapy treatments in patients with allergic asthma (Vaughn). 2011;127:286 (Correspondence)
Montelukast might improve compliance with subcutaneous immunotherapy treatments in patients with allergic asthma (Majak and Stelmach). 2011;127:286 (Letter reply)

Mortality
Costs of asthma in the United States: 2002-2007 (Barnett and Nurmagambetov). 2011;127:145-52
Hypersensitivity to systemic corticosteroids: an infrequent but potentially life-threatening condition (Rachid et al). 2011;127:524-8 (Letter to the editor)
Office-based oral immunotherapy for food allergy is safe and effective (Wasserman et al). 2011;127:290-1 (Correspondence)
Office-based oral immunotherapy for food allergy is safe and effective (Thyagarajan et al). 2011;127:291-2 (Letter reply)

Mucus
A nonredundant role for mouse Serpinb3a in the induction of mucus production in asthma (Sivaprasad et al). 2011;127:254-61
Identification of a novel regulator of mucus production in patients with asthma (Leung and Szefler). 2011;127:129 (The editors' choice)

Mustard allergy
Improvement of mustard *(Sinapis alba)* allergy diagnosis and management by linking clinical features and component-resolved approaches (Vereda et al). 2011;127:1304-7 (Letter to the editor)

N

NADPH oxidase
Leukocyte nicotinamide adenine dinucleotide phosphate-reduced oxidase is required for isocyanate-induced lung inflammation (Liu et al). 2011;127:1014-23

Nasal obstruction
Petasol butenoate complex (Ze 339) relieves allergic rhinitis–induced nasal obstruction more effectively than desloratadine (Dumitru et al). 2011;127:1515-21

Nasal polyposis
Increased nasal IL-5 levels act as a predisposing factor of asthma in southern China (Fan et al). 2011;127:1312-3 (Correspondence)
Increased nasal IL-5 levels act as a predisposing factor of asthma in southern China (Bachert et al). 2011;127:1313-4 (Letter reply)
Role of p63/p73 in epithelial remodeling and their response to steroid treatment in nasal polyposis (Li et al). 2011;127:765-72
Run-in oral steroids improve topical nasal steroid response (Rothenberg and Bousquet). 2011;127:1317-8 (News beyond our pages)

Nasal provocation test
Nasal AMP and histamine challenge within and outside the pollen season in patients with seasonal allergic rhinitis (Vaidyanathan et al). 2011;127:173-8

Nebulizers and inhalers
Salbutamol inhaler misuse resulting in skin burn (Bonniaud et al). 2011;127:295 (Correspondence)

Neutrophils
Human phagocyte defect caused by a *Rac2* mutation detected by means of neonatal screening for T-cell lymphopenia (Accetta et al). 2011;127:535-8 (Letter to the editor)
Neutrophils and IgG are required in active and passive anaphylaxis in mice (Rothenberg and Bousquet). 2011;127:1317-8 (News beyond our pages)
Nitric oxide
Allergen exposure modifies the relation of sensitization to fraction of exhaled nitric oxide levels in children at risk for allergy and asthma (Sordillo et al). 2011;127:1165-72
Exhaled nitric oxide in prednisone-dependent asthma to identify the eosinophilic positive phenotype (Silkoff and Loza). 2011;127:834 (Correspondence)
Exhaled nitric oxide in prednisone-dependent asthma to identify the eosinophilic positive phenotype (Nair et al). 2011;127:834 (Letter reply)
Nogo-A/Nogo-B
A new mediator of inflammation of the lung (Rothenberg and Bousquet). 2011;127:297 (News beyond our pages)
Nonsteroidal anti-inflammatory drugs (NSAIDs)
Long-term follow-up of patients with hypersensitivity to nonsteroidal anti-inflammatory drugs reveals shortcomings in compliance and care (Buhl et al). 2011;127:284-5 (Letter to the editor)
Paracetamol, nonsteroidal anti-inflammatory drugs, and risk of asthma in adult survivors of childhood cancer (Marquis et al). 2011;127:270-2 (Letter to the editor)
Nut hypersensitivity; *see also* Peanut hypersensitivity
Effect of birch pollen-specific immunotherapy on birch pollen-related hazelnut allergy (van Hoffen et al). 2011;127:100-1 (Letter to the editor)
Shea butter contains no IgE-binding soluble proteins (Chawla et al). 2011;127:680-2 (Letter to the editor)
Single–tree nut immunotherapy attenuates allergic reactions in mice with hypersensitivity to multiple tree nuts (Kulis et al). 2011;127:81-8
Nutrition; *see also* Breast-feeding; Infant nutrition
Bacterial components plus vitamin D: the ultimate solution to the asthma (autoimmune disease) epidemic? (Weiss). 2011;127:1128-30 (Editorial)
Fruit and vegetable consumption in relation to allergy: disease-related modification of consumption? (Rosenlund et al). 2011;127:1219-25
Nutrients and foods for the primary prevention of asthma and allergy: systematic review and meta-analysis (Nurmatov et al). 2011;127:724-33
Vitamin D levels and food and environmental allergies in the United States: results from the National Health and Nutrition Examination Survey 2005-2006 (Sharief et al). 2011;127:1195-202

O

Obesity
Association between obesity and atopic dermatitis in childhood: a case-control study (Silverberg et al). 2011;127:1180-6
Decreased response to inhaled steroids in overweight and obese asthmatic children (Forno et al). 2011;127:741-9
Gut microbiota, probiotics, and vitamin D: interrelated exposures influencing allergy, asthma, and obesity? (Ly et al). 2011;127:1087-94
Metabolic dysfunction associated with asthma and obesity (Rothenberg and Bousquet). 2011;127:841 (News beyond our pages)
Obese/overweight asthmatic children have decreased response to inhaled steroids (Leung and Szefler). 2011;127:722 (The editors' choice)
Obesity and asthma: an association modified by age of asthma onset (Holguin et al). 2011;127:1486-93.e2
Occupational exposure
Advances in environmental and occupational respiratory disease in 2010 (Peden and Bush). 2011;127:696-700
Occupational endotoxin exposure and a novel luminol-enhanced chemiluminescence assay of nasal lavage neutrophil activation (Seth et al). 2011;127:272-5 (Letter to the editor)
Personal sampling of small mold spores using slit cassettes (Pityn and Anderson). 2011;127:1063-4 (Letter to the editor)
Ocular symptoms
Fluticasone furoate nasal spray is the only intranasal corticosteroid to reduce the ocular symptoms of seasonal allergic rhinitis consistently (Keith and Lee). 2011;127:288-9 (Correspondence)
Fluticasone furoate nasal spray is the only intranasal corticosteroid to reduce the ocular symptoms of seasonal allergic rhinitis consistently (Prenner et al). 2011;127:289 (Letter reply)
Oligosaccharides
The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1,3-galactose (Commins et al). 2011;127:1286-93
Tick bites: a common cause of IgE antibodies to alpha-gal (Leung and Szefler). 2011;127:1131 (The editors' choice)
Omalizumab
A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy (Sampson et al). 2011;127:1309-10 (Letter to the editor)
Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge (Corren et al). 2011;127:398-405
Improvement of treatment-refractory atopic dermatitis by immunoadsorption: a pilot study

(Kasperkiewicz et al). 2011;127:267-70 (Letter to the editor)
Lack of pretreatment cost-effectiveness and side effects of omalizumab versus prednisone/montelukast on tolerability of immunotherapy (Rosenberg). 2011;127:548 (Correspondence)
Lack of pretreatment cost-effectiveness and side effects of omalizumab versus prednisone/montelukast on tolerability of immunotherapy (Massanari et al). 2011;127:548-9 (Letter reply)
Omalizumab add-on therapy improves asthma outcomes in children (Rothenberg and Bousquet). 2011;127:1317-8 (News beyond our pages)
Omalizumab is effective in nonautoimmune urticaria (Ferrer et al). 2011;127:1300-2 (Letter to the editor)
Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy (Nadeau et al). 2011;127:1622-4 (Letter to the editor)

Oral allergy syndrome
Freezing does not alter antigenic properties of fresh fruits for skin testing in patients with birch tree pollen–induced oral allergy syndrome (Bégin et al). 2011;127:1624-6.e3 (Letter to the editor)

Oral challenge; *see* Food challenge

***ORMDL3* expression**
Endotyping early childhood asthma by quantitative symptom assessment (Bisgaard et al). 2011;127:1155-64
Novel findings for a functional role of asthma-associated polymorphisms in the 17q21 locus (Leung and Szefler). 2011;127:1438-9 (The editors' choice)

Oxidative stress
Thiol redox disturbances in children with severe asthma are associated with posttranslational modification of the transcription factor nuclear factor (erythroid-derived 2)–like 2 (Fitzpatrick et al). 2011;127:1604-11
Unraveling mechanisms of severe asthma in childhood (Leung and Szefler). 2011;127:1438-9 (The editors' choice)

Oxymetazoline
Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis (Baroody et al). 2011;127:927-34

P

Palivizumab
The effect of prophylactic palivizumab on recurrent wheezing in children with an atopic family history (Gaffin et al). 2011;127:292-3 (Correspondence)
The effect of prophylactic palivizumab on recurrent wheezing in children with an atopic family history (Simões et al). 2011;127:293 (Letter reply)

Paracetamol
Paracetamol, nonsteroidal anti-inflammatory drugs, and risk of asthma in adult survivors of childhood cancer (Marquis et al). 2011;127:270-2 (Letter to the editor)

Parasites
Impaired allergy diagnostics among parasite-infected patients caused by IgE antibodies to the carbohydrate epitope galactose-α1,3-galactose (Arkestål et al). 2011;127:1024-8
Insights into the helminth-allergy interface through allergen cross-reactivity (Leung and Szefler). 2011;127:362 (The editors' choice)
Structural and immunologic cross-reactivity among filarial and mite tropomyosin: implications for the hygiene hypothesis (Santiago et al). 2011;127:479-86

Parathyroid glands
Induction of tolerance to parental parathyroid grafts using allogeneic thymus tissue in patients with DiGeorge anomaly (Chinn and Markert). 2011;127:1351-5 (Current perspectives)

Particulate matter
Adhesion of *Streptococcus pneumoniae* to human airway epithelial cells exposed to urban particulate matter (Mushtaq et al). 2011;127:1236-42

Patient compliance
Enhancing patients' expectations of asthma medication might improve medication adherence (Leung and Szefler). 2011;127:361 (The editors' choice)
Long-term follow-up of patients with hypersensitivity to nonsteroidal anti-inflammatory drugs reveals shortcomings in compliance and care (Buhl et al). 2011;127:284-5 (Letter to the editor)
Montelukast might improve compliance with subcutaneous immunotherapy treatments in patients with allergic asthma (Vaughn). 2011;127:286 (Correspondence)
Montelukast might improve compliance with subcutaneous immunotherapy treatments in patients with allergic asthma (Majak and Stelmach). 2011;127:286 (Letter reply)
Patient characteristics associated with allergen immunotherapy initiation and adherence (Hankin and Lockey). 2011;127:46-8 (Editorial)
The Madison Avenue effect: how drug presentation style influences adherence and outcome in patients with asthma (Clerisme-Beaty et al). 2011;127:406-11
Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy (Tabar et al). 2011;127:57-63

Patient education
The Madison Avenue effect: how drug presentation style influences adherence and outcome in patients with asthma (Clerisme-Beaty et al). 2011;127:406-11

Peanut hypersensitivity
A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy (Sampson et al). 2011;127:1309-10 (Letter to the editor)
A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response (Varshney et al). 2011;127:654-60
Ara h 2 peptides containing dominant $CD4^+$T-cell epitopes: candidates for a peanut allergy therapeutic (Prickett et al). 2011;127:608-15
Ara h 1–reactive T cells in individuals with peanut allergy (DeLong et al). 2011;127:1211-8
Can early introduction of food reduce the risk of food allergy? (Leung and Szefler). 2011;127:1131 (The editors' choice)
Distinct immune effector pathways contribute to the full expression of peanut-induced anaphylactic reactions in mice (Arias et al). 2011;127:1553-62.e1
Incidence, prevalence, and trends of general practitioner–recorded diagnosis of peanut allergy in England, 2001 to 2005 (Kotz et al). 2011;127:623-30
Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy (Brown et al). 2011;127:661-7
Oral immunotherapy: ready for prime time? (Katz et al). 2011;127:289-90 (Correspondence)
Peanut allergy: clinical and immunologic differences among patients from 3 different geographic regions (Vereda et al). 2011;127:603-7
Peanut allergy: overestimated in epidemiology or underdiagnosed in primary care? (Custovic and Nicolaou). 2011;127:631-2 (Editorial)
Quantification of specific IgE to whole peanut extract and peanut components in prediction of peanut allergy (Nicolaou et al). 2011;127:684-5 (Letter to the editor)
Skin drives the immune system nuts (Leung and Szefler). 2011;127:722 (The editors' choice)
Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization (Kim et al). 2011;127:640-6
Tetramers offer a new approach for monitoring patients with peanut allergy receiving immunotherapy (Leung and Szefler). 2011;127:1132 (The editors' choice)
Pediatric patients; *see* Asthma, pediatric; Infants
Penicillin hypersensitivity
Penicillin allergy might not be very common in subjects with cephalosporin allergy (Macy). 2011;127:1638 (Correspondence)
Penicillin allergy might not be very common in subjects with cephalosporin allergy (Romano et al). 2011;127:1638-9 (Letter reply)
The role of penicillin in benign skin rashes in childhood: a prospective study based on drug rechallenge (Caubet et al). 2011;127:218-22
Pentosidine
Potential roles of pentosidine in age-related and disease-related impairment of pulmonary functions in patients with asthma (Kanazawa et al). 2011;127:899-904
Peroxisome proliferator–activated receptors
Peroxisome proliferator–activated receptor γ-mediated suppression of dendritic cell function prevents the onset of atopic dermatitis in NC/Tnd mice (Jung et al). 2011;127:420-9
Pets; *see* Animals, domestic
Phagocytes
Human phagocyte defect caused by a *Rac2* mutation detected by means of neonatal screening for T-cell lymphopenia (Accetta et al). 2011;127:535-8 (Letter to the editor)
Phenotypes
Nonlesional atopic dermatitis skin reveals an abnormal phenotype (Leung and Szefler). 2011;127:874 (The editors' choice)
Sputum gene expression profiles define transcriptional phenotypes of asthma (Leung and Szefler). 2011;127:128 (The editors' choice)
Trajectories of childhood wheeze (von Mutius). 2011;127:1513-4 (Editorial)
Transcriptional phenotypes of asthma defined by gene expression profiling of induced sputum samples (Baines et al). 2011;127:153-60
Pneumococcal infections
Adhesion of *Streptococcus pneumoniae* to human airway epithelial cells exposed to urban particulate matter (Mushtaq et al). 2011;127:1236-42
Age- and serotype-dependent antibody response to pneumococcal polysaccharides (Bossuyt et al). 2011;127:1079-80 (Correspondence)
Age- and serotype-dependent antibody response to pneumococcal polysaccharides (Balloch et al). 2011;127:1080-1 (Letter reply)
Pollen allergy; *see also specific species*
Characterization of pollen antigen–induced IL-31 production by PBMCs in patients with allergic rhinitis (Okano et al). 2011;127:277-9 (Letter to the editor)
PRACTALL consensus report
Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome (Lötvall et al). 2011;127:355-60 (Rostrum)
Practice parameters; *see also* Guidelines
Allergen immunotherapy: a practice parameter third update (Cox et al). 2011;127:S1-S58 (Practice parameter)
Differences in recommendations between the Allergic Rhinitis and its Impact on Asthma Update 2010 and US Rhinitis Practice Parameters (Chipps et al). 2011;127:1640-1.e1 (Correspondence)

Stinging insect hypersensitivity: a practice parameter update 2011 (Golden et al). 2011;127:852-4 (Practice parameter)
World Allergy Organization anaphylaxis guidelines: summary (Simons et al). 2011;127:587-93

Prednisone
Lack of pretreatment cost-effectiveness and side effects of omalizumab versus prednisone/montelukast on tolerability of immunotherapy (Rosenberg). 2011;127:548 (Correspondence)
Lack of pretreatment cost-effectiveness and side effects of omalizumab versus prednisone/montelukast on tolerability of immunotherapy (Massanari et al). 2011;127:548-9 (Letter reply)

Pregnancy/prenatal exposure
A causal link between vitamin D deficiency and lung development (Rothenberg and Bousquet). 2011;127:842 (News beyond our pages)
Maternal allergy modulates cord blood hematopoietic progenitor Toll-like receptor expression and function (Reece et al). 2011;127:447-53
Maternal folate levels in pregnancy and asthma in children at age 3 years (Håberg et al). 2011;127:262-4 (Letter to the editor)
New evidence of lack of inhaled corticosteroid effects on the fetus (Rothenberg and Bousquet). 2011;127:1 (News beyond our pages)

Premature birth
Gestational age at birth and risk of allergic rhinitis in young adulthood (Crump et al). 2011;127:1173-9
Preterm birth protects against atopy in adult life (Leung and Szefler). 2011;127:874 (The editors' choice)
Preterm birth reduces the incidence of atopy in adulthood (Siltanen et al). 2011;127:935-42

Probiotics
Gut microbiota, probiotics, and vitamin D: interrelated exposures influencing allergy, asthma, and obesity? (Ly et al). 2011;127:1087-94

Psoriasis
Contrasting pathogenesis of atopic dermatitis and psoriasis—part I: clinical and pathologic concepts (Guttman-Yassky et al). 2011;127:1110-8 (Current perspectives)
Contrasting pathogenesis of atopic dermatitis and psoriasis—part II: Immune cell subsets and therapeutic concepts (Guttman-Yassky et al). 2011;127:1420-32 (Current perspectives)

Q

Quality of life
Quality of life and pets (Brenna). 2011;127:287 (Correspondence)
Quality of life and pets (Wegienka et al). 2011;127:287-8 (Letter reply)

R

***Rac2* mutation**
Human phagocyte defect caused by a *Rac2* mutation detected by means of neonatal screening for T-cell lymphopenia (Accetta et al). 2011;127:535-8 (Letter to the editor)

Racial/ethnic factors
Asthma control also for teenagers (Rothenberg and Bousquet). 2011;127:298 (News beyond our pages)

Receptors, Fc
Characterization of a novel human mast cell line that responds to stem cell factor and expresses functional FcεRI (Laidlaw et al). 2011;127:815-22

Receptors, histamine
Histamine receptor H1 signaling on dendritic cells plays a key role in the IFN-γ/IL-17 balance in T cell-mediated skin inflammation (Vanbervliet et al). 2011;127:943-53

Receptors, interleukin
IgE-mediated systemic anaphylaxis and impaired tolerance to food antigens in mice with enhanced IL-4 receptor signaling (Mathias et al). 2011;127:795-805
Interleukin-1 receptor–like 1 polymorphisms are associated with serum IL1RL1-a, eosinophils, and asthma in childhood (Savenije et al). 2011;127:750-6
Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbation (Meltzer et al). 2011;127:167-72

Receptors, T lymphocyte
Altered T-cell receptor signaling in the pathogenesis of allergic disease (Datta and Milner). 2011;127:351-4 (Rostrum)

Recombinant proteins
Inhaled vaccine shows persistent local and systemic immunization(Rothenberg and Bousquet). 2011;127:297 (News beyond our pages)
Microarrayed recombinant allergens for diagnostic testing (Shreffler). 2011;127:843-9
Recombinant allergens: What does the future hold? (Valenta et al). 2011;127:860-4 (Current perspectives)
Recombinant allergens for specific immunotherapy (Cromwell et al). 2011;127:865-72 (Current perspectives)
The advent of recombinant allergens and allergen cloning (Thomas). 2011;127:855-9 (Current perspectives)

Research; *see also* Clinical trials
A call for action: comparative effectiveness research in asthma (Krishnan et al). 2011;127:123-7 (Rostrum)
The Severe Asthma Research Program (SARP) (Rothenberg and Bousquet). 2011;127:1085-6 (News beyond our pages)

Respiration disorders
A causal link between vitamin D deficiency and lung development (Rothenberg and Bousquet). 2011;127:842 (News beyond our pages)
Respiratory function tests; *see also* Lung function
Angiogenesis linked to IL-25–mediated asthma (Rothenberg and Bousquet). 2011;127:553-4 (News beyond our pages)
Anti–IL-13 evaluated in mild asthma (Rothenberg and Bousquet). 2011;127:297-8 (News beyond our pages)
Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge (Corren et al). 2011;127:398-405
Forced expiratory flow between 25% and 75% of vital capacity may be a marker of bronchial impairment in allergic rhinitis (Ciprandi and Cirillo). 2011;127:549 (Correspondence), 2011;127:550-1 (Letter reply)
Forced expiratory flow between 25% and 75% of vital capacity may be a marker of bronchial impairment in allergic rhinitis (Simon et al). 2011;127:550 (Letter reply)
Predicting asthma exacerbations: peak expiratory flow revisited (Fuhlbrigge). 2011;127:1503-4 (Editorial)
Predicting future risk of asthma exacerbations using individual conditional probabilities (Thamrin et al). 2011;127:1494-502
Sex dependence of airflow limitation and air trapping in children with severe asthma (Sorkness et al). 2011;127:1073-4 (Letter to the editor)
Respiratory tract diseases
Advances in environmental and occupational respiratory disease in 2010 (Peden and Bush). 2011;127:696-700
Respiratory tract infections
Host and viral factors associated with severity of human rhinovirus–associated infant respiratory tract illness (Miller et al). 2011;127:883-91
Vitamin D supplementation in children may prevent asthma exacerbation triggered by acute respiratory infection (Majak et al). 2011;127:1294-6 (Letter to the editor)
When should we put evidence into clinical practice? (Türktas et al). 2011;127:1078 (Correspondence)
When should we put evidence into clinical practice? (Razi and Harmanci). 2011;127:1078-9 (Letter reply)
Retraction notice
Retraction notice to "Children with asthma and no URTI, more commonly have rhinovirus in their exhaled breath, than in mucous" (Tovey et al) (2009;123:S171). 2011;127:551 (Retraction notice)
Rhinitis
A lower prevalence of asthma among patients with chronic rhinosinusitis in southern China (Fan et al). 2011;127:520-2 (Letter to the editor)
Advances in upper airway diseases and allergen immunotherapy (Sabin et al). 2011;127:342-50
Allergen immunotherapy: a practice parameter third update (Cox et al). 2011;127:S1-S58 (Practice parameter)
Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond (Calderón et al). 2011;127:30-8 (Current perspectives)
Characterization of pollen antigen–induced IL-31 production by PBMCs in patients with allergic rhinitis (Okano et al). 2011;127:277-9 (Letter to the editor)
Childhood eczema and rhinitis predict atopic but not nonatopic adult asthma: a prospective cohort study over 4 decades (Martin et al). 2011;127:1473-9.e1
Comments on Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (Spector et al). 2011;127:1641-2 (Correspondence)
Comments on Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (Brożek et al). 2011;127:1643-5 (Letter reply)
Differences in recommendations between the Allergic Rhinitis and its Impact on Asthma Update 2010 and US Rhinitis Practice Parameters (Chipps et al). 2011;127:1640-1.e1 (Correspondence)
Disease-modifying effect and economic implications of sublingual immunotherapy (Canonica and Passalacqua). 2011;127:44-5 (Editorial)
Forced expiratory flow between 25% and 75% of vital capacity may be a marker of bronchial impairment in allergic rhinitis (Ciprandi and Cirillo). 2011;127:549 (Correspondence), 2011;127:550-1 (Letter reply)
Forced expiratory flow between 25% and 75% of vital capacity may be a marker of bronchial impairment in allergic rhinitis (Simon et al). 2011;127:550 (Letter reply)
Fruit and vegetable consumption in relation to allergy: disease-related modification of consumption? (Rosenlund et al). 2011;127:1219-25
Gestational age at birth and risk of allergic rhinitis in young adulthood (Crump et al). 2011;127:1173-9
Health economics of allergen-specific immunotherapy in the United States (Lockey and Hankin). 2011;127:39-43 (Editorial)
How representative are clinical study patients with allergic rhinitis in primary care? (Costa et al). 2011;127:920-6
Local allergic rhinitis: allergen tolerance and immunologic changes after preseasonal immunotherapy with grass pollen (Rondón et al). 2011;127:1069-71 (Letter to the editor)
Petasol butenoate complex (Ze 339) relieves allergic rhinitis–induced nasal obstruction more effectively than desloratadine (Dumitru et al). 2011;127:1515-21

The march towards asthma in the first 4 decades (Leung and Szefler). 2011;127:1438-9 (The editors' choice)

Rhinitis, allergic, seasonal; *see* Hay fever

Rhinoconjunctivitis

Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults (Nelson et al). 2011;127:72-80

Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents (Blaiss et al). 2011;127:64-71

Identifying seasonal variation in allergic rhinoconjunctivitis (Flynn). 2011;127:1314-5 (Correspondence)

Rhinosinusitis; *see* Sinusitis

Rhinovirus

Exogenous IFN-β has antiviral and anti-inflammatory properties in primary bronchial epithelial cells from asthmatic subjects exposed to rhinovirus (Cakebread et al). 2011;127:1148-54

Host and viral factors associated with severity of human rhinovirus–associated infant respiratory tract illness (Miller et al). 2011;127:883-91

RNA, ribosomal

Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma (Huang et al). 2011;127:372-81

S

Salbutamol

Salbutamol inhaler misuse resulting in skin burn (Bonniaud et al). 2011;127:295 (Correspondence)

Sensitization

Allergy-related outcomes in relation to serum IgE: results from the National Health and Nutrition Examination Survey 2005-2006 (Salo et al). 2011;127:1226-35

Differences in the allergenicity of 6 different kiwifruit cultivars analyzed by prick-to-prick testing, open food challenges, and ELISA (Le et al). 2011;127:677-9 (Letter to the editor)

Early complementary feeding and risk of food sensitization in a birth cohort (Joseph et al). 2011;127:1203-10

Epidemiology of food allergy (Sicherer). 2011;127:594-602 (Current perspectives)

Heated egg white proteins are more susceptible to gastrointestinal degradation (Leung and Szefler). 2011;127:873 (The editors' choice)

Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program (Fitzpatrick et al). 2011;127:382-9

Mechanisms underlying differential food allergy response to heated egg (Martos et al). 2011;127:990-7

Serine proteinase inhibitors

A nonredundant role for mouse Serpinb3a in the induction of mucus production in asthma (Sivaprasad et al). 2011;127:254-61

Sesame allergy

Diagnosing IgE-mediated hypersensitivity to sesame by an immediate-reading "contact test" with sesame oil (Alonzi et al). 2011;127:1627-9 (Letter to the editor)

Severe combined immunodeficiency

In vivo T-cell dynamics during immune reconstitution after hematopoietic stem cell gene therapy in adenosine deaminase severe combined immune deficiency (Selleri et al). 2011;127:1368-75

Neonatal screening for severe combined immunodeficiency caused by an adenosine deaminase defect: a reliable and inexpensive method using tandem mass spectrometry (Azzari et al). 2011;127:1394-9

Polymorphous lymphoproliferative disorder with Hodgkin-like features in common γ-chain–deficient severe combined immunodeficiency (Slatter et al). 2011;127:533-5 (Letter to the editor)

Sex factors

Sex dependence of airflow limitation and air trapping in children with severe asthma (Sorkness et al). 2011;127:1073-4 (Letter to the editor)

Sex differences in asthma during the first 8 years of life: the Prevention and Incidence of Asthma and Mite Allergy (PIAMA) birth cohort study (Wijga et al). 2011;127:275-7 (Letter to the editor)

Shea butter

Shea butter contains no IgE-binding soluble proteins (Chawla et al). 2011;127:680-2 (Letter to the editor)

Sickle cell disease

Elevation of IgE in children with sickle cell disease is associated with doctor diagnosis of asthma and increased morbidity (An et al). 2011;127:1440-6

Sinusitis

A lower prevalence of asthma among patients with chronic rhinosinusitis in southern China (Fan et al). 2011;127:520-2 (Letter to the editor)

Advances in upper airway diseases and allergen immunotherapy (Sabin et al). 2011;127:342-50

Skin

Systemic glucocorticosteroids affect cutaneous immune response (Rothenberg and Bousquet). 2011;127:298 (News beyond our pages)

Skin barrier function

Contrasting pathogenesis of atopic dermatitis and psoriasis—part I: clinical and pathologic concepts (Guttman-Yassky et al). 2011;127:1110-8 (Current perspectives)

Nonlesional atopic dermatitis skin reveals an abnormal phenotype (Leung and Szefler). 2011;127:874 (The editors' choice)

The 2-hit theory for epidermal barrier disruption in atopic dermatitis (Leung and Szefler). 2011;127: 723 (The editors' choice)

Skin diseases

Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2010 (Sicherer and Leung). 2011;127: 326-35

Contrasting pathogenesis of atopic dermatitis and psoriasis—part II: Immune cell subsets and therapeutic concepts (Guttman-Yassky et al). 2011;127:1420-32 (Current perspectives)

Deficient expression of the transcription factor Sp1 might increase the propensity of patients with atopic dermatitis to disseminated viral skin infection (Leung and Szefler). 2011;127:362 (The editors' choice)

Eosinophil extracellular DNA traps in skin diseases (Simon et al). 2011;127:194-9

Skin rashes

The role of penicillin in benign skin rashes in childhood: a prospective study based on drug rechallenge (Caubet et al). 2011;127:218-22

Skin tests

A genome-wide association study to identify genetic determinants of atopy in subjects from the United Kingdom (Wan et al). 2011;127:223-31

Freezing does not alter antigenic properties of fresh fruits for skin testing in patients with birch tree pollen–induced oral allergy syndrome (Bégin et al). 2011;127:1624-6.e3 (Letter to the editor)

Preterm birth reduces the incidence of atopy in adulthood (Siltanen et al). 2011;127:935-42

Smith-Magenis syndrome

Lessons from Smith-Magenis syndrome: low transmembrane activator and calcium modulator and cyclophilin ligand interactor expression leads to B-cell dysfunction (Leung and Szefler). 2011;127:1438-9 (The editors' choice)

Transmembrane activator and CAML interactor (TACI) haploinsufficiency results in B-cell dysfunction in patients with Smith-Magenis syndrome (Chinen et al). 2011;127:1579-86

Smoking

Unexpected effect of inhibiting TLA_4H (Rothenberg and Bousquet). 2011;127:2 (News beyond our pages)

Smooth-muscle cells

A taste for relaxation (Rothenberg and Bousquet). 2011;127:1 (News beyond our pages)

T_H17 cytokines induce human airway smooth muscle cell migration (Chang et al). 2011;127:1046-53

Soybeans

The prevalence and natural course of food protein–induced enterocolitis syndrome to cow's milk: a large-scale, prospective population-based study (Katz et al). 2011;127:647-53

Specificity protein

Specificity protein 1 is pivotal in the skin's antiviral response (Bin et al). 2011;127:430-8

Staphylococcus aureus

Comparative proteomic profiling of patients with atopic dermatitis based on history of eczema herpeticum infection and *Staphylococcus aureus* colonization (Broccardo et al). 2011;127:186-93

Stem cell factor

Characterization of a novel human mast cell line that responds to stem cell factor and expresses functional FcεRI (Laidlaw et al). 2011;127:815-22

Stem cells

IL-4 induces differentiation of human embryonic stem cells into fibrogenic fibroblast-like cells (Sato et al). 2011;127:1595-603

Induced pluripotent stem cells: a novel frontier in the study of human primary immunodeficiencies (Pessach et al). 2011;127:1400-7.e4

Induced pluripotent stem cells and primary immunodeficiencies: a new frontier reached, a new world beyond? (Gaspar). 2011;127:1408-9 (Editorial)

Stings; *see Hymenoptera;* Insect bites and stings

Stress, psychological

Parental psychosocial stress and asthma morbidity in Puerto Rican twins (Lange et al). 2011;127:734-40

Swimming

Airway hyperresponsiveness in elite swimmers: Is it a transient phenomenon? (Bougault et al). 2011;127: 892-8

T

T lymphocyte receptors; *see* Receptors, T lymphocyte

T lymphocyte subsets

A peptide derived from the Wiskott-Aldrich syndrome (WAS) protein-interacting protein (WIP) restores WAS protein level and actin cytoskeleton reorganization in lymphocytes from patients with WAS mutations that disrupt WIP binding (Massaad et al). 2011;127:998-1005

A physiologic signature for asthma (Rothenberg and Bousquet). 2011;127:553 (News beyond our pages)

Decreased T-cell receptor signaling through CARD11 differentially compromises forkhead box protein 3–positive regulatory versus T_H2 effector cells to cause allergy (Altin et al). 2011;127:1277-85

T lymphocytes

Alleviating allergic airway diseases by means of short-term administration of IL-2 and dexamethasone (Ma et al). 2011;127:1447-56

Ara h 1–reactive T cells in individuals with peanut allergy (DeLong et al). 2011;127:1211-8

$CD8^+$T cells are recruited early to allergen exposure sites in atopy patch test reactions in human atopic dermatitis (Hennino et al). 2011;127:1064-7 (Letter to the editor)

Diffuse large B-cell lymphoma as presenting feature of Zap-70 deficiency (Newell et al). 2011;127:517-20 (Letter to the editor)

Enhanced antigenicity leads to altered immunogenicity in sulfamethoxazole-hypersensitive patients with cystic fibrosis (Elsheikh et al). 2011;127:1543-51
Immune pathomechanism of drug hypersensitivity reactions (Pichler et al). 2011;127:S74-S81
In vivo T-cell dynamics during immune reconstitution after hematopoietic stem cell gene therapy in adenosine deaminase severe combined immune deficiency (Selleri et al). 2011;127:1368-75

T lymphocytes, helper-inducer
Altered T-cell receptor signaling in the pathogenesis of allergic disease (Datta and Milner). 2011;127:351-4 (Rostrum)
Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong T_H17/T_H1T-cell responses (Hänsel et al). 2011;127:787-94
Human T_H17 cells express a functional IL-13 receptor and IL-13 attenuates IL-17A production (Newcomb et al). 2011;127:1006-13
Inhibition of differentiation, amplification, and function of human T_H17 cells by intravenous immunoglobulin (Maddur et al). 2011;127:823-30
New host defense mechanisms against *Candida* species clarify the basis of clinical phenotypes (Hanna and Etzoni). 2011;127:1433-7 (Current perspectives)
New T_H2 cell line described (Rothenberg and Bousquet). 2011;127:1-2 (News beyond our pages)
Plastic IL-17 cells (Rothenberg and Bousquet). 2011;127:1317-8 (News beyond our pages)
Pollen metabolome analysis reveals adenosine as a major regulator of dendritic cell-primed T_H cell responses (Gilles et al). 2011;127:454-61
Reshaping the Bet v 1 fold modulates T_H polarization (Wallner et al). 2011;127:1571-8.e9
T_H17 cytokines induce human airway smooth muscle cell migration (Chang et al). 2011;127:1046-53
The adenylate cyclase toxin of *Bacillus anthracis* is a potent promoter of T_H17 cell development (Paccani et al). 2011;127:1636-7 (Letter to the editor)

T lymphocytes, regulatory
Allergen-specific immunotherapy: regulatory T cells account for a well-balanced immune response (Leung and Szefler). 2011;127:362 (The editors' choice)
Bet v 1–specific T-cell receptor/forkhead box protein 3 transgenic T cells suppress Bet v 1–specific T-cell effector function in an activation-dependent manner (Schmetterer et al). 2011;127:238-45
Customized regulatory T cells for immunomodulation of allergen-specific T cells (Leung and Szefler). 2011;127:129 (The editors' choice)
Defective IL-10 signaling characteristic of hyper-IgE syndrome (Rothenberg and Bousquet). 2011;127:841 (News beyond our pages)
Mechanisms of allergen-specific immunotherapy (Akdis and Akdis). 2011;127:18-27
Vitamin D3 targets epidermal and dermal dendritic cells for induction of distinct regulatory T cells (van der Aar et al). 2011;127:1532-40
Wasp venom immunotherapy induces activation and homing of $CD4^+CD25^+$ forkhead box protein 3–positive regulatory T cells controlling T_H1 responses (Kerstan et al). 2011;127:495-501

Tandem mass spectrometry
Neonatal screening for severe combined immunodeficiency caused by an adenosine deaminase defect: a reliable and inexpensive method using tandem mass spectrometry (Azzari et al). 2011;127:1394-9

Taste perception
A taste for relaxation (Rothenberg and Bousquet). 2011;127:1 (News beyond our pages)

Terminal differentiation
Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities (Suárez-Fariñas et al). 2011;127:954-64

Thymic stromal lymphopoietin
Dexamethasone regulation of thymic stromal lymphopoietin receptor expression on mast cells and their precursors (Allakhverdi et al). 2011;127:523-4 (Letter to the editor)

Ticks
The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1,3-galactose (Commins et al). 2011;127:1286-93
Tick bites: a common cause of IgE antibodies to alpha-gal (Leung and Szefler). 2011;127:1131 (The editors' choice)

Tight junctions
Tight junction defects in patients with atopic dermatitis (De Benedetto et al). 2011;127:773-86

Tolerance; *see* Immune tolerance

Toll-like receptors
Differences in innate immune function between allergic and nonallergic children: new insights into immune ontogeny (Tulic et al). 2011;127:470-8
Effect of day care on asthma development differs by *TLR2* genotype (Leung and Szefler). 2011;127:361 (The editors' choice)
Maternal allergy modulates cord blood hematopoietic progenitor Toll-like receptor expression and function (Reece et al). 2011;127:447-53
The L412F variant of Toll-like receptor 3 *(TLR3)* is associated with cutaneous candidiasis, increased susceptibility to cytomegalovirus, and autoimmunity (Nahum et al). 2011;127:528-31 (Letter to the editor)
Toll-like receptor 7 agonists are potent and rapid bronchodilators in guinea pigs (Kaufman et al). 2011;127:462-9

Transcription factors
Deficient expression of the transcription factor Sp1 might increase the propensity of patients with

atopic dermatitis to disseminated viral skin infection (Leung and Szefler). 2011;127:362 (The editors' choice)
Steroids and extracellular signal-regulated kinase 1/2 activity suppress activating transcription factor 3 expression in patients with severe asthma (Roussel et al). 2011;127:1632-5 (Letter to the editor)
Thiol redox disturbances in children with severe asthma are associated with posttranslational modification of the transcription factor nuclear factor (erythroid-derived 2)–like 2 (Fitzpatrick et al). 2011;127:1604-11

Transforming growth factors
Characterization of an IL-1 family cytokine (Rothenberg and Bousquet). 2011;127:2 (News beyond our pages)

Transmembrane activator and CAML
Lessons from Smith-Magenis syndrome: low transmembrane activator and calcium modulator and cyclophilin ligand interactor expression leads to B-cell dysfunction (Leung and Szefler). 2011;127:1438-9 (The editors' choice)
The C76R transmembrane activator and calcium modulator cyclophilin ligand interactor mutation disrupts antibody production and B-cell homeostasis in heterozygous and homozygous mice (Bacchelli et al). 2011;127:1253-9
Transmembrane activator and CAML interactor (TACI) haploinsufficiency results in B-cell dysfunction in patients with Smith-Magenis syndrome (Chinen et al). 2011;127:1579-86

Transplants; *see also* Hematopoietic stem cell transplantation
Induction of tolerance to parental parathyroid grafts using allogeneic thymus tissue in patients with DiGeorge anomaly (Chinn and Markert). 2011;127:1351-5 (Current perspectives)
Management of post–liver transplant–associated IgE-mediated food allergy in children (Maarof et al). 2011;127:1296-8 (Letter to the editor)

Transposons
Gene therapy for primary immunodeficiencies: looking ahead, toward gene correction (Pessach and Notarangelo). 2011;127:1344-50 (Current perspectives)

Treg cells; *see* T lymphocytes, regulatory

Trypanosoma cruzi
Sequence variation in the *IL4* gene and resistance to *Trypanosoma cruzi* infection in Bolivians (Alvarado Arnez et al). 2011;127:279-82 (Letter to the editor)

Tumor necrosis factor
Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: relevance to atopic dermatitis (Zhang et al). 2011;127:1522-31
TNF-like weak inducer of apoptosis (TWEAK) and TNF-α cooperate in the induction of keratinocyte apoptosis (Zimmermann et al). 2011;127:200-7

U

Urban health
Omalizumab add-on therapy improves asthma outcomes in children (Rothenberg and Bousquet). 2011;127:1317-8 (News beyond our pages)
Relationships among environmental exposures, cord blood cytokine responses, allergy, and wheeze at 1 year of age in an inner-city birth cohort (Urban Environment and Childhood Asthma study) (Wood et al). 2011;127:913-9

Urine tests
Metabolomic profiling of asthma: diagnostic utility of urine nuclear magnetic resonance spectroscopy (Saude et al). 2011;127:757-64
The magnetic power of urine in the diagnosis of asthma (Leung and Szefler). 2011;127:722 (The editors' choice)

Urticaria
Clinical utility of the Chronic Urticaria Index (Biagtan et al). 2011;127:1626-7 (Letter to the editor)
Omalizumab is effective in nonautoimmune urticaria (Ferrer et al). 2011;127:1300-2 (Letter to the editor)

V

Vaccinia virus
Specificity protein 1 is pivotal in the skin's antiviral response (Bin et al). 2011;127:430-8

Vehicle emissions
Effects of distance from a heavily transited avenue on asthma and atopy in a periurban shantytown in Lima, Peru (Baumann et al). 2011;127:875-82

Venom immunotherapy
Honeybee venom immunotherapy in children using a 50-μg maintenance dose (Houliston et al). 2011;127:98-9 (Letter to the editor)

Virus diseases
Toll-like receptor 7 agonists are potent and rapid bronchodilators in guinea pigs (Kaufman et al). 2011;127:462-9

Vitamin A
Location, location, location: when vitamin A supports inflammation (Rothenberg and Bousquet). 2011;127:841-2 (News beyond our pages)

Vitamin D
A causal link between vitamin D deficiency and lung development (Rothenberg and Bousquet). 2011;127:842 (News beyond our pages)
Bacterial components plus vitamin D: the ultimate solution to the asthma (autoimmune disease) epidemic? (Weiss). 2011;127:1128-30 (Editorial)
Circulating levels of 25-hydroxyvitamin D and human cathelicidin in healthy adults (Bhan et al). 2011;127:1302-4 (Letter to the editor)
Gut microbiota, probiotics, and vitamin D: interrelated exposures influencing allergy, asthma, and obesity? (Ly et al). 2011;127:1087-94

The many routes of dendritic cells to ensure immune regulation (Palomares et al). 2011;127:1541-2 (Editorial)
Vitamin D levels and food and environmental allergies in the United States: results from the National Health and Nutrition Examination Survey 2005-2006 (Sharief et al). 2011;127:1195-202
Vitamin D supplementation in children may prevent asthma exacerbation triggered by acute respiratory infection (Majak et al). 2011;127:1294-6 (Letter to the editor)
Vitamin D3 targets epidermal and dermal dendritic cells for induction of distinct regulatory T cells (van der Aar et al). 2011;127:1532-40

W

WAS protein
A peptide derived from the Wiskott-Aldrich syndrome (WAS) protein-interacting protein (WIP) restores WAS protein level and actin cytoskeleton reorganization in lymphocytes from patients with WAS mutations that disrupt WIP binding (Massaad et al). 2011;127:998-1005
NanoWIP wipes *WAS/XLT* mutations (Leung and Szefler). 2011;127:874 (The editors' choice)
Wasp allergy; *see Hymenoptera*
Wheezing
Allergen-specific IgG antibody levels modify the relationship between allergen-specific IgE and wheezing in childhood (Custovic et al). 2011;127:1480-5
Comparison of childhood wheezing phenotypes in 2 birth cohorts: ALSPAC and PIAMA (Savenije et al). 2011;127:1502-12
First results from the Urban Environment and Childhood Asthma study (Leung and Szefler). 2011;127:873 (The editors' choice)
Parental psychosocial stress and asthma morbidity in Puerto Rican twins (Lange et al). 2011;127:734-40
Sex differences in asthma during the first 8 years of life: the Prevention and Incidence of Asthma and Mite Allergy (PIAMA) birth cohort study (Wijga et al). 2011;127:275-7 (Letter to the editor)
The Asthma Predictive Index: not a useful tool in clinical practice (Brand). 2011;127:293-4 (Correspondence)
The asthma predictive index remains a useful tool to predict asthma in young children with recurrent wheeze in clinical practice (Castro-Rodriguez et al). 2011;127:1082-3 (Correspondence)
The effect of prophylactic palivizumab on recurrent wheezing in children with an atopic family history (Gaffin et al). 2011;127:292-3 (Correspondence)
The effect of prophylactic palivizumab on recurrent wheezing in children with an atopic family history (Simões et al). 2011;127:293 (Letter reply)
The risk of wheezing decreases with increasing allergen-specific IgG antibody levels (Leung and Szefler). 2011;127:1438-9 (The editors' choice)
To wheeze or not to wheeze—that is NOT the question (Leung and Szefler). 2011;127:1132 (The editors' choice)
Trajectories of childhood wheeze (von Mutius). 2011;127:1513-4 (Editorial)
Validation of the Asthma Predictive Index and comparison with simpler clinical prediction rules (Leonardi et al). 2011;127:1466-72.e6
When should we put evidence into clinical practice? (Türktas et al). 2011;127:1078 (Correspondence)
When should we put evidence into clinical practice? (Razi and Harmanci). 2011;127:1078-9 (Letter reply)
Wiskott-Aldrich syndrome
A peptide derived from the Wiskott-Aldrich syndrome (WAS) protein-interacting protein (WIP) restores WAS protein level and actin cytoskeleton reorganization in lymphocytes from patients with WAS mutations that disrupt WIP binding (Massaad et al). 2011;127:998-1005
Gene therapy for primary adaptive immune deficiencies (Fischer et al). 2011;127:1356-9 (Current perspectives)
Lentiviral-mediated gene therapy leads to improvement of B-cell functionality in a murine model of Wiskott-Aldrich syndrome (Bosticardo et al). 2011;127:1376-84
NanoWIP wipes *WAS/XLT* mutations (Leung and Szefler). 2011;127:874 (The editors' choice)

X

X-linked inhibitor of apoptosis
Two new families with X-linked inhibitor of apoptosis deficiency and a review of all 26 published cases (Horn et al). 2011;127:544-6 (Letter to the editor)

Z

Zap-70 deficiency
Diffuse large B-cell lymphoma as presenting feature of Zap-70 deficiency (Newell et al). 2011;127:517-20 (Letter to the editor)